DDD 3D Systems Corporation

---

---

---

---

---

---

---

(1) Basis of Presentation

The accompanying unaudited condensed consolidated financial statements include the accounts of 3D Systems Corporation and all majority and wholly-owned subsidiaries and entities in which a controlling interest is maintained (“3D Systems” or the “Company” or “we” or “our” or “us”). All significant intercompany accounts and transactions have been eliminated in consolidation. 

A non-controlling interest in a subsidiary reflects an ownership interest in a majority-owned subsidiary that is not attributable to the Company. For the periods presented, the Company's financial statements include a redeemable non-controlling interest (“RNCI”), which has been reported in temporary equity in the consolidated balance sheets. The net income (loss) attributable to the RNCI is presented as an adjustment to the Company's consolidated net income (loss) to arrive at net income (loss) attributable to 3D Systems Corporation in the consolidated statements of operations and consolidated statements of comprehensive income (loss). Furthermore, adjustments to record the RNCI at its redemption value are recorded to additional paid-in capital, and the excess redemption value is recognized as a reduction to the net income, or increase to the net loss, attributable to 3D Systems’ shareholders for purposes of reporting earnings or loss per share. See Note 11 for a summary of the activity related to the reported RNCI balance during the period.

The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) applicable to interim reports. Accordingly, our unaudited condensed consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022 (“2022 Form 10-K”). The year-end balance sheet data reported on our unaudited condensed consolidated balance sheet has been derived from the balance sheet included in our 2022 Form 10-K.

The Company believes that the disclosures included in this Form 10-Q are adequate to make the information presented not misleading. In the opinion of management, the unaudited condensed consolidated financial statements include all adjustments, consisting of adjustments of a normal recurring nature, necessary to present fairly the financial position, results of operations, and cash flows for the periods presented. The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results may differ from those estimates and assumptions.

Our annual reporting period is the calendar year. Our results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for the full year. All dollar amounts and other amounts presented in the accompanying footnotes are presented in thousands, except for per share information.

Summary of Significant Accounting Policies

The significant accounting policies included in our 2022 Form 10-K have been updated as follows.

Goodwill

Goodwill is the excess of the cost of an acquired entity over the amounts assigned to the assets acquired and liabilities assumed in a business combination. Goodwill is not amortized. Goodwill is tested for impairment annually during the fourth quarter of each year, and is tested for impairment between annual tests if an event occurs or circumstances change that would indicate the carrying amount may be impaired. Impairment testing for goodwill is done at a reporting unit level, with all goodwill assigned to a reporting unit.

The test for impairment of goodwill requires the Company to make several estimates related to projected future cash flows to determine the fair value of the goodwill reporting units. The Company calculates the excess of each reporting unit's fair value over its carrying amount, including goodwill, utilizing a discounted cash flow analysis and other valuation techniques, as deemed appropriate. Internal operational budgets and long-range strategic plans are used as a basis for the cash flow analysis. The Company also utilizes assumptions for working capital, capital expenditures, and terminal growth rates. The discount rate applied to the cash flow analysis is based on the weighted average cost of capital (“WACC”) for each reporting unit. An impairment is recognized when the carrying amount of the reporting unit’s net assets exceeds the estimated fair value of the reporting unit.

---

During the quarter ended September 30, 2023, the Company experienced a significant decline in its market capitalization as a result of a decrease in its stock price, and during the month ended September 30, 2023, the Company’s market capitalization fell slightly below its consolidated stockholders’ equity balance. We do not consider this to constitute a sustained decrease in the Company’s stock price as of September 30, 2023. Furthermore, the Company performed a qualitative goodwill impairment assessment as of September 30, 2023 and concluded that it is not more likely than not that the fair value of either of its reporting units is less than the reporting unit’s carrying value as of September 30, 2023. As a result, we concluded that no triggering event had occurred that would require the Company to perform a quantitative goodwill impairment test for either of its two reporting units as of September 30, 2023. However, the Company’s market capitalization has declined further since September 30, 2023, and if such a decline results in the estimated fair value of either of our reporting units being lower than the respective reporting unit’s carrying value, the Company would need to record a non-cash goodwill impairment charge, which could be material, in a future period – including as of our upcoming annual impairment testing date of November 1, 2023 (reflecting our annual goodwill impairment testing date commencing as of the current fiscal year).

Variable Interest Entities (VIEs)

Upon making an investment in an entity, we assess whether the entity is a VIE. The determination of whether an entity in which we hold a direct or indirect variable interest is a VIE is based on several factors, including whether the entity’s total equity investment at risk upon inception is sufficient to finance the entity’s activities without additional subordinated financial support. We make judgments regarding the sufficiency of the equity at risk based first on a qualitative analysis, and then a quantitative analysis, if necessary.

We analyze any investments in VIEs to determine if we are the primary beneficiary. We perform this assessment at the time that we become involved with a VIE and reevaluate our conclusion upon the occurrence of a reconsideration event. In evaluating whether we are the primary beneficiary, we evaluate our direct and indirect economic interests in the entity. Determining which reporting entity, if any, is the primary beneficiary of a VIE is primarily a qualitative approach focused on identifying which reporting entity has both (1) the power to direct the activities of a VIE that most significantly impact such entity’s economic performance and (2) the obligation to absorb losses or the right to receive benefits from such entity that could potentially be significant to such entity. Performance of such analysis requires the exercise of judgment, and we consider a variety of factors in identifying the entity that holds the power to direct matters that most significantly impact a VIE’s economic performance including, but not limited to, the ability to direct a VIE’s operating decisions and activities. In addition, we consider the rights of other investors to participate in those decisions.

We concluded that our investments in Theradaptive and the Saudi Arabian Industrial Investments Company ("Dussur") are each a VIE. These investments are not consolidated because we concluded that the Company is not the primary beneficiary. As of September 30, 2023, our maximum exposure to losses associated with the VIEs is limited to the $13,782 carrying value of our investments in the VIEs, which is included in other assets on our condensed consolidated balance sheet. We have no other investments in unconsolidated entities that have been determined to be VIEs.

Equity Securities without a Readily Determinable Value

We recognize investments in equity securities without a readily determinable fair value at cost minus impairment. We assess these investments for potential impairment if an event occurs or circumstances change that would indicate the carrying amount may be impaired. If applicable, impairment charges taken with respect to these investments are reported within interest and other income (expense), net in the consolidated statements of operations in the period in which an investment becomes impaired (see Note 7).

Equity Method of Accounting

The Company accounts for an investment in a joint venture using the equity method of accounting because it does not have a controlling interest and is not the primary beneficiary; however, the Company has the ability to exert significant influence. Under the equity method of accounting, the initial investment is recorded at cost, and the investment is subsequently adjusted for the Company’s proportionate share of the net earnings or losses and other comprehensive income or loss of the investee. Intra-entity profits or losses associated with the Company’s equity method investment are eliminated until realized by the investee in transactions with third parties. Income or loss from this investment is recorded as a separate line item in the consolidated statements of operations on a three-month lag. We evaluate material events occurring during the three-month lag period to determine whether the effects of such events should be disclosed in our financial statements. The Company will evaluate its investment in the joint venture for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment may not be recoverable.

---

Other Accounting Policy Updates

All other significant accounting policies described in the 2022 Form 10-K remain unchanged.

(2) Acquisitions

Wematter

On July 1, 2023, the Company completed the previously announced acquisition of Wematter AB (“Wematter”), a Swedish 3D printer manufacturer that will broaden 3D Systems’ Selective Laser Sintering (SLS) portfolio. Wematter's reported results are expected to be included in our Industrial Solutions segment. The acquisition resulted in the Company acquiring 100% of the outstanding voting interest of Wematter. Consideration for this acquisition consisted of approximately $10,224 in cash, subject to customary post-closing adjustments. The Company also may be required to pay an additional €2,000 in cash, contingent upon the achievement of certain post-closing performance conditions and the continued employment of certain key Wematter employees for two years after the closing date. If earned, the €2,000 is expected to be recognized as compensation expense over the two-year service period that the key employees must remain employed at 3D Systems. As of September 30, 2023, management believes that the achievement of the post-closing performance conditions is probable and, accordingly, the Company has commenced the recognition of the related compensation expense. In addition, the Company incurred $847 of acquisition-related expenses that are reported in selling, general and administrative expenses in the condensed consolidated statements of operations.

In a separate transaction, the Company had extended a loan to Wematter during the three months ended June 30, 2023. The carrying value of the Wematter loan was $942 as of the acquisition date, and was previously reported in prepaid and other current assets on the Company's condensed consolidated balance sheet as of June 30, 2023. Upon the close of the acquisition, we determined that the loan was effectively settled in the business combination as a preexisting contractual relationship. No gain or loss was recognized in connection with the effective settlement, as the carrying value of the loan was not materially different from the pricing for a current market transaction for similar items. The effective settlement of this loan receivable results in an increase to the consideration transferred in connection with this transaction (i.e., above the cash consideration paid) and a corresponding increase to goodwill.

We accounted for the acquisition of Wematter using the acquisition method, as prescribed by ASC 805, “Business Combinations” (“ASC 805”). In accordance with valuation methodologies described in ASC 820, “Fair Value Measurement” (“ASC 820”), the acquired assets and assumed liabilities were recorded at their estimated fair values as of the date of the Wematter acquisition.

---

Shown below is the preliminary purchase price allocation, which summarizes the fair values of the assets acquired and liabilities assumed at the date of acquisition:

(in thousands)
Current assets, including cash acquired of $148												$	835
Intangible assets:
Trade names						$	1,487
Product technology						2,231
Customer relationships						347
Total intangible assets												4,065
Goodwill												6,878
Other assets												475
Liabilities:
Accounts payable and accrued liabilities						$	794
Long term liabilities						293
Total liabilities												1,087
Net assets acquired												$	11,166

The goodwill recognized is attributable to synergies that are expected to enhance and expand the Company’s overall product portfolio and opportunities in new and existing markets, future products that have yet to be determined and Wematter’s assembled workforce. This goodwill is not expected to be deductible for tax purposes.

The following table presents the finite-lived intangible assets acquired and their respective estimated useful lives:

			Useful Life
Trade names			5
Product technology			15
Customer relationships			10

As of September 30, 2023, the purchase price allocation for Wematter is preliminary. The Company continues to review the final closing balance sheet of Wematter and may further adjust the acquisition-date fair values of acquired assets and assumed liabilities based on this review. The Company also continues to review Wematter’s pre-acquisition tax returns to determine the final tax positions, including net operating losses and any required valuation allowance. The final purchase price allocations will be completed when the Company has finished its valuation activities and the review of Wematter’s closing balance sheet and the pre-acquisition tax returns. These final allocations could differ materially from the current preliminary allocations. The final allocations may include (1) changes in the preliminary allocations to acquired intangible assets and goodwill and (2) changes in the preliminary allocations to other assets and liabilities, including but not limited to tax assets and liabilities, inclusive of deferred taxes. The estimated useful lives of acquired intangible assets are also preliminary.

The post-acquisition revenues of Wematter included in our condensed consolidated statements of operations for both the three and nine months ended September 30, 2023 are immaterial and, accordingly, Wematter's results are dilutive to our earnings.

Unaudited Pro Forma Financial Information

The following unaudited pro forma financial information summarizes the combined results of the Company and Wematter as if the acquisition had occurred on January 1, 2022. The pro forma results have been prepared for comparative purposes only, and do not necessarily represent what the results of operations would have been had the acquisition been completed on January 1, 2022. In addition, these pro forma results are not intended to be a projection of future operating results and do not reflect synergies that might be achieved.

---

The unaudited pro forma financial information includes adjustments for the pro forma impact of our preliminary purchase price allocation, including the amortization for newly acquired intangible assets, the impact of transaction costs, and the alignment of accounting policies. Transaction costs have been included in the pro forma results for the periods ended September 30, 2022, consistent with the pro forma assumption that the acquisition occurred on January 1, 2022. Pro forma revenue information has not been presented, as pre-acquisition revenue reported by Wematter was not material and, accordingly, the impact on our reported consolidated revenue also would not have been material. Pro forma net loss is not presented in the table below for the three months ended September 30, 2023 because Wematter's results are reflected in 3D Systems consolidated numbers for the full period.

												Three Months Ended September 30,						Nine Months Ended September 30,
(in thousands)												2022						2023						2022
Net (loss) income attributable to 3D Systems Corporation												$	(38,407)					$	(71,076)					$	(100,185)

dp polar

On October 4, 2022, we completed the acquisition of 100% of dp polar GmbH (“dp polar”), a German-based designer and manufacturer of a manufacturing system designed for true high-speed mass production of customized components, for $25,866 (including customary post-closing adjustments), which includes $19,604 paid in cash at closing, $7,091 paid at closing via the issuance of the Company’s common stock, and a provisional $829 estimated post-closing purchase price adjustment due to the Company from the sellers. See Note 12 for the discussion of an earnout arrangement with a key individual from dp polar.

The Company acquired dp polar for access to dp polar's patented continuous printing process. Central to dp polar’s patented continuous printing process is a large-scale, segmented, rotating print platform that eliminates the start/stop operations of virtually all additive manufacturing platforms. With dp polar’s technology and patented polar coordinate control, the print heads remain stationary above the rotating platform, providing a continuous print process.

We accounted for the acquisition of dp polar using the acquisition method, as prescribed by ASC 805. In accordance with valuation methodologies described in ASC 820, the acquired assets and assumed liabilities were recorded at their estimated fair values as of the date of the dp polar acquisition.

Shown below is the final purchase price allocation, which summarizes the fair values of the assets acquired and liabilities assumed at the date of acquisition:

(in thousands)
Current assets, including cash acquired of $243												$	301
Intangible assets:
In-process research and development						$	4,989
Trade name						3,930
Total intangible assets												8,919
Goodwill												17,090
Other assets												765
Liabilities:
Accounts payable and accrued liabilities						$	364
Deferred tax liability						845
Total liabilities												1,209
Net assets acquired												$	25,866

The goodwill recognized in connection with this acquisition is attributable to synergies that are expected to enhance and expand the Company’s overall product portfolio and opportunities in new and existing markets, future products that have yet to be determined and dp polar’s assembled workforce. This goodwill will not be deductible for tax purposes.

---

Kumovis

On April 1, 2022, we completed the acquisition of 93.75% of Kumovis GmbH (“Kumovis”) for an all-cash purchase price of $37,875 (including customary post-closing adjustments), plus an estimated RNCI of $1,559. $3,628 of the cash payment was deferred for up to fifteen months from the closing date, and was paid in July 2023. Kumovis, which is part of the Healthcare Solutions segment and reporting unit, utilizes polyether ether keton or “PEEK” materials, which has properties that lend it to many medical applications that fit into our personalized healthcare solutions operations, including many implant applications.

In conjunction with the Kumovis acquisition, the Company and the non-controlling shareholders entered into a put/call option agreement, whereby, at a later date, the Company has the option to purchase from the non-controlling shareholders, and the non-controlling shareholders have the option to sell to the Company, the remaining 6.25% ownership interest in Kumovis for an exercise price calculated based on the achievement of pre-determined revenue and gross profit targets. Fifty percent of the Kumovis common shares related to the put/call can be exercised upon the achievement of an initial revenue and gross profit target, while the remaining 50% can be exercised upon the achievement of a second revenue and gross profit target. If one or both sets of targets have not been met within 5.75 years from the acquisition date, there is a floor strike price that must be exercised. Up to 50% of the exercise price can be paid in Company common stock at the election of 3D Systems. This arrangement results in the recognition of RNCI, for which an estimated fair value of $1,559 was recorded as of the acquisition date.

We accounted for the acquisition of Kumovis using the acquisition method, as prescribed by ASC 805, and we have completed the allocation of the final purchase price. In accordance with valuation methodologies described in ASC 820, the acquired assets and assumed liabilities were recorded at their estimated fair values as of the date of the Kumovis acquisition. The table below reflects the fair value of both the consideration transferred and the RNCI attributable to this acquisition:

(in thousands)
Cash paid at acquisition			$	34,098
Deferred cash consideration			3,628
Estimated fair value of RNCI			1,559
Post-closing net working capital adjustment			149
Total fair value of consideration transferred			$	39,434

Shown below is the final purchase price allocation, summarizing the fair values of the assets acquired and liabilities assumed at the date of acquisition:

(in thousands)
Current assets, including cash acquired of $125												$	1,407
Intangible assets:
Product technology						$	20,770
Trade name						5,802
Total intangible assets												26,572
Goodwill												17,618
Other assets												705
Liabilities:
Accounts payable and accrued liabilities						$	332
Deferred revenue						70
Deferred tax liability						6,466
Total liabilities												6,868
Net assets acquired												$	39,434

---

The goodwill recognized in connection with this acquisition is attributable to synergies that are expected to enhance and expand the Company’s overall product portfolio and opportunities in new and existing markets, future products that have yet to be determined and Kumovis’s assembled workforce. This goodwill will not be deductible for tax purposes.

Titan

On April 1, 2022, we completed the acquisition of 100% of Titan Additive LLC (“Titan”) for an all-cash purchase price of $39,040. Titan, which is part of the Industrial Solutions segment and reporting unit, is a pellet-based extrusion platform that addresses customer applications requiring large build volumes, superior performance, and improved productivity at significantly lower cost. We believe the acquisition of Titan will open up new markets in the Industrial Solutions segment.

We accounted for the acquisition of Titan using the acquisition method, as prescribed by ASC 805, and we have completed the allocation of the purchase price. Shown below is the final purchase price allocation, summarizing the fair values of the assets acquired and liabilities assumed, as determined at the date of acquisition in accordance with valuation methodologies described in ASC 820:

(in thousands)
Current assets												$	661
Intangible assets:
Product technology						$	15,940
Trade name						5,580
Total intangible assets												21,520
Goodwill												17,430
Other assets												68
Liabilities:
Accounts payable and accrued liabilities						$	229
Deferred revenue						410
Total liabilities												639
Net assets acquired												$	39,040

The goodwill recognized in connection with this acquisition is attributable to synergies that are expected to enhance and expand the Company’s overall product portfolio and opportunities in new and existing markets, future products that have yet to be determined and Titan’s assembled workforce. This goodwill is deductible for tax purposes.

Acquisitions of Non-controlling Interests

As of December 31, 2018, the Company owned approximately 70% of the capital and voting rights of Easyway, a service bureau and distributor of 3D printing and scanning products in China. The remaining 30% of the capital and voting rights of Easyway were acquired on January 21, 2019 for $13,500, which has been paid in installments. The Company made the final installment payment of $2,300 related to the acquisition of the remaining 30% interest in Easyway during the three months ended March 31, 2022.

(3) Revenue

Revenue is recognized when control of the promised products or services is transferred to customers.

Performance Obligations

At September 30, 2023, we had $62,579 of outstanding performance obligations, comprised of deferred revenue, customer order backlog and customer deposits. We expect to recognize approximately 90.0% of the $39,418 of deferred revenue and customer deposits as revenue within the next twelve months, an additional 4.0% by the end of 2024 and the remaining balance thereafter.

---

Collaboration and Licensing Agreements

We enter into collaboration and licensing agreements with third parties. The nature of the activities to be performed and the consideration exchanged under these agreements varies on a contract-by-contract basis. We evaluate these agreements to determine whether they meet the definition of a customer relationship for which revenue should be recorded. These contracts may contain multiple performance obligations and may contain fees for licensing, research and development services, contingent milestone payments upon the achievement of contractual developmental criteria and/or royalty fees based on the licensees’ product revenue. We determine the revenue to be recognized for these agreements based on an evaluation of the distinct performance obligations, the identification and evaluation of material rights, the estimation of variable consideration and the determination of the pattern of transfer of control for each distinct performance obligation. During the three and nine-month periods ended September 30, 2023, the Company recognized $7,896 and $16,099, respectively, of revenue related to collaboration arrangements with customers. During the three and nine-month periods ended September 30, 2022, the Company recognized $3,301 and $9,075, respectively, of revenue related to collaboration arrangements with customers.

Our revenue recognized under collaboration and licensing agreements for the three and nine months ended September 30, 2023 includes the effect of the Company increasing its estimate of the variable consideration included in the transaction price related to one of its licensing agreements. The increase in estimated recognizable variable consideration was due to (1) the execution of a modification to the related customer contract and (2) the Company's determination that incremental revenue attributable to milestone payments that are contingent upon the achievement of contractual developmental criteria would be earned under the modified contract. As a result, during the quarter ended September 30, 2023, the Company recognized incremental services revenue of $4,452, which reduced our reported basic and diluted loss per share by $0.03 and $0.03, respectively, for each of the three and nine months ended September 30, 2023.

Contract Balances

During the nine months ended September 30, 2023, we recognized revenue of $23,498 related to our contract liabilities at December 31, 2022. During the nine months ended September 30, 2022, we recognized revenue of $28,850 related to our contract liabilities at December 31, 2021.

Contract assets were $7,379 and $677 as of September 30, 2023 and December 31, 2022, respectively. The increase in the contract assets balance as of September 30, 2023 primarily relates to the increase in the estimated variable consideration included in the transaction price related to one of the Company's collaboration and licensing agreements (refer to the discussion above of Collaboration and Licensing Agreements), which has resulted in the recognition of incremental revenue for which the Company did not have the right to invoice as of the balance sheet date.

Revenue Concentrations

For the three and nine months ended September 30, 2023, one customer accounted for approximately 10.7% and 14.4% of our consolidated revenue, respectively. For the three and nine months ended September 30, 2022, one customer accounted for approximately 20.8% and 24.1% of our consolidated revenue, respectively. We expect to maintain our relationship with this customer.

---

Revenue by geographic region for the three and nine months ended September 30, 2023 and 2022 was as follows:

			Three Months Ended
(in thousands)			September 30, 2023						September 30, 2022
Americas			$	69,714					$	80,455
EMEA			43,141						36,913
APAC			10,936						14,885
Total			$	123,791					$	132,253
United States (included in Americas above)			$	68,840					$	78,910

			Nine Months Ended
(in thousands)			September 30, 2023						September 30, 2022
Americas			$	214,956					$	234,511
EMEA			127,150						122,788
APAC			31,115						48,000
Total			$	373,221					$	405,299
United States (included in Americas above)			$	211,717					$	231,557

(4) Inventories

Components of inventories at September 30, 2023 and December 31, 2022 are summarized as follows:

(in thousands)			September 30, 2023						December 31, 2022
Raw materials			$	61,314					$	59,907
Work in process			3,922						4,972
Finished goods and parts			87,769						72,953
Total inventories			$	153,005					$	137,832

The inventory reserve was $16,711 and $15,550 as of September 30, 2023 and December 31, 2022, respectively.

---

(5) Intangible Assets

Intangible Assets with Finite Lives

At September 30, 2023 and December 31, 2022, the Company's intangible assets with finite lives were as follows:

			September 30, 2023																		December 31, 2022
(in thousands)			Gross						Accumulated Amortization						Net						Gross						Accumulated Amortization						Net
Intangible assets with finite lives:
Customer relationships			$	51,160					$	(49,417)					$	1,743					$	51,137					$	(48,695)					$	2,442
Acquired technology			45,894						(11,925)						33,969						55,480						(10,707)						44,773
Trade names			30,496						(13,705)						16,791						35,930						(12,455)						23,475
Patent costs			18,714						(10,823)						7,891						18,673						(10,909)						7,764
Acquired patents			16,426						(14,716)						1,710						17,499						(15,661)						1,838
Other			13,170						(9,120)						4,050						13,255						(8,765)						4,490
Total intangible assets			$	175,860					$	(109,706)					$	66,154					$	191,974					$	(107,192)					$	84,782

Impairment of Intangible Assets with Finite Lives

During the quarter ended September 30, 2023, the Company concluded that it is more likely than not that it will sell or otherwise dispose of Oqton MOS, a business which the Company acquired in 2021. Oqton MOS represents a discrete asset group within the Industrial Solutions segment, as its identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities within the Industrial Solutions segment. Based upon the Company's expectation that it will sell or otherwise dispose of Oqton MOS, the long-term cash flow forecast for this asset group was revised. The revised long-term cash flow forecast indicated that the carrying amounts of Oqton MOS's long-lived assets, consisting primarily of product technology and trade name intangible assets initially recorded when Oqton MOS was acquired, may not be recoverable. Accordingly, the carrying value of Oqton MOS's long-lived assets was tested for impairment based upon an estimate of the associated discounted future cash flows. This fair value measurement approach required the use of Level 3 fair value measurement inputs, as defined in Note 19. As the present value of the estimated future cash flows expected to result from the use and eventual disposition of the asset group is less than the carrying value of the asset group, during the quarter ended September 30, 2023, the Company recognized $13,597 of impairment charges related to the acquired technology and trade names included in the Oqton MOS asset group.

Amortization of Intangible Assets with Finite Lives

Amortization expense related to our intangible assets with finite lives was $3,179 and $9,676 for the three and nine months ended September 30, 2023, respectively, compared to $4,293 and $10,273 for the three and nine months ended September 30, 2022, respectively. Amortization expense for intangible assets is estimated to be $2,085 for the remainder of 2023, $8,318 in 2024, $8,029 in 2025, $7,083 in 2026 and $6,733 in 2027.

Indefinite-Life Intangible Assets (Excluding Goodwill)

Total intangible assets reported on our September 30, 2023 and December 31, 2022 consolidated balance sheets include in-process research and development (“IPR&D”), which the Company recognized as an acquired indefinite-life intangible asset in connection with its acquisition of dp polar on October 4, 2022 (see Note 2). The carrying value of this indefinite-life intangible asset was $5,382 and $5,448 as of September 30, 2023 and December 31, 2022, respectively.

---

The following table reflects the changes in the carrying amount of goodwill by reporting unit for the nine months ended September 30, 2023:

			Nine Months Ended September 30, 2023
			Healthcare																		Industrial																		Consolidated
(in thousands)			Gross Goodwill						Impairments						Net Goodwill						Gross Goodwill						Impairments						Net Goodwill						Gross Goodwill						Impairments						Net Goodwill
Balance at beginning of year			$	143,431					$	(32,055)					$	111,376					$	316,265					$	(42,329)					$	273,936					$	459,696					$	(74,384)					$	385,312
Acquisitions and measurement period adjustments			1,005						—						1,005						7,735						—						7,735						8,740						—						8,740
Foreign currency translation adjustments			(1,175)						—						(1,175)						(1,552)						—						(1,552)						(2,727)						—						(2,727)
Balance at end of period			$	143,261					$	(32,055)					$	111,206					$	322,448					$	(42,329)					$	280,119					$	465,709					$	(74,384)					$	391,325

The effect of foreign currency exchange rates in the table above reflects the impact on goodwill of amounts recorded in currencies other than the U.S. dollar in the financial statements of foreign subsidiaries and the resulting effect of foreign currency translation between the applicable functional currency and the U.S. dollar.

---

(7) Investments and Notes Receivable

The Company holds various investments in equity and debt instruments that are included in other assets on our condensed consolidated balance sheets. The following table summarizes our investment balances as of September 30, 2023 and December 31, 2022:

(in thousands)						September 30, 2023						December 31, 2022
Equity investments under the equity method of accounting						$	5,782					$	—
Equity investments without readily determinable fair values						20,962						12,953
Other(1)						200						200
Total equity investments						$	26,944					$	13,153
Long-term note receivable(2)						$	530					$	515
Total notes receivable						$	530					$	515

(1) Reflects warrant investment carried at fair value. The fair value of these warrants is measured using Level 3 fair value measurement inputs. Refer to Note 19 for a description of these inputs.

(2) Includes interest amounts that have been accrued on, recorded to and reported as part of the notes receivable balance.

Equity Investments under the Equity Method of Accounting

Dussur

In March 2022, we and Dussur signed an agreement to form a joint venture intended to expand the use of additive manufacturing within the Kingdom of Saudi Arabia and surrounding geographies, including the Middle East and North Africa. The joint venture is to enable the development of Saudi Arabia’s domestic additive manufacturing production capabilities, consistent with the Kingdom’s ‘Vision 2030,’ which is focused on diversification of the economy and long-term sustainability. 3D Systems had committed to an initial investment in the joint venture of approximately $6,500, of which $3,435 had been deposited into an escrow account as of December 31, 2022 and, accordingly, was reported as restricted cash within other assets on the December 31, 2022 balance sheet. In February 2023, the Company officially became a shareholder in the joint venture. During April 2023, the $3,435 held in escrow, as well as the additional amount of approximately $3,065 owed to the joint venture as of March 31, 2023, was deposited into a bank account of the joint venture for use in its operations. Additional future investments in the joint venture are contingent upon the achievement of certain milestones. As of September 30, 2023, the Company owns 49% of the joint venture's common stock. The impact of this investment on the Company’s future financial condition and cash flows is expected to be limited to the cash outflow(s) related to any future contingent investments, if required.

The Company accounts for the joint venture under the equity method of accounting, which requires the Company to recognize its proportionate share of the joint venture's reported net income or loss. Due to the timing of when the joint venture's reported financial information is expected to be available, the Company records amounts required to be recognized pursuant to the equity method of accounting on a one quarter lag. For the three and nine months ended September 30, 2023, Company has recorded and separately reported a loss on equity method investment in the condensed consolidated statements of operations.

---

Equity Investments without Readily Determinable Fair Values

Theradaptive

In June 2023, we made an $8.0 million investment in Theradaptive, Inc. ("Theradaptive"), via the purchase of Series A Preferred Stock, pursuant to which we hold an approximate 9.15%, or 8.25% fully-diluted, ownership interest in Theradaptive. Theradaptive is currently developing a protein that encourages bone growth. This biotechnology could be applied to 3D printed metal splints for patients who otherwise may require amputation of a limb because the lost bone is too vast to replace with a splint. The Company expects to account for its investment in Theradaptive on a cost basis, subject to assessment for impairment, as (1) the fair value of Theradaptive's equity is not readily determinable and (2) the investment is not subject to the equity method of accounting due to the Company's lack of significant influence. The investment in Theradaptive is not expected to materially impact our future financial position, results of operations, or cash flows. No impairment charges were recognized with respect to this investment during the three or nine month periods ended September 30, 2023.

Enhatch

In March 2022, we made a $10,000 investment in convertible preferred shares for an approximate 26.6% ownership interest in Enhatch Inc. (“Enhatch”), the developer of the Intelligent Surgery Ecosystem. We simultaneously entered into a supply agreement with Enhatch. We also obtained warrants to purchase additional shares of Enhatch, as well as the right to purchase in the future (“call option”) the remaining shares of Enhatch that 3D Systems does not own if certain revenue targets are achieved. As of the original investment date, the fair values of the convertible preferred shares, inclusive of the embedded call option, and warrants were bifurcated and were $9,670 and $330, respectively. The investment, including the embedded call option and the warrants, is recorded in other assets on the consolidated balance sheets.

Enhatch’s Intelligent Surgery Ecosystem provides technologies which streamline and scale the design and delivery of patient-specific medical devices by automating the process. Incorporating these capabilities into 3D Systems’ workflow for patient-specific solutions, which includes advanced software, expert treatment planning services, custom implants and instrumentation design, and industry-leading production processes, will help more efficiently meet the growing demand for personalized medical devices.

(8) Leases

We have various lease agreements for our facilities, equipment and vehicles with remaining lease terms ranging from one to fifteen years. During the nine months ended September 30, 2023, two buildings previously under construction were completed and became available for use by the Company as leased premises. As a result, these leases were deemed to have commenced during the period. Additionally, during the nine months ended September 30, 2023, we extended material existing leases related to two buildings with office and production spaces. Rented spaces under these new and extended leases totaled 396,100 square feet. As of September 30, 2023, the aggregate remaining minimum base lease payments related to the new building leases and extended leases described above total $47,634 and consist of $1,006, $4,516, $5,093, $5,234, $5,380, and $26,405 due, respectively, during the years ended December 31, 2023, 2024, 2025, 2026, 2027 and thereafter.

Classifications of the lease amounts reported on our balance sheets as of September 30, 2023 and December 31, 2022 are summarized below:

						September 30, 2023																		December 31, 2022
(in thousands)						Right-of-use assets						Current lease liabilities						Long-term lease liabilities						Right-of-use assets						Current lease liabilities						Long-term lease liabilities
Operating leases						$	60,973					$	9,616					$	59,428					$	39,502					$	8,343					$	38,499
Finance leases						12,047						1,068						11,867						3,244						693						3,280
Total						$	73,020					$	10,684					$	71,295					$	42,746					$	9,036					$	41,779

---

(9) Accrued and Other Liabilities

Short-Term Accrued Liabilities

Accrued liabilities at September 30, 2023 and December 31, 2022 are summarized as follows:

(in thousands)			September 30, 2023						December 31, 2022
Compensation and benefits			$	15,492					$	19,814
Accrued taxes			9,633						10,694
Legal contingencies			4,850						9,948
Product warranty liability			2,409						3,677
Other accrued liabilities			11,191						11,438
Total			$	43,575					$	55,571

Changes in the product warranty obligation for the nine months ended September 30, 2023 and 2022 are summarized below:

(in thousands)						Beginning Balance						Settlements Made						Accruals for Warranties Issued						Ending Balance
September 30, 2023						$	3,677					$	(2,983)					$	1,715					$	2,409
September 30, 2022						$	3,585					$	(5,266)					$	5,257					$	3,576

Other Long-Term Liabilities

Other liabilities at September 30, 2023 and December 31, 2022 are summarized as follows:

(in thousands)			September 30, 2023						December 31, 2022
Long-term employee indemnity			$	4,634					$	4,817
Long-term tax liability			5,568						5,711
Defined benefit pension obligation			4,963						5,050
Long-term deferred revenue			1,858						4,974
Earnout liability			—						17,244
Legal contingencies			2,916						6,096
Other long-term liabilities			428						289
Total			$	20,367					$	44,181

---

(10) Borrowings

On November 16, 2021, the Company issued $460,000 in aggregate principal amount of 0% Convertible Senior Notes due November 15, 2026 (the “Notes”), pursuant to an Indenture dated November 16, 2021 (the “Indenture”) between the Company and The Bank of New York Mellon, N.A., as trustee. The net proceeds from the offering of the Notes were $446,534 after deducting the initial purchasers’ discounts and commissions and offering expenses payable by the Company in the amount of $13,466, of which $8,480 is unamortized at September 30, 2023. The annual effective interest rate of the Notes is 0.594% when including purchasers' discounts and commissions and offering expenses incurred by the Company. The Notes are senior, unsecured obligations of the Company, will not bear regular interest, and the principal amount of the Notes will not accrete. The Notes will mature on November 15, 2026, unless earlier redeemed, repurchased or converted in accordance with their terms.

The Notes will be convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding August 15, 2026, only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2022 (and only during such quarter), if the last reported sale price of the Company’s common stock, par value $0.001 per share, is equal to or greater than 130% of the conversion price for each of at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter on each applicable trading day; (2) during the five business day period after any five consecutive trading day period (the “measurement period”) in which the trading price (as defined in the Indenture) per $1 principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of the common stock and the conversion rate on each such trading day; (3) if the Company calls such Notes for redemption at any time prior to the close of business on the second scheduled trading day immediately preceding the redemption date; and (4) upon the occurrence of specified corporate events, including a Fundamental Change (as defined in the Indenture), or distributions of the common stock. On or after August 15, 2026, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their Notes at any time, at the option of the holder, regardless of the foregoing circumstances. Upon conversion, the Company will pay cash up to the aggregate principal amount of the Notes to be converted and pay or deliver, as the case may be, cash, shares of common stock, or a combination of cash and shares of common stock, at the Company’s election, in respect of the remainder, if any, of the Company’s conversion obligation in excess of the aggregate principal amount of the Notes being converted. The Notes have an initial conversion rate of 27.8364 shares of common stock per $1 principal amount of Notes (which is subject to adjustment in certain circumstances). This is equivalent to an initial conversion price of approximately $35.92 per share. The conversion rate is subject to customary adjustments under certain circumstances in accordance with the terms of the Indenture. Holders of the Notes have the right to require the Company to repurchase for cash all or a portion of their Notes at 100% of their principal amount, plus any accrued and unpaid special interest, upon the occurrence of a Fundamental Change. The Company is also required to increase the conversion rate for holders who convert their Notes in connection with a Fundamental Change or convert their Notes that are called for redemption, as the case may be, prior to the maturity date. The Company may not redeem the Notes prior to November 20, 2024. The Notes are redeemable, in whole or in part, for cash at the Company’s option at any time, and from time to time, on or after November 20, 2024 and before the 41st scheduled trading day immediately preceding the maturity date, but only if the last reported sale price per share of the common stock has been at least 130% of the conversion price then in effect for a specified period of time. As of September 30, 2023, none of the conditions that would trigger the right to convert the Notes had been met.

The Notes are the Company’s senior unsecured obligations and will rank senior in right of payment to any of the Company’s existing and future indebtedness that is expressly subordinated in right of payment to the Notes; rank equal in right of payment to any of the Company’s future unsecured indebtedness that is not so subordinated; be effectively subordinated in right of payment to any of the Company’s existing and future secured indebtedness to the extent of the value of the collateral securing such indebtedness; and structurally subordinated to all existing and future indebtedness and other liabilities (including trade payables) of current or future subsidiaries of the Company. The Indenture also contains covenants, events of default and other provisions which are customary for offerings of convertible notes. We are in compliance with all covenants as of September 30, 2023. At September 30, 2023, the fair value of the Notes is $331,297. This is based on the quoted market price where the volume of activity is limited and not active and, thus, this is deemed a Level 2 fair value measurement.

The Company incurred $671 and $2,010 of debt issuance cost accretion for the three and nine months ended September 30, 2023, respectively, as compared to $670 and $2,006 for the three and nine months ended September 30, 2022, respectively. Debt issuance cost accretion of $673, $2,698, $2,714, and $2,395 is expected to be incurred in the remaining three months of 2023 and in 2024, 2025 and 2026, respectively.

---

(11) Redeemable Non-Controlling Interest

Upon consummation of the Company's acquisition of Kumovis, existing shareholders of Kumovis retained a 6.25% ownership interest in Kumovis that the Company reports as RNCI due to put and call terms that could result in the Company redeeming this remaining ownership interest at a future date (see Note 2). The following table shows changes in the reported RNCI balance during the nine months ended September 30, 2023:

						Nine Months Ended September 30, 2023
(in thousands)
Balance at December 31, 2022						$	1,760
Net loss						(149)
Redemption value in excess of carrying value						321
Translation adjustments						(4)
Balance at September 30, 2023						$	1,928

The following table shows changes in the reported RNCI balance during the nine months ended September 30, 2022:

						Nine Months Ended September 30, 2022
(in thousands)
Balance at December 31, 2021						$	—
Fair value at the date of acquisition						1,559
Net Loss						(184)
Redemption value in excess of carrying value						462
Translation Adjustments						(183)
Balance at September 30, 2022						$	1,654

(12) Stock-Based Compensation

Stock Incentive Plans

2015 Incentive Plan

The Company is authorized to grant shares of restricted stock, restricted stock units (“RSUs”), stock appreciation rights, cash incentive awards and options to purchase shares of Common Stock to employees and non-employees inclusive of directors pursuant to its 2015 Incentive Plan (the “2015 Plan”). The 2015 Plan also designates measures that may be used for performance-based awards and market-based awards. The vesting period for awards granted under the 2015 Plan is generally determined by the Board of Directors at the date of the grant. Generally, the awards vest one third each year, over 3 years.

Systemic Bio Phantom Unit Plan

During the three months ended September 30, 2023, we began granting phantom unit awards ("Phantom Units") under a new compensation plan designed for employees and non-employees performing services for Systemic Bio, a wholly-owned subsidiary of 3D Systems Corporation. All awards granted under the plan are subsidiary-level awards.

---

The Phantom Units granted under the plan include both a time-based vesting condition (generally 4 years, subject to acceleration in connection with specified liquidity events) and a market condition that is met if (1) the value of Systemic Bio exceeds a specified multiple of the capital invested in this subsidiary (the "hurdle") and (2) the business achieves a specified minimum internal rate of return. The market condition will be assessed upon (A) a trigger event (e.g., change-in-control, IPO, or plan expiration of December 31, 2030) and/or (B) an interim liquidity event (defined as January 1, 2028) that occurs prior to a trigger event. All awards granted under the plan will be liability-classified due to our intention to settle these awards with cash; although, we have discretion to partially or fully settle these awards in equity upon vesting. Liability classification of the awards requires them to be remeasured at their fair value at the end of each reporting period. Due to the presence of the market-condition and the fact that Systemic Bio does not have a readily available share price, the awards are valued using a Monte Carlo simulation with the assistance of a third party valuation firm.

Other Compensation Arrangements that Include Share Settlement

Regenerative Medicine Earnout Payments and Performance-Based Stock Units

On December 1, 2021, the Company acquired Volumetric. Pursuant to the terms of the related acquisition agreement, the Company may be required to pay milestone-based payments of up to $355,000 in the aggregate, all of which are incremental to the acquisition purchase price, upon (1) the achievement of seven discrete non-financial milestones that require attainment prior to either December 31, 2030 or December 31, 2035 and (2) the continued employment of certain key individuals from Volumetric. Each potential milestone-based payment is considered compensation expense, which the Company will recognize ratably from the point in time when a milestone is deemed probable of achievement through the estimated date of achievement. Each milestone payment will be settled approximately half in cash and half in shares of the Company’s Common Stock and, accordingly, the portion of the Company’s accrued liability (see Note 9) that is ultimately expected to be settled with the Company’s common stock is reflected in the disclosure of stock-based compensation included herein.

In addition, the Company has granted performance-based stock units (“PSUs”), with vesting terms that are based upon four individually-measured, non-financial milestones, to other employees who work on advancements in regenerative medicine related to lungs and tissue organs. The PSUs associated with each individual milestone are recognized as compensation expense over the period commencing on the date that the respective milestone is deemed probable of being met through the anticipated date of achievement.

Prior to the quarter ended September 30, 2023, the Company recognized compensation expense related to (1) one Volumetric milestone-based payment, for which the potential amount due to the sellers would be $65,000, and (2) one PSU milestone (“the RegMed Awards”), for which the aggregate grant date fair value of the outstanding and unvested awards was $4,773 as of June 30, 2023, as the related milestone was deemed probable of achievement. During the quarter ended June 30, 2023, as a result of the Company's decision to reduce budgeted funding related to the research and development efforts required to achieve the milestone, the estimated timing for achievement of both the Volumetric milestone and the PSU milestone shifted from the end of fiscal year 2025 to the end of fiscal year 2026. During the quarter ended September 30, 2023, the Company decided to further reduce its budgeted funding for the research and development related to the Volumetric Earnout and RegMed Award milestone, which resulted in the Company concluding that it is no longer probable that the milestone will be achieved by the end of the term of the Volumetric Earnout arrangement or prior to the expiration of the RegMed Awards. In concluding that the Volumetric and RegMed Award milestone would no longer be achieved, the Company reversed all of the previously accrued compensation expense, one half of which was expected to be settled with common shares, which had an income statement impact of $21,527 and $18,392 for the three and nine-months ended September 30, 2023, respectively. The reversals of the previously expensed Volumetric Earnout and RegMed Award reduced our reported net loss per basic and diluted share of common stock by $0.17 and $0.14 for the three and nine months ended September 30, 2023, respectively.

dp polar Earnout

On October 4, 2022, the Company acquired dp polar. Pursuant to the terms of the related acquisition agreement, the Company may be required to pay an additional $2,229, incremental to the acquisition purchase price, which will be settled via the issuance of 250 shares of the Company’s Common Stock. The issuance and vesting of these shares is contingent on the continued service of a certain key individual from dp polar through October 4, 2024. Upon assessment, management concluded that this potential obligation for the payment of an additional 250 shares of Common Stock will be accounted for as compensation expense recognized over the required service period of the individual to whom the amount will potentially be paid and, accordingly, the related expense is reflected in the disclosure of stock-based compensation included herein. During the nine months ended September 30, 2023, we modified the service period of this arrangement to end on December 31, 2024. The impact of this modification on stock-based compensation expense is immaterial.

---

Stock-Based Compensation Activity and Expense

2015 Incentive Plan

During the three and nine months ended September 30, 2023, the Company granted 111 and 3,990 shares of restricted stock, respectively, which had a weighted-average grant date fair value of $8.11 and $10.95 per share, respectively. The restricted stock awards generally vest ratably over three years, except for those awards that the Company granted to settle a portion of its accrued annual bonus liability at December 31, 2022, which were fully vested immediately upon issuance.

The restricted stock granted during the nine months ended September 30, 2023 included 681 shares of market-based awards, whereby the number of shares that ultimately vest will be based upon the three-year performance of the Company's share price as compared to an index. These awards were valued using a Monte Carlo simulation, and the grant date fair value was $18.91 per share.

The following table shows the stock-based compensation expense recognized during the three and nine months ended September 30, 2023 and 2022:

						Three Months Ended September 30,												Nine Months Ended September 30,
(in thousands)						2023						2022						2023						2022
Stock-based compensation expense						$	(3,142)					$	11,447					$	15,140					$	31,508
Tax benefit						$	—					$	—					$	—					$	—

Included in stock-based compensation expense recognized for the three and nine months ended September 30, 2023 are $(1,055) and $0, respectively, and $1,282 and $3,123 for the three and nine months ended September 30, 2022, respectively, of accrued expense pertaining to annual bonus incentive compensation for which settlement is ultimately expected to occur using shares of the Company’s Common Stock. Also included in stock-based compensation expense are $(10,140) and $(8,640) for the three and nine months ended September 30, 2023, respectively, and $1,989 and $5,969 for the three and nine months ended September 30, 2022, respectively, which relate to the portion of the Volumetric Earnout expense reversed or recognized during each period that is expected to be settled using the Company’s Common Stock. Further, stock-based compensation expense for the three and nine months ended September 30, 2023 includes $175 and $727, respectively, of expense related to the dp polar earnout arrangement. Finally, stock-based compensation expense includes $(1,246) and $(1,113) for the three and nine months ended September 30, 2023, respectively, and $254 and $746 for the three and nine months ended September 30, 2022, respectively, of expense related to the RegMed awards.

As of September 30, 2023, there was $52,508 of unrecognized stock-based compensation expense related to all unvested share-based payment awards that the Company expects to recognize over a weighted-average period of 2.0 years.

Systemic Bio Phantom Unit Plan

During the three months ended September 30, 2023, we granted 589 units under the Systemic Bio Phantom Unit Plan, all of which remained outstanding as of September 30, 2023. Compensation expense attributable to these awards is being recognized over 40.5 months or 48 months, based upon the recipient. As the awards include graded, time-based vesting and a market condition, compensation expense is being recognized under the graded vesting (accelerated attribution) method. Compensation expense and the associated liability recognized during the three months ended September 30, 2023 were $183.

---

(13) Interest and Other Income (Expense), Net

Interest and other income (expense), net consisted of the following amounts for the three and nine months ended September 30, 2023 and 2022:

						Three Months Ended												Nine Months Ended
(in thousands)						September 30, 2023						September 30, 2022						September 30, 2023						September 30, 2022
Interest and other income (expense), net
Foreign exchange (loss), net						$	(2,202)					$	(764)					$	(3,847)					$	(4,193)
Interest income, net						4,909						2,029						13,118						4,019
Other (expense) income, net						(105)						(4,767)						420						(5,282)
Total interest and other income (expense), net						$	2,602					$	(3,502)					$	9,691					$	(5,456)

Interest and other income (expense), net includes (1) interest income of $5,841 and $15,730 for the three and nine months ended September 30, 2023, respectively, and $2,753 and $6,103 for the three and nine months ended September 30, 2022, respectively, and (2) interest expense of $932 and $2,612 for the three and nine months ended September 30, 2023 respectively, and $724 and $2,084 for the three and nine months ended September 30, 2022, respectively.

(14) Income Taxes

We maintain the exception under ASC 740-270-30-36(b), “Accounting for Income Taxes,” for jurisdictions that do not have reliable estimates of ordinary income. Based on volatility in the industry, we have continued to use a year-to-date methodology in determining the effective tax rate for the three and nine months ended September 30, 2023.

For the three and nine months ended September 30, 2023, the Company’s effective tax rate was (1.6)% and (0.6)%, respectively. For the three and nine months ended September 30, 2022, the Company’s effective tax rate was (0.9)% and (3.1)%, respectively. The differences between the U.S. statutory tax rate and the effective tax rates for the three and nine months ended September 30, 2023 and September 30, 2022 are primarily driven by a full valuation allowance in various jurisdictions.

---

(15) Net Earnings (Loss) Per Share

Basic net income (loss) per share is calculated by dividing net income (loss) attributable to 3D Systems’ Common Stock shareholders by the weighted average number of Common Stock shares outstanding during the applicable period. Diluted net income (loss) per share incorporates the additional shares issuable upon the assumed exercise of stock options, the vesting of restricted stock and RSUs, and the assumed conversion of debt, except in such cases when (1) the inclusion of such shares or potential shares would be anti-dilutive or (2) when the vesting of restricted stock or RSUs is contingent upon one or more performance conditions that have not been met as of the balance sheet date.

			Three Months Ended												Nine Months Ended
(in thousands, except per share amounts)			September 30, 2023						September 30, 2022						September 30, 2023						September 30, 2022
Numerator for basic and diluted net (loss) income per share:
Net (loss) income attributable to 3D Systems Corporation			$	(11,704)					$	(37,398)					$	(70,020)					$	(97,158)
Redeemable non-controlling interest redemption value in excess of carrying value			(61)						(462)						(321)						(462)
Net (loss) income attributable to common stock shareholders			$	(11,765)					$	(37,860)					$	(70,341)					$	(97,620)
Denominator for net (loss) income per share:
Weighted average shares – basic and diluted(1)			130,263						127,991						129,780						127,478
Net income (loss) per share – basic and diluted			$	(0.09)					$	(0.30)					$	(0.54)					$	(0.77)

(1) Equity awards are deemed anti-dilutive for the three and nine month periods ended September 30, 2023 and 2022 because we reported a net loss for these periods.

The following table presents the potentially dilutive shares that have been excluded from the computation of diluted earnings (loss) per share attributable to Common Stock shareholders because their effect is considered anti-dilutive for the three and nine months ended September 30, 2023 and 2022:

			Three and Nine Months Ended
(in thousands)			September 30, 2023						September 30, 2022
Restricted stock and restricted stock units			6,653						5,030
Stock options			420						420
Total			7,073						5,450

For the three and nine months ended September 30, 2023, the table above excludes an estimate of 110 shares that are contingently issuable under the dp polar earnout arrangement, as discussed in Note 12. As of September 30, 2023, there are no contingently issuable shares related to the Volumetric Earnout arrangement or the fiscal year 2023 annual bonus incentive compensation plan.

For the three and nine months ended September 30, 2022, the table above excludes the following: (1) an estimate of 506 shares contingently issuable to settle the September 30, 2022 liability accrued for the assumed achievement of one milestone in the Volumetric Earnout arrangement, as discussed in Note 12, and (2) an estimate of 233 shares for the payment of the portion of the fiscal year 2022 annual bonus incentive compensation that was accrued as of September 30, 2022 and expected to be settled in shares. These share estimates are based upon the aggregate liabilities reported at September 30, 2022 for the Volumetric Earnout arrangement and a ratable portion of the fiscal year 2022 annual bonus incentive compensation that was settled using shares of the Company's Common Stock in the quarter ended June 30, 2023, divided by the Company's year-to-date average share price of $13.11 per share.

---

(16) Accumulated Other Comprehensive Loss

For the three and nine months ended September 30, 2023 and 2022, the changes in the balances of accumulated other comprehensive loss by component are as follows:

			Three Months Ended September 30, 2023
(in thousands)			Foreign currency translation adjustment						Defined benefit pension plan												Unrealized loss on short-term investments						Total
Balance at June 30, 2023			$	(50,069)					$	689											$	—					$	(49,380)
Other comprehensive income (loss)			(7,352)						(20)												—						(7,372)
Amounts reclassified from accumulated other comprehensive income (loss)			—						(11)												—						(11)
Balance at September 30, 2023			$	(57,421)					$	658											$	—					$	(56,763)
			Nine Months Ended September 30, 2023
(in thousands)			Foreign currency translation adjustment						Defined benefit pension plan												Unrealized loss on short-term investments						Total
Balance at December 31, 2022			$	(54,194)					$	700											$	(328)					$	(53,822)
Other comprehensive income (loss)			(3,227)						(8)												108						(3,127)
Amounts reclassified from accumulated other comprehensive income (loss) (a)			—						(34)												220						186
Balance at September 30, 2023			$	(57,421)					$	658											$	—					$	(56,763)
			Three Months Ended September 30, 2022
(in thousands)			Foreign currency translation adjustment						Defined benefit pension plan												Unrealized loss on short-term investments						Total
Balance at June 30, 2022			$	(55,196)					$	(1,976)											$	(4,023)					$	(61,195)
Other comprehensive income (loss)			(22,135)						164												(32)						(22,003)
Amounts reclassified from accumulated other comprehensive income (loss) (a)			—						(8)												2,402						2,394
Balance at September 30, 2022			$	(77,331)					$	(1,820)											$	(1,653)					$	(80,804)
			Nine Months Ended September 30, 2022
(in thousands)			Foreign currency translation adjustment						Defined benefit pension plan												Unrealized loss on short-term investments						Total
Balance at December 31, 2021			$	(35,464)					$	(2,242)											$	—					$	(37,706)
Other comprehensive income (loss)			(41,867)						311												(4,055)						(45,611)
Amounts reclassified from accumulated other comprehensive income (loss) (a)			—						111												2,402						2,513
Balance at September 30, 2022			$	(77,331)					$	(1,820)											$	(1,653)					$	(80,804)

---

(17) Segment Information

The Company’s operations are comprised of two reportable segments: Healthcare Solutions and Industrial Solutions. Effective as of January 1, 2023, and for periods subsequent thereto, Adjusted EBITDA reflects the measure of profitability used by the Company’s chief operating decision maker (“CODM”) to evaluate the performance of the Company’s reportable segments. In addition, as of January 1, 2023, the Company's methodology for allocating certain costs between its segments was revised to more closely reflect changes in the Company's business and estimates of the usage of shared resources by the Company's segments. Prior year amounts have been reclassified to conform with current year presentation in connection with the changes referenced above. The following tables set forth our operating results by segment for the three and nine months ended September 30, 2023 and 2022:

			Revenue												Adjusted EBITDA
			Three Months Ended September 30,												Three Months Ended September 30,
(in thousands)			2023						2022						2023						2022
Healthcare Solutions			$	52,429					$	64,203					$	13,869					$	13,787
Industrial Solutions			71,362						68,050						7,662						7,180
Total Reportable segments			123,791						132,253						21,531						20,967
Corporate and Other(1)			—						—						(16,805)						(21,288)
Total Company			$	123,791					$	132,253					$	4,726					$	(321)

			Revenue												Adjusted EBITDA
			Nine Months Ended September 30,												Nine Months Ended September 30,
(in thousands)			2023						2022						2023						2022
Healthcare Solutions			$	162,028					$	200,294					$	30,328					$	45,705
Industrial Solutions			211,193						205,005						16,828						16,473
Total Reportable segments			373,221						405,299						47,156						62,178
Corporate and Other(1)			—						—						(59,422)						(63,155)
Total Company			$	373,221					$	405,299					$	(12,266)					$	(977)

(1) Corporate and Other is not an operating segment, but reflects expenses not directly attributable to and, accordingly, not allocated to our reportable segments. These expenses relate to corporate functions such as human resources, finance, and legal and include expenses such as salaries, benefits, and other related costs. Similar to the Company's operating segments, Corporate results are reported to and reviewed by the Company’s CODM on the basis of Adjusted EBITDA.

---

(18) Commitments and Contingencies

Indemnification

In the normal course of business, we periodically enter into agreements to indemnify customers or suppliers against claims of intellectual property infringement that may be made by third parties and arise from the use of our products. Historically, costs related to these indemnification provisions have not been significant, and we are unable to estimate the maximum potential impact of these indemnification provisions on our future results of operations.

To the extent permitted under Delaware law, we indemnify our directors and officers for certain events or occurrences, when the director or officer is, or was, serving at our request in such capacity, subject to limited exceptions. The maximum potential amount of future payments we could be required to make under these indemnification obligations is unlimited; however, we have directors and officers insurance coverage that may enable us to recover future amounts paid, subject to a deductible and the policy limits. There is no assurance that the policy limits will be sufficient to cover all damages, if any.

Other Commitments

Government Settlement

As previously disclosed, beginning in October 2017, the Company undertook an internal investigation relating to possible violations of U.S. export control laws, including the International Traffic in Arms Regulations administered by the Directorate of Defense Trade Controls of the Department of State (“DDTC”) and the Export Administration Regulations administered by the Bureau of Industry and Security of the Department of Commerce (“BIS”). In February 2023, the Company settled these matters with the U.S. Department of Justice (“DOJ”), DDTC and BIS. As a part of these settlement agreements, the Company agreed to pay $15,048 in civil monetary penalties to these agencies, with an additional $10,000 in suspended penalty amounts to be allocated to remedial compliance measures required by DDTC. The penalty amounts were broken down as follows: DDTC, $10,000 (in three installments over a three-year period); BIS, $2,778; and DOJ, $2,270. The first penalty installment payment to DDTC and the full penalty payments to BIS and to DOJ were made in the first quarter of 2023. The $10,000 suspended penalty has not been recognized as a liability as of September 30, 2023 and will be recognized as incurred during the three-year term of the settlement agreement and any portion not expended at the end of the three-year term of the settlement agreement will be paid by the Company to DDTC.

---

Litigation

Shareholder Suits

The Company and certain of its current and former executive officers have been named as defendants in a consolidated putative stockholder class action lawsuit pending in the United States District Court for the Eastern District of New York (the “District Court”). The action is styled In re 3D Systems Securities Litigation, No. 1:21-cv-01920-NGG-TAM (E.D.N.Y.) (the “Securities Class Action”). On July 14, 2021, the Court appointed a Lead Plaintiff for the putative class and approved his choice of Lead Counsel. Lead Plaintiff filed his Consolidated Amended Complaint (the “Amended Complaint”) on September 13, 2021, alleging that defendants violated the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and SEC Rule 10b-5 promulgated thereunder by making false and misleading statements and omissions, and that the current and former executive officers named as defendants are control persons under Section 20(a) of the Exchange Act. The Amended Complaint was filed on behalf of stockholders who purchased shares of the Company’s Common Stock between May 6, 2020 and March 5, 2021, and seeks monetary damages on behalf of the purported class. Defendant moved to dismiss the Amended Complaint on February 15, 2022, and the motion was fully briefed in May 2022. On October 28, 2022, the parties notified the District Court that they reached an agreement in principle resolving this action, and on December 19, 2022, Lead Plaintiff filed a motion seeking entry of an order preliminarily approving the settlement and establishing notice procedures. The settlement is subject to both preliminary and final approval by the District Court. On June 5, 2023, following the District Court’s referral of Lead Plaintiff’s motion to a Magistrate Judge for a Report and Recommendation on the motion, the Magistrate Judge issued a Report and Recommendation recommending that the District Court grant Lead Plaintiff’s motion for preliminary approval of the settlement. The District Court adopted the Report and Recommendation and preliminarily approved the settlement on July 19, 2023. A final hearing on the settlement is scheduled for November 21, 2023. The settlement is subject to both preliminary and final approval by the District Court. On April 15, 2022, the Company was informed that the SEC is conducting a formal investigation of the Company related to, among other things, the allegations in the Securities Class Action, and the Company received subpoenas from the SEC for the production of documents and information related to its investigation as a follow on to a previous voluntary request for documents. The Company is cooperating with the SEC.

The Company has been named as a nominal defendant and certain of its current and former executive officers and directors have been named as defendants in derivative lawsuits pending in the United States District Court for the Eastern District of New York, the South Carolina Court of Common Pleas for the 16th Circuit, York County, and the Supreme Court of the State of New York, Kings County. The actions are styled Nguyen v. Joshi, et al., No. 21-cv-03389-NGG-TAM (E.D.N.Y.) (the “Nguyen Action”), Lesar v. Graves, et al., No. 2021CP4602308 (S.C., Ct. of Common Pleas for the 16th Judicial Cir., Cty. of York) (the “Lesar Action”), Scanlon v. Graves, et al., No. 2021CP4602312 (S.C., Ct. of Common Pleas for the 16th Judicial Cir., Cty. of York) (the “Scanlon Action”), Bohus v. Joshi, et al., No. 22-cv-2203-CBA-RML (E.D.N.Y.) (the “Bohus Action”), and Fernicola v. Clinton, et. al., No. 512613/2022 (N.Y., Kings County Supreme Court) (the “Fernicola Action”). The Complaints in the Nguyen and Bohus Actions, which were filed on June 15, 2021 and April 18, 2022, respectively, assert breach of fiduciary duty claims against all defendants and claims for contribution under the federal securities laws against certain of the defendants. The Complaints in the Lesar and Scanlon Actions, which were filed on July 26, 2021, assert breach of fiduciary duty and unjust enrichment claims against the defendants. The Complaint in the Fernicola Action was filed on May 2, 2022, and asserts claims for breach of fiduciary duty and waste of corporate assets against the director defendants. On August 27, 2021, the Nguyen Action was stayed until 30 days after the earlier of: (i) the close of discovery in the Securities Class Action, or (ii) the deadline for appealing a dismissal of the Securities Class Action with prejudice. On October 26, 2021, the Lesar Action and the Scanlon Action were consolidated into a single stockholder derivative action, styled as In Re 3D Systems Corp. Shareholder Derivative Litigation, No. 2021CP4602308 (S.C., Ct. of Common Pleas for the 16th Judicial Cir., Cty. Of York) (the “South Carolina Derivative Action”). On March 3, 2022, the South Carolina Derivative Action was stayed until 30 days after the earlier of: (i) the close of discovery in the Securities Class Action, or (ii) the deadline for appealing a dismissal of the Securities Class Action with prejudice. On June 16, 2022, the Bohus Action was consolidated with the Nguyen Action (the “E.D.N.Y. Derivative Action”). The E.D.N.Y. Derivative Action is stayed until 30 days after the earlier of: (i) the close of discovery in the Securities Class Action, or (ii) the deadline for appealing a dismissal of the Securities Class Action with prejudice. On August 15, 2022, the Fernicola Action was voluntarily dismissed without prejudice.

The Company believes the claims alleged in the putative securities class action and derivative lawsuits are without merit and the Company intends to defend itself and its current and former officers vigorously.

---

Letter of Credit

On June 2, 2023, we issued $1,161 of guarantees in the form of a standby letter of credit as security for a long-term real estate lease. The letter of credit has an initial maturity date of June 2024 with automatic one-year extensions not beyond July 1, 2033. We have not recorded any liability for this guarantee as we believe the likelihood of having to perform under the letter of credit is remote. In connection with this transaction, we pledged an equal amount of cash to the issuing bank of this letter of credit. The cash pledged is recorded as restricted cash, included in other assets on our condensed consolidated balance sheets.

Other

We are involved in various other legal matters incidental to our business. Although we cannot predict the results of the litigation with certainty, we believe that the disposition of all of these various other legal matters will not have a material adverse effect, individually or in the aggregate, on our consolidated results of operations, consolidated cash flows or consolidated financial position.

In connection with the foregoing matters, we recognized a liability of $16,044 during the year ended December 31, 2022, which includes the $10,000 DDTC civil monetary penalty being recognized at a discount using the risk-free interest rate in effect at the time of recognition. During the nine months ended September 30, 2023, we have paid $8,548 of this liability in accordance with the settlement agreements discussed above. Refer to Note 9 for details regarding our remaining short-term and long-term liabilities recorded for legal contingencies.

(19) Fair Value Measurements

Fair value is the exchange price to sell an asset or transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. Fair value measurements use market data or assumptions market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs may be readily observable, corroborated by market data, or generally unobservable. Valuation techniques maximize the use of observable inputs and minimize use of unobservable inputs. The accounting guidance for fair value measurements and disclosures establishes a three-level fair value hierarchy:

•Level 1 - Inputs are based on quoted prices in active markets for identical assets and liabilities.

•Level 2 - Inputs are based on observable inputs other than quoted prices in active markets for identical or similar assets and liabilities.

•Level 3 - One or more inputs are unobservable and significant.

Financial and nonfinancial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

Cash equivalents are valued utilizing the market approach to measure fair value for financial assets and liabilities. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. The carrying amounts of our cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities approximate fair value as of September 30, 2023 and December 31, 2022 because of the relatively short duration of these instruments.

We did not have any transfers of assets or liabilities between Level 1, Level 2 and Level 3 of the fair value measurement hierarchy during the three and nine months ended September 30, 2023.

---

Assets measured at fair value on a recurring basis as of December 31, 2022 are summarized below. During the three months ended September 30, 2023, we sold all of our remaining Level 2 short-term investments included in the table below.

			Fair Value Measurement as of December 31, 2022
			Fair Value Measurement																								Balance Sheet Classification
(in thousands)			Fair Value Level						Cost Basis						Unrealized Gains (Losses)						Fair Value						Cash and Cash Equivalents						Short-term Investments
Money market funds			Level 1						$	232,018					$	—					$	232,018					$	232,018					$	—
Certificates of deposit			Level 2						990						6						996						—						996
Commercial paper			Level 2						1,281						6						1,287						—						1,287
Short-term bond mutual funds			Level 2						100,242						(99)						100,143						—						100,143
Corporate bonds(a)			Level 2						78,418						(241)						78,177						—						78,177
Total									$	412,949					$	(328)					$	412,621					$	232,018					$	180,603

(a) Includes $745 and $743 of cost basis and fair market value, respectively, with a weighted average maturity of 1.3 years.

(20) Restructuring

During the three months ended June 30, 2023, the Company announced a restructuring initiative intended to improve internal operating efficiencies, as well as long-term valuation creation. Actions taken by the Company primarily consisted of a reduction in headcount of approximately 6% of the Company's workforce, with the majority of the workforce reduction occurring in corporate and business support functions predominately located in the US and Europe. Since initiating the plan, the Company has accrued severance and termination costs totaling $3,724, which have been reported within selling, general, and administrative expense on the Company's condensed consolidated statement of operations and reflect the total costs expected to be incurred in connection with this activity. As the reduction in workforce was concentrated within corporate and business support functions, the reported results of the Company's Healthcare Solutions and Industrial Solutions segments were not impacted by this restructuring initiative. The settlement of all costs accrued in connection with this restructuring initiative is expected to occur prior to the end of the year ending December 31, 2023. The following table provides additional details regarding the restructuring costs incurred during the period, the portion of such costs that were settled with cash as of September 30, 2023, and the remaining accrued liability reported in our condensed consolidated balance sheet as of September 30, 2023:

(in thousands)						Accrued liability as of December 31, 2022						Costs incurred during 2023												Amounts settled with cash						Accrued liability as of September 30, 2023
Severance, termination benefits and other employee costs						$	—					$	3,724											$	2,693					$	1,031
Total						$	—					$	3,724											$	2,693					$	1,031

In addition to the recognition of severance and termination costs, the Company recognized an impairment charge of $628 related to certain fixed assets that were retired.

---

(21) Subsequent Events

On October 25, 2023, the Company announced the next evolution of its restructuring initiative designed to improve operating efficiencies throughout the organization and drive long-term value creation. This additional phase of the restructuring initiative will target to deliver expected annualized savings of between $45 million and $55 million by the end of 2024, with the majority of the cost takeout to occur by the end of the first quarter of 2024. This initiative is primarily targeted at continuing to rationalize headcount and geographic locations in all functions across the Company. As this latest phase of the Company's multi-faceted restructuring initiative contemplates the execution of new strategic actions that may be taken with respect to certain of the Company’s previously acquired businesses and/or other asset groups, certain asset groups could become subject to impairment tests triggered by (1) an adverse change in the extent or manner in which the long-lived asset (or asset group) is being used, (2) a current expectation that it is more likely than not that the long-lived asset (or asset group) will be sold or otherwise disposed of significantly before the end of its previously estimated useful life, or (3) other factors triggered by the Company's restructuring initiative. If required, a quantitative impairment test related to any of our asset groups could result in the recognition of a material impairment charge.

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

v3.23.3

Cover Page - shares	9 Months Ended
	Sep. 30, 2023	Nov. 06, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-34220
Entity Registrant Name	3D SYSTEMS CORPORATION
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	95-4431352
Entity Address, Address Line One	333 Three D Systems Circle
Entity Address, City or Town	Rock Hill
Entity Address, State or Province	SC
Entity Address, Postal Zip Code	29730
City Area Code	803
Local Phone Number	326-3900
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	DDD
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		133,434,049
Amendment Flag	false
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity Central Index Key	0000910638

v3.23.3

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 445,554	$ 388,134
Short-term investments	0	180,603
Accounts receivable, net of reserves — $3,315 and $3,114	104,516	93,886
Inventories	153,005	137,832
Prepaid expenses and other current assets	36,638	33,790
Total current assets	739,713	834,245
Property and equipment, net	63,535	58,072
Intangible assets, net	71,536	90,230
Goodwill	391,325	385,312
Right-of-use assets	73,020	42,746
Deferred income tax asset	7,042	7,038
Other assets	46,583	28,970
Total assets	1,392,754	1,446,613
Current liabilities:
Current lease liabilities	10,684	9,036
Accounts payable	46,108	53,826
Accrued and other liabilities	43,575	55,571
Customer deposits	6,793	6,911
Deferred revenue	30,768	26,464
Total current liabilities	137,928	151,808
Long-term debt, net of deferred financing costs	451,520	449,510
Long-term lease liabilities	71,295	41,779
Deferred income tax liability	10,178	7,631
Other liabilities	20,367	44,181
Total liabilities	691,288	694,909
Commitments and contingencies (Note 18)
Redeemable non-controlling interest	1,928	1,760
Stockholders’ equity:
Common stock, $0.001 par value, authorized 220,000 shares; shares issued 133,575 and 131,207 as of September 30, 2023 and December 31, 2022, respectively	133	131
Additional paid-in capital	1,570,150	1,547,597
Accumulated deficit	(813,982)	(743,962)
Accumulated other comprehensive loss	(56,763)	(53,822)
Total stockholders’ equity	699,538	749,944
Total liabilities, redeemable non-controlling interest and stockholders’ equity	$ 1,392,754	$ 1,446,613

v3.23.3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Accounts receivable, reserves	$ 3,315	$ 3,114
Stockholders’ equity:
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	220,000,000	220,000,000
Common stock, shares issued (in shares)	133,575,000	131,207,000

v3.23.3

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue:
Total revenue	$ 123,791	$ 132,253	$ 373,221	$ 405,299
Cost of sales:
Total cost of sales	68,441	79,583	220,757	245,696
Gross profit	55,350	52,670	152,464	159,603
Operating expenses:
Selling, general and administrative	33,355	65,579	150,623	185,398
Research and development	21,982	20,796	66,953	63,180
Impairment of intangible assets	13,597	0	13,597	0
Total operating expenses	68,934	86,375	231,173	248,578
Loss from operations	(13,584)	(33,705)	(78,709)	(88,975)
Interest and other income (expense), net	2,602	(3,502)	9,691	(5,456)
(Loss) income before income taxes	(10,982)	(37,207)	(69,018)	(94,431)
(Provision) benefit for income taxes	(174)	(338)	(404)	(2,911)
(Loss) on equity method investment, net of income taxes	(605)	0	(747)	0
Net (loss) income before redeemable non-controlling interest	(11,761)	(37,545)	(70,169)	(97,342)
Less: net (loss) income attributable to redeemable non-controlling interest	(57)	(147)	(149)	(184)
Net (loss) income attributable to 3D Systems Corporation	$ (11,704)	$ (37,398)	$ (70,020)	$ (97,158)
Net (loss) income per common share:
Basic (in dollars per share)	$ (0.09)	$ (0.30)	$ (0.54)	$ (0.77)
Diluted (in dollars per share)	$ (0.09)	$ (0.30)	$ (0.54)	$ (0.77)
Weighted average shares outstanding:
Basic (in shares)	130,263	127,991	129,780	127,478
Diluted (in shares)	130,263	127,991	129,780	127,478
Products
Revenue:
Total revenue	$ 80,415	$ 96,337	$ 253,968	$ 300,662
Cost of sales:
Total cost of sales	47,427	58,042	153,442	181,845
Services
Revenue:
Total revenue	43,376	35,916	119,253	104,637
Cost of sales:
Total cost of sales	$ 21,014	$ 21,541	$ 67,315	$ 63,851

v3.23.3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Statement of Comprehensive Income [Abstract]
Net (loss) income before redeemable non-controlling interest	$ (11,761)	$ (37,545)	$ (70,169)	$ (97,342)
Other comprehensive (loss) income, net of taxes:
Pension plan adjustments	(31)	156	(42)	422
Foreign currency translation	(7,352)	(22,135)	(3,227)	(41,867)
Unrealized gain (loss) on short-term investments	0	2,370	328	(1,653)
Total other comprehensive (loss) income, net of taxes:	(7,383)	(19,609)	(2,941)	(43,098)
Total comprehensive (loss), net of taxes	(19,144)	(57,154)	(73,110)	(140,440)
Less: comprehensive (loss) attributable to redeemable non-controlling interest	(57)	(147)	(149)	(184)
Comprehensive (loss) attributable to 3D Systems Corporation	$ (19,087)	$ (57,301)	$ (72,961)	$ (140,624)

v3.23.3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands		9 Months Ended
		Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net (loss) income before redeemable non-controlling interest		$ (70,169)	$ (97,342)
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation, amortization and accretion of debt discount		27,054	28,264
Stock-based compensation		15,140	31,508
Loss on short-term investments		6	2,609
Non-cash operating lease expense		6,552	4,796
Provision for inventory obsolescence and revaluation		6,061	646
Provision for bad debts		197	329
Loss (gain) on the disposition of businesses, property, equipment and other assets		51	(365)
Provision for deferred income taxes and reserve adjustments		141	1,666
Loss on equity method investment		747	0
Asset impairment		14,856	2,359
Changes in operating accounts:
Accounts receivable		(11,706)	(1,513)
Inventories		(23,106)	(30,342)
Prepaid expenses and other current assets		(2,790)	2,562
Accounts payable		(7,717)	(1,666)
Deferred revenue and customer deposits		1,351	(3,468)
Accrued and other liabilities		(16,066)	12,387
All other operating activities		(12,495)	(4,879)
Net cash (used in) provided by operating activities		(71,893)	(52,449)
Cash flows from investing activities:
Purchases of property and equipment		(20,995)	(17,055)
Purchases of short-term investments		0	(384,406)
Sales and maturities of short-term investments		180,925	112,050
Acquisitions and other investments, net of cash acquired		(29,241)	(84,705)
Net cash provided by (used in) investing activities		130,689	(374,116)
Cash flows from financing activities:
Purchase of non-controlling interests		0	(2,300)
Taxes paid related to net-share settlement of equity awards		(4,752)	(10,195)
Other financing activities		(463)	(486)
Net cash (used in) provided by financing activities		(5,215)	(12,981)
Effect of exchange rate changes on cash, cash equivalents and restricted cash		1,561	(7,911)
Net increase (decrease) in cash, cash equivalents and restricted cash		55,142	(447,457)
Cash, cash equivalents and restricted cash at the beginning of the year	[1]	391,975	789,970
Cash, cash equivalents and restricted cash at the end of the year	[1]	447,117	342,513
Supplemental cash flow information
Lease assets obtained in exchange for new lease liabilities		37,513	2,422
Cash interest payments		231	148
Cash income tax payments, net		4,815	3,575
Transfer of equipment from inventory to property and equipment, net	[2]	$ 1,316	$ 1,063
[1] The amounts for cash and cash equivalents and restricted cash shown above include restricted cash of $118 and $114 as of September 30, 2023 and December 31, 2022, respectively, which are included in prepaid expenses and other current assets. In addition, included in cash and cash equivalents and restricted cash above as of September 30, 2023, and December 31, 2022 is $1,445 and $3,727, respectively, of restricted cash included in other non-current assets. [2] Inventory is transferred to property and equipment at cost when we require additional machines for training or demonstration or for placement into on demand manufacturing services locations.

v3.23.3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Statement of Cash Flows [Abstract]
Restricted cash, current	$ 118	$ 114
Restricted cash noncurrent	$ 1,445	$ 3,727

v3.23.3

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)
Beginning balance (in shares) at Dec. 31, 2021		128,375
Beginning balance at Dec. 31, 2021	$ 842,381	$ 128	$ 1,501,210	$ (621,251)	$ (37,706)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares withheld related to net-share settlement of equity awards (in shares)		2,044
Shares withheld related to net-share settlement of equity awards	(10,153)	$ 2	(10,155)
Stock-based compensation expense	42,746		42,746
Net loss attributable to 3D Systems Corporation	(97,158)			(97,158)
Pension plan adjustment	422				422
Unrealized gain on short-term investments	(1,653)				(1,653)
Redeemable non-controlling interest redemption value in excess of carrying value	(462)		(462)
Foreign currency translation adjustment	(41,867)				(41,867)
Ending balance (in shares) at Sep. 30, 2022		130,419
Ending balance at Sep. 30, 2022	734,256	$ 130	1,533,339	(718,409)	(80,804)
Beginning balance (in shares) at Jun. 30, 2022		130,304
Beginning balance at Jun. 30, 2022	783,658	$ 130	1,525,734	(681,011)	(61,195)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares withheld related to net-share settlement of equity awards (in shares)		115
Shares withheld related to net-share settlement of equity awards	(108)		(108)
Stock-based compensation expense	8,175		8,175
Net loss attributable to 3D Systems Corporation	(37,398)			(37,398)
Pension plan adjustment	156				156
Unrealized gain on short-term investments	2,370				2,370
Redeemable non-controlling interest redemption value in excess of carrying value	(462)		(462)
Foreign currency translation adjustment	(22,135)				(22,135)
Ending balance (in shares) at Sep. 30, 2022		130,419
Ending balance at Sep. 30, 2022	734,256	$ 130	1,533,339	(718,409)	(80,804)
Beginning balance (in shares) at Dec. 31, 2022		131,207
Beginning balance at Dec. 31, 2022	749,944	$ 131	1,547,597	(743,962)	(53,822)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued, vested & expired under compensation (in shares)		2,886
Shares issued, vested & expired under equity incentive plans	2	$ 2
Shares withheld related to net-share settlement of equity awards (in shares)		(518)
Shares withheld related to net-share settlement of equity awards	(4,752)		(4,752)
Stock-based compensation expense	27,626		27,626
Net loss attributable to 3D Systems Corporation	(70,020)			(70,020)
Pension plan adjustment	(42)				(42)
Unrealized gain on short-term investments	328				328
Redeemable non-controlling interest redemption value in excess of carrying value	(321)		(321)
Foreign currency translation adjustment	(3,227)				(3,227)
Ending balance (in shares) at Sep. 30, 2023		133,575
Ending balance at Sep. 30, 2023	699,538	$ 133	1,570,150	(813,982)	(56,763)
Beginning balance (in shares) at Jun. 30, 2023		133,504
Beginning balance at Jun. 30, 2023	711,004	$ 133	1,562,529	(802,278)	(49,380)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued, vested & expired under compensation (in shares)		100
Shares withheld related to net-share settlement of equity awards (in shares)		(29)
Shares withheld related to net-share settlement of equity awards	(188)		(188)
Stock-based compensation expense	7,870		7,870
Net loss attributable to 3D Systems Corporation	(11,704)			(11,704)
Pension plan adjustment	(31)				(31)
Unrealized gain on short-term investments	0
Redeemable non-controlling interest redemption value in excess of carrying value	(61)		(61)
Foreign currency translation adjustment	(7,352)				(7,352)
Ending balance (in shares) at Sep. 30, 2023		133,575
Ending balance at Sep. 30, 2023	$ 699,538	$ 133	$ 1,570,150	$ (813,982)	$ (56,763)

v3.23.3

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Nov. 16, 2021
Statement of Stockholders' Equity [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001	$ 0.001

v3.23.3

Basis of Presentation	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	(1) Basis of Presentation The accompanying unaudited condensed consolidated financial statements include the accounts of 3D Systems Corporation and all majority and wholly-owned subsidiaries and entities in which a controlling interest is maintained (“3D Systems” or the “Company” or “we” or “our” or “us”). All significant intercompany accounts and transactions have been eliminated in consolidation.  A non-controlling interest in a subsidiary reflects an ownership interest in a majority-owned subsidiary that is not attributable to the Company. For the periods presented, the Company's financial statements include a redeemable non-controlling interest (“RNCI”), which has been reported in temporary equity in the consolidated balance sheets. The net income (loss) attributable to the RNCI is presented as an adjustment to the Company's consolidated net income (loss) to arrive at net income (loss) attributable to 3D Systems Corporation in the consolidated statements of operations and consolidated statements of comprehensive income (loss). Furthermore, adjustments to record the RNCI at its redemption value are recorded to additional paid-in capital, and the excess redemption value is recognized as a reduction to the net income, or increase to the net loss, attributable to 3D Systems’ shareholders for purposes of reporting earnings or loss per share. See Note 11 for a summary of the activity related to the reported RNCI balance during the period. The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) applicable to interim reports. Accordingly, our unaudited condensed consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022 (“2022 Form 10-K”). The year-end balance sheet data reported on our unaudited condensed consolidated balance sheet has been derived from the balance sheet included in our 2022 Form 10-K. The Company believes that the disclosures included in this Form 10-Q are adequate to make the information presented not misleading. In the opinion of management, the unaudited condensed consolidated financial statements include all adjustments, consisting of adjustments of a normal recurring nature, necessary to present fairly the financial position, results of operations, and cash flows for the periods presented. The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results may differ from those estimates and assumptions. Our annual reporting period is the calendar year. Our results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for the full year. All dollar amounts and other amounts presented in the accompanying footnotes are presented in thousands, except for per share information. Summary of Significant Accounting Policies The significant accounting policies included in our 2022 Form 10-K have been updated as follows. Goodwill Goodwill is the excess of the cost of an acquired entity over the amounts assigned to the assets acquired and liabilities assumed in a business combination. Goodwill is not amortized. Goodwill is tested for impairment annually during the fourth quarter of each year, and is tested for impairment between annual tests if an event occurs or circumstances change that would indicate the carrying amount may be impaired. Impairment testing for goodwill is done at a reporting unit level, with all goodwill assigned to a reporting unit. The test for impairment of goodwill requires the Company to make several estimates related to projected future cash flows to determine the fair value of the goodwill reporting units. The Company calculates the excess of each reporting unit's fair value over its carrying amount, including goodwill, utilizing a discounted cash flow analysis and other valuation techniques, as deemed appropriate. Internal operational budgets and long-range strategic plans are used as a basis for the cash flow analysis. The Company also utilizes assumptions for working capital, capital expenditures, and terminal growth rates. The discount rate applied to the cash flow analysis is based on the weighted average cost of capital (“WACC”) for each reporting unit. An impairment is recognized when the carrying amount of the reporting unit’s net assets exceeds the estimated fair value of the reporting unit. During the quarter ended September 30, 2023, the Company experienced a significant decline in its market capitalization as a result of a decrease in its stock price, and during the month ended September 30, 2023, the Company’s market capitalization fell slightly below its consolidated stockholders’ equity balance. We do not consider this to constitute a sustained decrease in the Company’s stock price as of September 30, 2023. Furthermore, the Company performed a qualitative goodwill impairment assessment as of September 30, 2023 and concluded that it is not more likely than not that the fair value of either of its reporting units is less than the reporting unit’s carrying value as of September 30, 2023. As a result, we concluded that no triggering event had occurred that would require the Company to perform a quantitative goodwill impairment test for either of its two reporting units as of September 30, 2023. However, the Company’s market capitalization has declined further since September 30, 2023, and if such a decline results in the estimated fair value of either of our reporting units being lower than the respective reporting unit’s carrying value, the Company would need to record a non-cash goodwill impairment charge, which could be material, in a future period – including as of our upcoming annual impairment testing date of November 1, 2023 (reflecting our annual goodwill impairment testing date commencing as of the current fiscal year). Variable Interest Entities (VIEs) Upon making an investment in an entity, we assess whether the entity is a VIE. The determination of whether an entity in which we hold a direct or indirect variable interest is a VIE is based on several factors, including whether the entity’s total equity investment at risk upon inception is sufficient to finance the entity’s activities without additional subordinated financial support. We make judgments regarding the sufficiency of the equity at risk based first on a qualitative analysis, and then a quantitative analysis, if necessary. We analyze any investments in VIEs to determine if we are the primary beneficiary. We perform this assessment at the time that we become involved with a VIE and reevaluate our conclusion upon the occurrence of a reconsideration event. In evaluating whether we are the primary beneficiary, we evaluate our direct and indirect economic interests in the entity. Determining which reporting entity, if any, is the primary beneficiary of a VIE is primarily a qualitative approach focused on identifying which reporting entity has both (1) the power to direct the activities of a VIE that most significantly impact such entity’s economic performance and (2) the obligation to absorb losses or the right to receive benefits from such entity that could potentially be significant to such entity. Performance of such analysis requires the exercise of judgment, and we consider a variety of factors in identifying the entity that holds the power to direct matters that most significantly impact a VIE’s economic performance including, but not limited to, the ability to direct a VIE’s operating decisions and activities. In addition, we consider the rights of other investors to participate in those decisions. We concluded that our investments in Theradaptive and the Saudi Arabian Industrial Investments Company ("Dussur") are each a VIE. These investments are not consolidated because we concluded that the Company is not the primary beneficiary. As of September 30, 2023, our maximum exposure to losses associated with the VIEs is limited to the $13,782 carrying value of our investments in the VIEs, which is included in other assets on our condensed consolidated balance sheet. We have no other investments in unconsolidated entities that have been determined to be VIEs. Equity Securities without a Readily Determinable Value We recognize investments in equity securities without a readily determinable fair value at cost minus impairment. We assess these investments for potential impairment if an event occurs or circumstances change that would indicate the carrying amount may be impaired. If applicable, impairment charges taken with respect to these investments are reported within interest and other income (expense), net in the consolidated statements of operations in the period in which an investment becomes impaired (see Note 7). Equity Method of Accounting The Company accounts for an investment in a joint venture using the equity method of accounting because it does not have a controlling interest and is not the primary beneficiary; however, the Company has the ability to exert significant influence. Under the equity method of accounting, the initial investment is recorded at cost, and the investment is subsequently adjusted for the Company’s proportionate share of the net earnings or losses and other comprehensive income or loss of the investee. Intra-entity profits or losses associated with the Company’s equity method investment are eliminated until realized by the investee in transactions with third parties. Income or loss from this investment is recorded as a separate line item in the consolidated statements of operations on a three-month lag. We evaluate material events occurring during the three-month lag period to determine whether the effects of such events should be disclosed in our financial statements. The Company will evaluate its investment in the joint venture for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment may not be recoverable. Other Accounting Policy Updates All other significant accounting policies described in the 2022 Form 10-K remain unchanged.

v3.23.3

Acquisitions	9 Months Ended
	Sep. 30, 2023
Business Combination and Asset Acquisition [Abstract]
Acquisitions	(2) Acquisitions Wematter On July 1, 2023, the Company completed the previously announced acquisition of Wematter AB (“Wematter”), a Swedish 3D printer manufacturer that will broaden 3D Systems’ Selective Laser Sintering (SLS) portfolio. Wematter's reported results are expected to be included in our Industrial Solutions segment. The acquisition resulted in the Company acquiring 100% of the outstanding voting interest of Wematter. Consideration for this acquisition consisted of approximately $10,224 in cash, subject to customary post-closing adjustments. The Company also may be required to pay an additional €2,000 in cash, contingent upon the achievement of certain post-closing performance conditions and the continued employment of certain key Wematter employees for two years after the closing date. If earned, the €2,000 is expected to be recognized as compensation expense over the two-year service period that the key employees must remain employed at 3D Systems. As of September 30, 2023, management believes that the achievement of the post-closing performance conditions is probable and, accordingly, the Company has commenced the recognition of the related compensation expense. In addition, the Company incurred $847 of acquisition-related expenses that are reported in selling, general and administrative expenses in the condensed consolidated statements of operations. In a separate transaction, the Company had extended a loan to Wematter during the three months ended June 30, 2023. The carrying value of the Wematter loan was $942 as of the acquisition date, and was previously reported in prepaid and other current assets on the Company's condensed consolidated balance sheet as of June 30, 2023. Upon the close of the acquisition, we determined that the loan was effectively settled in the business combination as a preexisting contractual relationship. No gain or loss was recognized in connection with the effective settlement, as the carrying value of the loan was not materially different from the pricing for a current market transaction for similar items. The effective settlement of this loan receivable results in an increase to the consideration transferred in connection with this transaction (i.e., above the cash consideration paid) and a corresponding increase to goodwill. We accounted for the acquisition of Wematter using the acquisition method, as prescribed by ASC 805, “Business Combinations” (“ASC 805”). In accordance with valuation methodologies described in ASC 820, “Fair Value Measurement” (“ASC 820”), the acquired assets and assumed liabilities were recorded at their estimated fair values as of the date of the Wematter acquisition. Shown below is the preliminary purchase price allocation, which summarizes the fair values of the assets acquired and liabilities assumed at the date of acquisition: (in thousands) Current assets, including cash acquired of $148 $ 835  Intangible assets: Trade names $ 1,487  Product technology 2,231  Customer relationships 347  Total intangible assets 4,065  Goodwill 6,878  Other assets 475  Liabilities: Accounts payable and accrued liabilities $ 794  Long term liabilities 293  Total liabilities 1,087  Net assets acquired $ 11,166  The goodwill recognized is attributable to synergies that are expected to enhance and expand the Company’s overall product portfolio and opportunities in new and existing markets, future products that have yet to be determined and Wematter’s assembled workforce. This goodwill is not expected to be deductible for tax purposes. The following table presents the finite-lived intangible assets acquired and their respective estimated useful lives: Useful Life Trade names 5 Product technology 15 Customer relationships 10 As of September 30, 2023, the purchase price allocation for Wematter is preliminary. The Company continues to review the final closing balance sheet of Wematter and may further adjust the acquisition-date fair values of acquired assets and assumed liabilities based on this review. The Company also continues to review Wematter’s pre-acquisition tax returns to determine the final tax positions, including net operating losses and any required valuation allowance. The final purchase price allocations will be completed when the Company has finished its valuation activities and the review of Wematter’s closing balance sheet and the pre-acquisition tax returns. These final allocations could differ materially from the current preliminary allocations. The final allocations may include (1) changes in the preliminary allocations to acquired intangible assets and goodwill and (2) changes in the preliminary allocations to other assets and liabilities, including but not limited to tax assets and liabilities, inclusive of deferred taxes. The estimated useful lives of acquired intangible assets are also preliminary. The post-acquisition revenues of Wematter included in our condensed consolidated statements of operations for both the three and nine months ended September 30, 2023 are immaterial and, accordingly, Wematter's results are dilutive to our earnings. Unaudited Pro Forma Financial Information The following unaudited pro forma financial information summarizes the combined results of the Company and Wematter as if the acquisition had occurred on January 1, 2022. The pro forma results have been prepared for comparative purposes only, and do not necessarily represent what the results of operations would have been had the acquisition been completed on January 1, 2022. In addition, these pro forma results are not intended to be a projection of future operating results and do not reflect synergies that might be achieved. The unaudited pro forma financial information includes adjustments for the pro forma impact of our preliminary purchase price allocation, including the amortization for newly acquired intangible assets, the impact of transaction costs, and the alignment of accounting policies. Transaction costs have been included in the pro forma results for the periods ended September 30, 2022, consistent with the pro forma assumption that the acquisition occurred on January 1, 2022. Pro forma revenue information has not been presented, as pre-acquisition revenue reported by Wematter was not material and, accordingly, the impact on our reported consolidated revenue also would not have been material. Pro forma net loss is not presented in the table below for the three months ended September 30, 2023 because Wematter's results are reflected in 3D Systems consolidated numbers for the full period. Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2022 2023 2022 Net (loss) income attributable to 3D Systems Corporation $ (38,407) $ (71,076) $ (100,185) dp polar On October 4, 2022, we completed the acquisition of 100% of dp polar GmbH (“dp polar”), a German-based designer and manufacturer of a manufacturing system designed for true high-speed mass production of customized components, for $25,866 (including customary post-closing adjustments), which includes $19,604 paid in cash at closing, $7,091 paid at closing via the issuance of the Company’s common stock, and a provisional $829 estimated post-closing purchase price adjustment due to the Company from the sellers. See Note 12 for the discussion of an earnout arrangement with a key individual from dp polar. The Company acquired dp polar for access to dp polar's patented continuous printing process. Central to dp polar’s patented continuous printing process is a large-scale, segmented, rotating print platform that eliminates the start/stop operations of virtually all additive manufacturing platforms. With dp polar’s technology and patented polar coordinate control, the print heads remain stationary above the rotating platform, providing a continuous print process. We accounted for the acquisition of dp polar using the acquisition method, as prescribed by ASC 805. In accordance with valuation methodologies described in ASC 820, the acquired assets and assumed liabilities were recorded at their estimated fair values as of the date of the dp polar acquisition. Shown below is the final purchase price allocation, which summarizes the fair values of the assets acquired and liabilities assumed at the date of acquisition: (in thousands) Current assets, including cash acquired of $243 $ 301  Intangible assets: In-process research and development $ 4,989  Trade name 3,930  Total intangible assets 8,919  Goodwill 17,090  Other assets 765  Liabilities: Accounts payable and accrued liabilities $ 364  Deferred tax liability 845  Total liabilities 1,209  Net assets acquired $ 25,866  The goodwill recognized in connection with this acquisition is attributable to synergies that are expected to enhance and expand the Company’s overall product portfolio and opportunities in new and existing markets, future products that have yet to be determined and dp polar’s assembled workforce. This goodwill will not be deductible for tax purposes. Kumovis On April 1, 2022, we completed the acquisition of 93.75% of Kumovis GmbH (“Kumovis”) for an all-cash purchase price of $37,875 (including customary post-closing adjustments), plus an estimated RNCI of $1,559. $3,628 of the cash payment was deferred for up to fifteen months from the closing date, and was paid in July 2023. Kumovis, which is part of the Healthcare Solutions segment and reporting unit, utilizes polyether ether keton or “PEEK” materials, which has properties that lend it to many medical applications that fit into our personalized healthcare solutions operations, including many implant applications. In conjunction with the Kumovis acquisition, the Company and the non-controlling shareholders entered into a put/call option agreement, whereby, at a later date, the Company has the option to purchase from the non-controlling shareholders, and the non-controlling shareholders have the option to sell to the Company, the remaining 6.25% ownership interest in Kumovis for an exercise price calculated based on the achievement of pre-determined revenue and gross profit targets. Fifty percent of the Kumovis common shares related to the put/call can be exercised upon the achievement of an initial revenue and gross profit target, while the remaining 50% can be exercised upon the achievement of a second revenue and gross profit target. If one or both sets of targets have not been met within 5.75 years from the acquisition date, there is a floor strike price that must be exercised. Up to 50% of the exercise price can be paid in Company common stock at the election of 3D Systems. This arrangement results in the recognition of RNCI, for which an estimated fair value of $1,559 was recorded as of the acquisition date. We accounted for the acquisition of Kumovis using the acquisition method, as prescribed by ASC 805, and we have completed the allocation of the final purchase price. In accordance with valuation methodologies described in ASC 820, the acquired assets and assumed liabilities were recorded at their estimated fair values as of the date of the Kumovis acquisition. The table below reflects the fair value of both the consideration transferred and the RNCI attributable to this acquisition: (in thousands) Cash paid at acquisition $ 34,098  Deferred cash consideration 3,628  Estimated fair value of RNCI 1,559  Post-closing net working capital adjustment 149  Total fair value of consideration transferred $ 39,434  Shown below is the final purchase price allocation, summarizing the fair values of the assets acquired and liabilities assumed at the date of acquisition: (in thousands) Current assets, including cash acquired of $125 $ 1,407  Intangible assets: Product technology $ 20,770  Trade name 5,802  Total intangible assets 26,572  Goodwill 17,618  Other assets 705  Liabilities: Accounts payable and accrued liabilities $ 332  Deferred revenue 70  Deferred tax liability 6,466  Total liabilities 6,868  Net assets acquired $ 39,434  The goodwill recognized in connection with this acquisition is attributable to synergies that are expected to enhance and expand the Company’s overall product portfolio and opportunities in new and existing markets, future products that have yet to be determined and Kumovis’s assembled workforce. This goodwill will not be deductible for tax purposes. Titan On April 1, 2022, we completed the acquisition of 100% of Titan Additive LLC (“Titan”) for an all-cash purchase price of $39,040. Titan, which is part of the Industrial Solutions segment and reporting unit, is a pellet-based extrusion platform that addresses customer applications requiring large build volumes, superior performance, and improved productivity at significantly lower cost. We believe the acquisition of Titan will open up new markets in the Industrial Solutions segment. We accounted for the acquisition of Titan using the acquisition method, as prescribed by ASC 805, and we have completed the allocation of the purchase price. Shown below is the final purchase price allocation, summarizing the fair values of the assets acquired and liabilities assumed, as determined at the date of acquisition in accordance with valuation methodologies described in ASC 820: (in thousands) Current assets $ 661  Intangible assets: Product technology $ 15,940  Trade name 5,580  Total intangible assets 21,520  Goodwill 17,430  Other assets 68  Liabilities: Accounts payable and accrued liabilities $ 229  Deferred revenue 410  Total liabilities 639  Net assets acquired $ 39,040  The goodwill recognized in connection with this acquisition is attributable to synergies that are expected to enhance and expand the Company’s overall product portfolio and opportunities in new and existing markets, future products that have yet to be determined and Titan’s assembled workforce. This goodwill is deductible for tax purposes. Acquisitions of Non-controlling Interests As of December 31, 2018, the Company owned approximately 70% of the capital and voting rights of Easyway, a service bureau and distributor of 3D printing and scanning products in China. The remaining 30% of the capital and voting rights of Easyway were acquired on January 21, 2019 for $13,500, which has been paid in installments. The Company made the final installment payment of $2,300 related to the acquisition of the remaining 30% interest in Easyway during the three months ended March 31, 2022.

v3.23.3

Revenue	9 Months Ended
	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue	(3) Revenue Revenue is recognized when control of the promised products or services is transferred to customers. Performance Obligations At September 30, 2023, we had $62,579 of outstanding performance obligations, comprised of deferred revenue, customer order backlog and customer deposits. We expect to recognize approximately 90.0% of the $39,418 of deferred revenue and customer deposits as revenue within the next twelve months, an additional 4.0% by the end of 2024 and the remaining balance thereafter. Collaboration and Licensing Agreements We enter into collaboration and licensing agreements with third parties. The nature of the activities to be performed and the consideration exchanged under these agreements varies on a contract-by-contract basis. We evaluate these agreements to determine whether they meet the definition of a customer relationship for which revenue should be recorded. These contracts may contain multiple performance obligations and may contain fees for licensing, research and development services, contingent milestone payments upon the achievement of contractual developmental criteria and/or royalty fees based on the licensees’ product revenue. We determine the revenue to be recognized for these agreements based on an evaluation of the distinct performance obligations, the identification and evaluation of material rights, the estimation of variable consideration and the determination of the pattern of transfer of control for each distinct performance obligation. During the three and nine-month periods ended September 30, 2023, the Company recognized $7,896 and $16,099, respectively, of revenue related to collaboration arrangements with customers. During the three and nine-month periods ended September 30, 2022, the Company recognized $3,301 and $9,075, respectively, of revenue related to collaboration arrangements with customers. Our revenue recognized under collaboration and licensing agreements for the three and nine months ended September 30, 2023 includes the effect of the Company increasing its estimate of the variable consideration included in the transaction price related to one of its licensing agreements. The increase in estimated recognizable variable consideration was due to (1) the execution of a modification to the related customer contract and (2) the Company's determination that incremental revenue attributable to milestone payments that are contingent upon the achievement of contractual developmental criteria would be earned under the modified contract. As a result, during the quarter ended September 30, 2023, the Company recognized incremental services revenue of $4,452, which reduced our reported basic and diluted loss per share by $0.03 and $0.03, respectively, for each of the three and nine months ended September 30, 2023. Contract Balances During the nine months ended September 30, 2023, we recognized revenue of $23,498 related to our contract liabilities at December 31, 2022. During the nine months ended September 30, 2022, we recognized revenue of $28,850 related to our contract liabilities at December 31, 2021. Contract assets were $7,379 and $677 as of September 30, 2023 and December 31, 2022, respectively. The increase in the contract assets balance as of September 30, 2023 primarily relates to the increase in the estimated variable consideration included in the transaction price related to one of the Company's collaboration and licensing agreements (refer to the discussion above of Collaboration and Licensing Agreements), which has resulted in the recognition of incremental revenue for which the Company did not have the right to invoice as of the balance sheet date. Revenue Concentrations For the three and nine months ended September 30, 2023, one customer accounted for approximately 10.7% and 14.4% of our consolidated revenue, respectively. For the three and nine months ended September 30, 2022, one customer accounted for approximately 20.8% and 24.1% of our consolidated revenue, respectively. We expect to maintain our relationship with this customer. Revenue by geographic region for the three and nine months ended September 30, 2023 and 2022 was as follows: Three Months Ended (in thousands) September 30, 2023 September 30, 2022 Americas $ 69,714  $ 80,455  EMEA 43,141  36,913  APAC 10,936  14,885  Total $ 123,791  $ 132,253  United States (included in Americas above) $ 68,840  $ 78,910  Nine Months Ended (in thousands) September 30, 2023 September 30, 2022 Americas $ 214,956  $ 234,511  EMEA 127,150  122,788  APAC 31,115  48,000  Total $ 373,221  $ 405,299  United States (included in Americas above) $ 211,717  $ 231,557

v3.23.3

Inventories	9 Months Ended
	Sep. 30, 2023
Inventory Disclosure [Abstract]
Inventories	(4) Inventories Components of inventories at September 30, 2023 and December 31, 2022 are summarized as follows: (in thousands) September 30, 2023 December 31, 2022 Raw materials $ 61,314  $ 59,907  Work in process 3,922  4,972  Finished goods and parts 87,769  72,953  Total inventories $ 153,005  $ 137,832  The inventory reserve was $16,711 and $15,550 as of September 30, 2023 and December 31, 2022, respectively. In the second quarter of 2023, we notified one of our contract manufacturers of our intent to terminate the manufacturing services arrangement and in-source the assembly and production process. The exit agreement was finalized in June 2023 and included a $450 exit fee expensed in the second quarter of 2023. There is an associated commitment to purchase $2,735 of inventory from the assembly manufacturer as of September 30, 2023.

v3.23.3

Intangible Assets	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	(5) Intangible Assets Intangible Assets with Finite Lives At September 30, 2023 and December 31, 2022, the Company's intangible assets with finite lives were as follows: September 30, 2023 December 31, 2022 (in thousands) Gross Accumulated Amortization Net Gross Accumulated Amortization Net Intangible assets with finite lives: Customer relationships $ 51,160  $ (49,417) $ 1,743  $ 51,137  $ (48,695) $ 2,442  Acquired technology 45,894  (11,925) 33,969  55,480  (10,707) 44,773  Trade names 30,496  (13,705) 16,791  35,930  (12,455) 23,475  Patent costs 18,714  (10,823) 7,891  18,673  (10,909) 7,764  Acquired patents 16,426  (14,716) 1,710  17,499  (15,661) 1,838  Other 13,170  (9,120) 4,050  13,255  (8,765) 4,490  Total intangible assets $ 175,860  $ (109,706) $ 66,154  $ 191,974  $ (107,192) $ 84,782  Impairment of Intangible Assets with Finite Lives During the quarter ended September 30, 2023, the Company concluded that it is more likely than not that it will sell or otherwise dispose of Oqton MOS, a business which the Company acquired in 2021. Oqton MOS represents a discrete asset group within the Industrial Solutions segment, as its identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities within the Industrial Solutions segment. Based upon the Company's expectation that it will sell or otherwise dispose of Oqton MOS, the long-term cash flow forecast for this asset group was revised. The revised long-term cash flow forecast indicated that the carrying amounts of Oqton MOS's long-lived assets, consisting primarily of product technology and trade name intangible assets initially recorded when Oqton MOS was acquired, may not be recoverable. Accordingly, the carrying value of Oqton MOS's long-lived assets was tested for impairment based upon an estimate of the associated discounted future cash flows. This fair value measurement approach required the use of Level 3 fair value measurement inputs, as defined in Note 19. As the present value of the estimated future cash flows expected to result from the use and eventual disposition of the asset group is less than the carrying value of the asset group, during the quarter ended September 30, 2023, the Company recognized $13,597 of impairment charges related to the acquired technology and trade names included in the Oqton MOS asset group. Amortization of Intangible Assets with Finite Lives Amortization expense related to our intangible assets with finite lives was $3,179 and $9,676 for the three and nine months ended September 30, 2023, respectively, compared to $4,293 and $10,273 for the three and nine months ended September 30, 2022, respectively. Amortization expense for intangible assets is estimated to be $2,085 for the remainder of 2023, $8,318 in 2024, $8,029 in 2025, $7,083 in 2026 and $6,733 in 2027. Indefinite-Life Intangible Assets (Excluding Goodwill) Total intangible assets reported on our September 30, 2023 and December 31, 2022 consolidated balance sheets include in-process research and development (“IPR&D”), which the Company recognized as an acquired indefinite-life intangible asset in connection with its acquisition of dp polar on October 4, 2022 (see Note 2). The carrying value of this indefinite-life intangible asset was $5,382 and $5,448 as of September 30, 2023 and December 31, 2022, respectively.

v3.23.3

Goodwill	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	(6) Goodwill The following table reflects the changes in the carrying amount of goodwill by reporting unit for the nine months ended September 30, 2023: Nine Months Ended September 30, 2023 Healthcare Industrial Consolidated (in thousands) Gross Goodwill Impairments Net Goodwill Gross Goodwill Impairments Net Goodwill Gross Goodwill Impairments Net Goodwill Balance at beginning of year $ 143,431  $ (32,055) $ 111,376  $ 316,265  $ (42,329) $ 273,936  $ 459,696  $ (74,384) $ 385,312  Acquisitions and measurement period adjustments 1,005  —  1,005  7,735  —  7,735  8,740  —  8,740  Foreign currency translation adjustments (1,175) —  (1,175) (1,552) —  (1,552) (2,727) —  (2,727) Balance at end of period $ 143,261  $ (32,055) $ 111,206  $ 322,448  $ (42,329) $ 280,119  $ 465,709  $ (74,384) $ 391,325  The effect of foreign currency exchange rates in the table above reflects the impact on goodwill of amounts recorded in currencies other than the U.S. dollar in the financial statements of foreign subsidiaries and the resulting effect of foreign currency translation between the applicable functional currency and the U.S. dollar.

v3.23.3

Investments and Notes Receivable	9 Months Ended
	Sep. 30, 2023
Equity Method Investments and Joint Ventures [Abstract]
Investments and Notes Receivable	(7) Investments and Notes Receivable The Company holds various investments in equity and debt instruments that are included in other assets on our condensed consolidated balance sheets. The following table summarizes our investment balances as of September 30, 2023 and December 31, 2022: (in thousands) September 30, 2023 December 31, 2022 Equity investments under the equity method of accounting $ 5,782  $ —  Equity investments without readily determinable fair values 20,962  12,953  Other(1) 200  200  Total equity investments $ 26,944  $ 13,153  Long-term note receivable(2) $ 530  $ 515  Total notes receivable $ 530  $ 515  (1) Reflects warrant investment carried at fair value. The fair value of these warrants is measured using Level 3 fair value measurement inputs. Refer to Note 19 for a description of these inputs. (2) Includes interest amounts that have been accrued on, recorded to and reported as part of the notes receivable balance. Equity Investments under the Equity Method of Accounting Dussur In March 2022, we and Dussur signed an agreement to form a joint venture intended to expand the use of additive manufacturing within the Kingdom of Saudi Arabia and surrounding geographies, including the Middle East and North Africa. The joint venture is to enable the development of Saudi Arabia’s domestic additive manufacturing production capabilities, consistent with the Kingdom’s ‘Vision 2030,’ which is focused on diversification of the economy and long-term sustainability. 3D Systems had committed to an initial investment in the joint venture of approximately $6,500, of which $3,435 had been deposited into an escrow account as of December 31, 2022 and, accordingly, was reported as restricted cash within other assets on the December 31, 2022 balance sheet. In February 2023, the Company officially became a shareholder in the joint venture. During April 2023, the $3,435 held in escrow, as well as the additional amount of approximately $3,065 owed to the joint venture as of March 31, 2023, was deposited into a bank account of the joint venture for use in its operations. Additional future investments in the joint venture are contingent upon the achievement of certain milestones. As of September 30, 2023, the Company owns 49% of the joint venture's common stock. The impact of this investment on the Company’s future financial condition and cash flows is expected to be limited to the cash outflow(s) related to any future contingent investments, if required. The Company accounts for the joint venture under the equity method of accounting, which requires the Company to recognize its proportionate share of the joint venture's reported net income or loss. Due to the timing of when the joint venture's reported financial information is expected to be available, the Company records amounts required to be recognized pursuant to the equity method of accounting on a one quarter lag. For the three and nine months ended September 30, 2023, Company has recorded and separately reported a loss on equity method investment in the condensed consolidated statements of operations. Equity Investments without Readily Determinable Fair Values Theradaptive In June 2023, we made an $8.0 million investment in Theradaptive, Inc. ("Theradaptive"), via the purchase of Series A Preferred Stock, pursuant to which we hold an approximate 9.15%, or 8.25% fully-diluted, ownership interest in Theradaptive. Theradaptive is currently developing a protein that encourages bone growth. This biotechnology could be applied to 3D printed metal splints for patients who otherwise may require amputation of a limb because the lost bone is too vast to replace with a splint. The Company expects to account for its investment in Theradaptive on a cost basis, subject to assessment for impairment, as (1) the fair value of Theradaptive's equity is not readily determinable and (2) the investment is not subject to the equity method of accounting due to the Company's lack of significant influence. The investment in Theradaptive is not expected to materially impact our future financial position, results of operations, or cash flows. No impairment charges were recognized with respect to this investment during the three or nine month periods ended September 30, 2023. Enhatch In March 2022, we made a $10,000 investment in convertible preferred shares for an approximate 26.6% ownership interest in Enhatch Inc. (“Enhatch”), the developer of the Intelligent Surgery Ecosystem. We simultaneously entered into a supply agreement with Enhatch. We also obtained warrants to purchase additional shares of Enhatch, as well as the right to purchase in the future (“call option”) the remaining shares of Enhatch that 3D Systems does not own if certain revenue targets are achieved. As of the original investment date, the fair values of the convertible preferred shares, inclusive of the embedded call option, and warrants were bifurcated and were $9,670 and $330, respectively. The investment, including the embedded call option and the warrants, is recorded in other assets on the consolidated balance sheets. Enhatch’s Intelligent Surgery Ecosystem provides technologies which streamline and scale the design and delivery of patient-specific medical devices by automating the process. Incorporating these capabilities into 3D Systems’ workflow for patient-specific solutions, which includes advanced software, expert treatment planning services, custom implants and instrumentation design, and industry-leading production processes, will help more efficiently meet the growing demand for personalized medical devices. As of September 30, 2023 and December 31, 2022, the reported carrying value of the Company's convertible preferred stock investment in Enhatch, inclusive of the call option, is $6,900, which reflects the cumulative impact of $2,770 of historical impairment charges that have been recognized since the date of the original investment. These impairment charges were recorded during the three months ended September 30, 2022. No impairment charges were recognized with respect to this investment during the three or nine month periods ended September 30, 2023.

v3.23.3

Leases	9 Months Ended
	Sep. 30, 2023
Leases [Abstract]
Leases	(8) Leases We have various lease agreements for our facilities, equipment and vehicles with remaining lease terms ranging from one to fifteen years. During the nine months ended September 30, 2023, two buildings previously under construction were completed and became available for use by the Company as leased premises. As a result, these leases were deemed to have commenced during the period. Additionally, during the nine months ended September 30, 2023, we extended material existing leases related to two buildings with office and production spaces. Rented spaces under these new and extended leases totaled 396,100 square feet. As of September 30, 2023, the aggregate remaining minimum base lease payments related to the new building leases and extended leases described above total $47,634 and consist of $1,006, $4,516, $5,093, $5,234, $5,380, and $26,405 due, respectively, during the years ended December 31, 2023, 2024, 2025, 2026, 2027 and thereafter. Classifications of the lease amounts reported on our balance sheets as of September 30, 2023 and December 31, 2022 are summarized below: September 30, 2023 December 31, 2022 (in thousands) Right-of-use assets Current lease liabilities Long-term lease liabilities Right-of-use assets Current lease liabilities Long-term lease liabilities Operating leases $ 60,973  $ 9,616  $ 59,428  $ 39,502  $ 8,343  $ 38,499  Finance leases 12,047  1,068  11,867  3,244  693  3,280  Total $ 73,020  $ 10,684  $ 71,295  $ 42,746  $ 9,036  $ 41,779
Leases	(8) Leases We have various lease agreements for our facilities, equipment and vehicles with remaining lease terms ranging from one to fifteen years. During the nine months ended September 30, 2023, two buildings previously under construction were completed and became available for use by the Company as leased premises. As a result, these leases were deemed to have commenced during the period. Additionally, during the nine months ended September 30, 2023, we extended material existing leases related to two buildings with office and production spaces. Rented spaces under these new and extended leases totaled 396,100 square feet. As of September 30, 2023, the aggregate remaining minimum base lease payments related to the new building leases and extended leases described above total $47,634 and consist of $1,006, $4,516, $5,093, $5,234, $5,380, and $26,405 due, respectively, during the years ended December 31, 2023, 2024, 2025, 2026, 2027 and thereafter. Classifications of the lease amounts reported on our balance sheets as of September 30, 2023 and December 31, 2022 are summarized below: September 30, 2023 December 31, 2022 (in thousands) Right-of-use assets Current lease liabilities Long-term lease liabilities Right-of-use assets Current lease liabilities Long-term lease liabilities Operating leases $ 60,973  $ 9,616  $ 59,428  $ 39,502  $ 8,343  $ 38,499  Finance leases 12,047  1,068  11,867  3,244  693  3,280  Total $ 73,020  $ 10,684  $ 71,295  $ 42,746  $ 9,036  $ 41,779

v3.23.3

Accrued and Other Liabilities	9 Months Ended
	Sep. 30, 2023
Payables and Accruals [Abstract]
Accrued and Other Liabilities	(9) Accrued and Other Liabilities Short-Term Accrued Liabilities Accrued liabilities at September 30, 2023 and December 31, 2022 are summarized as follows: (in thousands) September 30, 2023 December 31, 2022 Compensation and benefits $ 15,492  $ 19,814  Accrued taxes 9,633  10,694  Legal contingencies 4,850  9,948  Product warranty liability 2,409  3,677  Other accrued liabilities 11,191  11,438  Total $ 43,575  $ 55,571  Changes in the product warranty obligation for the nine months ended September 30, 2023 and 2022 are summarized below: (in thousands) Beginning Balance Settlements Made Accruals for Warranties Issued Ending Balance September 30, 2023 $ 3,677  $ (2,983) $ 1,715  $ 2,409  September 30, 2022 $ 3,585  $ (5,266) $ 5,257  $ 3,576  Other Long-Term Liabilities Other liabilities at September 30, 2023 and December 31, 2022 are summarized as follows: (in thousands) September 30, 2023 December 31, 2022 Long-term employee indemnity $ 4,634  $ 4,817  Long-term tax liability 5,568  5,711  Defined benefit pension obligation 4,963  5,050  Long-term deferred revenue 1,858  4,974  Earnout liability —  17,244  Legal contingencies 2,916  6,096  Other long-term liabilities 428  289  Total $ 20,367  $ 44,181  The reduction in the earnout liability balance is the result of the reversal of all previously recognized expense attributable to a potential post-acquisition milestone-based payment related to the Company's 2021 acquisition of Volumetric Biotechnologies, Inc. ("Volumetric"). During the three months ended September 30, 2023, the Company reversed the accrued compensation expense related to the potential earnout payment as the related milestone is no longer deemed probable of being achieved. Refer to Note 12 for additional details regarding the earnout arrangement and the financial impact of this milestone-based payment no longer being deemed probable of being paid.

v3.23.3

Borrowings	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Borrowings	(10) Borrowings On November 16, 2021, the Company issued $460,000 in aggregate principal amount of 0% Convertible Senior Notes due November 15, 2026 (the “Notes”), pursuant to an Indenture dated November 16, 2021 (the “Indenture”) between the Company and The Bank of New York Mellon, N.A., as trustee. The net proceeds from the offering of the Notes were $446,534 after deducting the initial purchasers’ discounts and commissions and offering expenses payable by the Company in the amount of $13,466, of which $8,480 is unamortized at September 30, 2023. The annual effective interest rate of the Notes is 0.594% when including purchasers' discounts and commissions and offering expenses incurred by the Company. The Notes are senior, unsecured obligations of the Company, will not bear regular interest, and the principal amount of the Notes will not accrete. The Notes will mature on November 15, 2026, unless earlier redeemed, repurchased or converted in accordance with their terms. The Notes will be convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding August 15, 2026, only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2022 (and only during such quarter), if the last reported sale price of the Company’s common stock, par value $0.001 per share, is equal to or greater than 130% of the conversion price for each of at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter on each applicable trading day; (2) during the five business day period after any five consecutive trading day period (the “measurement period”) in which the trading price (as defined in the Indenture) per $1 principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of the common stock and the conversion rate on each such trading day; (3) if the Company calls such Notes for redemption at any time prior to the close of business on the second scheduled trading day immediately preceding the redemption date; and (4) upon the occurrence of specified corporate events, including a Fundamental Change (as defined in the Indenture), or distributions of the common stock. On or after August 15, 2026, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their Notes at any time, at the option of the holder, regardless of the foregoing circumstances. Upon conversion, the Company will pay cash up to the aggregate principal amount of the Notes to be converted and pay or deliver, as the case may be, cash, shares of common stock, or a combination of cash and shares of common stock, at the Company’s election, in respect of the remainder, if any, of the Company’s conversion obligation in excess of the aggregate principal amount of the Notes being converted. The Notes have an initial conversion rate of 27.8364 shares of common stock per $1 principal amount of Notes (which is subject to adjustment in certain circumstances). This is equivalent to an initial conversion price of approximately $35.92 per share. The conversion rate is subject to customary adjustments under certain circumstances in accordance with the terms of the Indenture. Holders of the Notes have the right to require the Company to repurchase for cash all or a portion of their Notes at 100% of their principal amount, plus any accrued and unpaid special interest, upon the occurrence of a Fundamental Change. The Company is also required to increase the conversion rate for holders who convert their Notes in connection with a Fundamental Change or convert their Notes that are called for redemption, as the case may be, prior to the maturity date. The Company may not redeem the Notes prior to November 20, 2024. The Notes are redeemable, in whole or in part, for cash at the Company’s option at any time, and from time to time, on or after November 20, 2024 and before the 41st scheduled trading day immediately preceding the maturity date, but only if the last reported sale price per share of the common stock has been at least 130% of the conversion price then in effect for a specified period of time. As of September 30, 2023, none of the conditions that would trigger the right to convert the Notes had been met. The Notes are the Company’s senior unsecured obligations and will rank senior in right of payment to any of the Company’s existing and future indebtedness that is expressly subordinated in right of payment to the Notes; rank equal in right of payment to any of the Company’s future unsecured indebtedness that is not so subordinated; be effectively subordinated in right of payment to any of the Company’s existing and future secured indebtedness to the extent of the value of the collateral securing such indebtedness; and structurally subordinated to all existing and future indebtedness and other liabilities (including trade payables) of current or future subsidiaries of the Company. The Indenture also contains covenants, events of default and other provisions which are customary for offerings of convertible notes. We are in compliance with all covenants as of September 30, 2023. At September 30, 2023, the fair value of the Notes is $331,297. This is based on the quoted market price where the volume of activity is limited and not active and, thus, this is deemed a Level 2 fair value measurement. The Company incurred $671 and $2,010 of debt issuance cost accretion for the three and nine months ended September 30, 2023, respectively, as compared to $670 and $2,006 for the three and nine months ended September 30, 2022, respectively. Debt issuance cost accretion of $673, $2,698, $2,714, and $2,395 is expected to be incurred in the remaining three months of 2023 and in 2024, 2025 and 2026, respectively.

v3.23.3

Redeemable Non-Controlling Interest	9 Months Ended
	Sep. 30, 2023
Noncontrolling Interest [Abstract]
Redeemable Non-Controlling Interest	(11) Redeemable Non-Controlling Interest Upon consummation of the Company's acquisition of Kumovis, existing shareholders of Kumovis retained a 6.25% ownership interest in Kumovis that the Company reports as RNCI due to put and call terms that could result in the Company redeeming this remaining ownership interest at a future date (see Note 2). The following table shows changes in the reported RNCI balance during the nine months ended September 30, 2023: Nine Months Ended September 30, 2023 (in thousands) Balance at December 31, 2022 $ 1,760  Net loss (149) Redemption value in excess of carrying value 321  Translation adjustments (4) Balance at September 30, 2023 $ 1,928  The following table shows changes in the reported RNCI balance during the nine months ended September 30, 2022: Nine Months Ended September 30, 2022 (in thousands) Balance at December 31, 2021 $ —  Fair value at the date of acquisition 1,559  Net Loss (184) Redemption value in excess of carrying value 462  Translation Adjustments (183) Balance at September 30, 2022 $ 1,654

v3.23.3

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	(12) Stock-Based Compensation Stock Incentive Plans 2015 Incentive Plan The Company is authorized to grant shares of restricted stock, restricted stock units (“RSUs”), stock appreciation rights, cash incentive awards and options to purchase shares of Common Stock to employees and non-employees inclusive of directors pursuant to its 2015 Incentive Plan (the “2015 Plan”). The 2015 Plan also designates measures that may be used for performance-based awards and market-based awards. The vesting period for awards granted under the 2015 Plan is generally determined by the Board of Directors at the date of the grant. Generally, the awards vest one third each year, over 3 years. Systemic Bio Phantom Unit Plan During the three months ended September 30, 2023, we began granting phantom unit awards ("Phantom Units") under a new compensation plan designed for employees and non-employees performing services for Systemic Bio, a wholly-owned subsidiary of 3D Systems Corporation. All awards granted under the plan are subsidiary-level awards. The Phantom Units granted under the plan include both a time-based vesting condition (generally 4 years, subject to acceleration in connection with specified liquidity events) and a market condition that is met if (1) the value of Systemic Bio exceeds a specified multiple of the capital invested in this subsidiary (the "hurdle") and (2) the business achieves a specified minimum internal rate of return. The market condition will be assessed upon (A) a trigger event (e.g., change-in-control, IPO, or plan expiration of December 31, 2030) and/or (B) an interim liquidity event (defined as January 1, 2028) that occurs prior to a trigger event. All awards granted under the plan will be liability-classified due to our intention to settle these awards with cash; although, we have discretion to partially or fully settle these awards in equity upon vesting. Liability classification of the awards requires them to be remeasured at their fair value at the end of each reporting period. Due to the presence of the market-condition and the fact that Systemic Bio does not have a readily available share price, the awards are valued using a Monte Carlo simulation with the assistance of a third party valuation firm. Other Compensation Arrangements that Include Share Settlement Regenerative Medicine Earnout Payments and Performance-Based Stock Units On December 1, 2021, the Company acquired Volumetric. Pursuant to the terms of the related acquisition agreement, the Company may be required to pay milestone-based payments of up to $355,000 in the aggregate, all of which are incremental to the acquisition purchase price, upon (1) the achievement of seven discrete non-financial milestones that require attainment prior to either December 31, 2030 or December 31, 2035 and (2) the continued employment of certain key individuals from Volumetric. Each potential milestone-based payment is considered compensation expense, which the Company will recognize ratably from the point in time when a milestone is deemed probable of achievement through the estimated date of achievement. Each milestone payment will be settled approximately half in cash and half in shares of the Company’s Common Stock and, accordingly, the portion of the Company’s accrued liability (see Note 9) that is ultimately expected to be settled with the Company’s common stock is reflected in the disclosure of stock-based compensation included herein. In addition, the Company has granted performance-based stock units (“PSUs”), with vesting terms that are based upon four individually-measured, non-financial milestones, to other employees who work on advancements in regenerative medicine related to lungs and tissue organs. The PSUs associated with each individual milestone are recognized as compensation expense over the period commencing on the date that the respective milestone is deemed probable of being met through the anticipated date of achievement. Prior to the quarter ended September 30, 2023, the Company recognized compensation expense related to (1) one Volumetric milestone-based payment, for which the potential amount due to the sellers would be $65,000, and (2) one PSU milestone (“the RegMed Awards”), for which the aggregate grant date fair value of the outstanding and unvested awards was $4,773 as of June 30, 2023, as the related milestone was deemed probable of achievement. During the quarter ended June 30, 2023, as a result of the Company's decision to reduce budgeted funding related to the research and development efforts required to achieve the milestone, the estimated timing for achievement of both the Volumetric milestone and the PSU milestone shifted from the end of fiscal year 2025 to the end of fiscal year 2026. During the quarter ended September 30, 2023, the Company decided to further reduce its budgeted funding for the research and development related to the Volumetric Earnout and RegMed Award milestone, which resulted in the Company concluding that it is no longer probable that the milestone will be achieved by the end of the term of the Volumetric Earnout arrangement or prior to the expiration of the RegMed Awards. In concluding that the Volumetric and RegMed Award milestone would no longer be achieved, the Company reversed all of the previously accrued compensation expense, one half of which was expected to be settled with common shares, which had an income statement impact of $21,527 and $18,392 for the three and nine-months ended September 30, 2023, respectively. The reversals of the previously expensed Volumetric Earnout and RegMed Award reduced our reported net loss per basic and diluted share of common stock by $0.17 and $0.14 for the three and nine months ended September 30, 2023, respectively. dp polar Earnout On October 4, 2022, the Company acquired dp polar. Pursuant to the terms of the related acquisition agreement, the Company may be required to pay an additional $2,229, incremental to the acquisition purchase price, which will be settled via the issuance of 250 shares of the Company’s Common Stock. The issuance and vesting of these shares is contingent on the continued service of a certain key individual from dp polar through October 4, 2024. Upon assessment, management concluded that this potential obligation for the payment of an additional 250 shares of Common Stock will be accounted for as compensation expense recognized over the required service period of the individual to whom the amount will potentially be paid and, accordingly, the related expense is reflected in the disclosure of stock-based compensation included herein. During the nine months ended September 30, 2023, we modified the service period of this arrangement to end on December 31, 2024. The impact of this modification on stock-based compensation expense is immaterial. Stock-Based Compensation Activity and Expense 2015 Incentive Plan During the three and nine months ended September 30, 2023, the Company granted 111 and 3,990 shares of restricted stock, respectively, which had a weighted-average grant date fair value of $8.11 and $10.95 per share, respectively. The restricted stock awards generally vest ratably over three years, except for those awards that the Company granted to settle a portion of its accrued annual bonus liability at December 31, 2022, which were fully vested immediately upon issuance. The restricted stock granted during the nine months ended September 30, 2023 included 681 shares of market-based awards, whereby the number of shares that ultimately vest will be based upon the three-year performance of the Company's share price as compared to an index. These awards were valued using a Monte Carlo simulation, and the grant date fair value was $18.91 per share. The following table shows the stock-based compensation expense recognized during the three and nine months ended September 30, 2023 and 2022: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Stock-based compensation expense $ (3,142) $ 11,447  $ 15,140  $ 31,508  Tax benefit $ —  $ —  $ —  $ —  Included in stock-based compensation expense recognized for the three and nine months ended September 30, 2023 are $(1,055) and $0, respectively, and $1,282 and $3,123 for the three and nine months ended September 30, 2022, respectively, of accrued expense pertaining to annual bonus incentive compensation for which settlement is ultimately expected to occur using shares of the Company’s Common Stock. Also included in stock-based compensation expense are $(10,140) and $(8,640) for the three and nine months ended September 30, 2023, respectively, and $1,989 and $5,969 for the three and nine months ended September 30, 2022, respectively, which relate to the portion of the Volumetric Earnout expense reversed or recognized during each period that is expected to be settled using the Company’s Common Stock. Further, stock-based compensation expense for the three and nine months ended September 30, 2023 includes $175 and $727, respectively, of expense related to the dp polar earnout arrangement. Finally, stock-based compensation expense includes $(1,246) and $(1,113) for the three and nine months ended September 30, 2023, respectively, and $254 and $746 for the three and nine months ended September 30, 2022, respectively, of expense related to the RegMed awards. As of September 30, 2023, there was $52,508 of unrecognized stock-based compensation expense related to all unvested share-based payment awards that the Company expects to recognize over a weighted-average period of 2.0 years. Systemic Bio Phantom Unit Plan During the three months ended September 30, 2023, we granted 589 units under the Systemic Bio Phantom Unit Plan, all of which remained outstanding as of September 30, 2023. Compensation expense attributable to these awards is being recognized over 40.5 months or 48 months, based upon the recipient. As the awards include graded, time-based vesting and a market condition, compensation expense is being recognized under the graded vesting (accelerated attribution) method. Compensation expense and the associated liability recognized during the three months ended September 30, 2023 were $183.

v3.23.3

Interest and Other Income (Expense), Net	9 Months Ended
	Sep. 30, 2023
Other Income and Expenses [Abstract]
Interest and Other Income (Expense), Net	(13) Interest and Other Income (Expense), Net Interest and other income (expense), net consisted of the following amounts for the three and nine months ended September 30, 2023 and 2022: Three Months Ended Nine Months Ended (in thousands) September 30, 2023 September 30, 2022 September 30, 2023 September 30, 2022 Interest and other income (expense), net Foreign exchange (loss), net $ (2,202) $ (764) $ (3,847) $ (4,193) Interest income, net 4,909  2,029  13,118  4,019  Other (expense) income, net (105) (4,767) 420  (5,282) Total interest and other income (expense), net $ 2,602  $ (3,502) $ 9,691  $ (5,456) Interest and other income (expense), net includes (1) interest income of $5,841 and $15,730 for the three and nine months ended September 30, 2023, respectively, and $2,753 and $6,103 for the three and nine months ended September 30, 2022, respectively, and (2) interest expense of $932 and $2,612 for the three and nine months ended September 30, 2023 respectively, and $724 and $2,084 for the three and nine months ended September 30, 2022, respectively.

v3.23.3

Income Taxes	9 Months Ended
	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	(14) Income Taxes We maintain the exception under ASC 740-270-30-36(b), “Accounting for Income Taxes,” for jurisdictions that do not have reliable estimates of ordinary income. Based on volatility in the industry, we have continued to use a year-to-date methodology in determining the effective tax rate for the three and nine months ended September 30, 2023. For the three and nine months ended September 30, 2023, the Company’s effective tax rate was (1.6)% and (0.6)%, respectively. For the three and nine months ended September 30, 2022, the Company’s effective tax rate was (0.9)% and (3.1)%, respectively. The differences between the U.S. statutory tax rate and the effective tax rates for the three and nine months ended September 30, 2023 and September 30, 2022 are primarily driven by a full valuation allowance in various jurisdictions.

v3.23.3

Net Earnings (Loss) Per Share	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Net Earnings (Loss) Per Share	(15) Net Earnings (Loss) Per Share Basic net income (loss) per share is calculated by dividing net income (loss) attributable to 3D Systems’ Common Stock shareholders by the weighted average number of Common Stock shares outstanding during the applicable period. Diluted net income (loss) per share incorporates the additional shares issuable upon the assumed exercise of stock options, the vesting of restricted stock and RSUs, and the assumed conversion of debt, except in such cases when (1) the inclusion of such shares or potential shares would be anti-dilutive or (2) when the vesting of restricted stock or RSUs is contingent upon one or more performance conditions that have not been met as of the balance sheet date. Three Months Ended Nine Months Ended (in thousands, except per share amounts) September 30, 2023 September 30, 2022 September 30, 2023 September 30, 2022 Numerator for basic and diluted net (loss) income per share: Net (loss) income attributable to 3D Systems Corporation $ (11,704) $ (37,398) $ (70,020) $ (97,158) Redeemable non-controlling interest redemption value in excess of carrying value (61) (462) (321) (462) Net (loss) income attributable to common stock shareholders $ (11,765) $ (37,860) $ (70,341) $ (97,620) Denominator for net (loss) income per share: Weighted average shares – basic and diluted(1) 130,263  127,991  129,780  127,478  Net income (loss) per share – basic and diluted $ (0.09) $ (0.30) $ (0.54) $ (0.77) (1) Equity awards are deemed anti-dilutive for the three and nine month periods ended September 30, 2023 and 2022 because we reported a net loss for these periods. The following table presents the potentially dilutive shares that have been excluded from the computation of diluted earnings (loss) per share attributable to Common Stock shareholders because their effect is considered anti-dilutive for the three and nine months ended September 30, 2023 and 2022: Three and Nine Months Ended (in thousands) September 30, 2023 September 30, 2022 Restricted stock and restricted stock units 6,653  5,030  Stock options 420  420  Total 7,073  5,450  For the three and nine months ended September 30, 2023, the table above excludes an estimate of 110 shares that are contingently issuable under the dp polar earnout arrangement, as discussed in Note 12. As of September 30, 2023, there are no contingently issuable shares related to the Volumetric Earnout arrangement or the fiscal year 2023 annual bonus incentive compensation plan. For the three and nine months ended September 30, 2022, the table above excludes the following: (1) an estimate of 506 shares contingently issuable to settle the September 30, 2022 liability accrued for the assumed achievement of one milestone in the Volumetric Earnout arrangement, as discussed in Note 12, and (2) an estimate of 233 shares for the payment of the portion of the fiscal year 2022 annual bonus incentive compensation that was accrued as of September 30, 2022 and expected to be settled in shares. These share estimates are based upon the aggregate liabilities reported at September 30, 2022 for the Volumetric Earnout arrangement and a ratable portion of the fiscal year 2022 annual bonus incentive compensation that was settled using shares of the Company's Common Stock in the quarter ended June 30, 2023, divided by the Company's year-to-date average share price of $13.11 per share. On November 16, 2021, the Company issued $460,000 in aggregate principal amount of 0% Convertible Senior Notes due November 15, 2026, as discussed in Note 10. The Notes’ impact on weighted average diluted shares will be calculated using the if-converted method as prescribed in ASC 260. The Notes will increase the weighted average diluted share count when the Company's average share price over an interim or annual reporting period is greater than $35.92 per share, the conversion price of the Notes. For the three and nine months ended September 30, 2023 and 2022, the Notes were anti-dilutive on a stand-alone basis because (1) the Company's average share price during these periods did not exceed the conversion price and (2) we reported a net loss for each of the respective periods.

v3.23.3

Accumulated Other Comprehensive Loss	9 Months Ended
	Sep. 30, 2023
Stockholders' Equity Note [Abstract]
Accumulated Other Comprehensive Loss	(16) Accumulated Other Comprehensive Loss For the three and nine months ended September 30, 2023 and 2022, the changes in the balances of accumulated other comprehensive loss by component are as follows: Three Months Ended September 30, 2023 (in thousands) Foreign currency translation adjustment Defined benefit pension plan Unrealized loss on short-term investments Total Balance at June 30, 2023 $ (50,069) $ 689  $ —  $ (49,380) Other comprehensive income (loss) (7,352) (20) —  (7,372) Amounts reclassified from accumulated other comprehensive income (loss) —  (11) —  (11) Balance at September 30, 2023 $ (57,421) $ 658  $ —  $ (56,763) Nine Months Ended September 30, 2023 (in thousands) Foreign currency translation adjustment Defined benefit pension plan Unrealized loss on short-term investments Total Balance at December 31, 2022 $ (54,194) $ 700  $ (328) $ (53,822) Other comprehensive income (loss) (3,227) (8) 108  (3,127) Amounts reclassified from accumulated other comprehensive income (loss) (a) —  (34) 220  186  Balance at September 30, 2023 $ (57,421) $ 658  $ —  $ (56,763) Three Months Ended September 30, 2022 (in thousands) Foreign currency translation adjustment Defined benefit pension plan Unrealized loss on short-term investments Total Balance at June 30, 2022 $ (55,196) $ (1,976) $ (4,023) $ (61,195) Other comprehensive income (loss) (22,135) 164  (32) (22,003) Amounts reclassified from accumulated other comprehensive income (loss) (a) —  (8) 2,402  2,394  Balance at September 30, 2022 $ (77,331) $ (1,820) $ (1,653) $ (80,804) Nine Months Ended September 30, 2022 (in thousands) Foreign currency translation adjustment Defined benefit pension plan Unrealized loss on short-term investments Total Balance at December 31, 2021 $ (35,464) $ (2,242) $ —  $ (37,706) Other comprehensive income (loss) (41,867) 311  (4,055) (45,611) Amounts reclassified from accumulated other comprehensive income (loss) (a) —  111  2,402  2,513  Balance at September 30, 2022 $ (77,331) $ (1,820) $ (1,653) $ (80,804) (a) Amount reclassified into interest and other income (expense), net on the statement of operations. See Note 19 for details regarding fair value measurements and unrealized gains (losses) on short-term investments.The amounts presented in the table above are net of income taxes.

v3.23.3

Segment Information	9 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
Segment Information	(17) Segment Information The Company’s operations are comprised of two reportable segments: Healthcare Solutions and Industrial Solutions. Effective as of January 1, 2023, and for periods subsequent thereto, Adjusted EBITDA reflects the measure of profitability used by the Company’s chief operating decision maker (“CODM”) to evaluate the performance of the Company’s reportable segments. In addition, as of January 1, 2023, the Company's methodology for allocating certain costs between its segments was revised to more closely reflect changes in the Company's business and estimates of the usage of shared resources by the Company's segments. Prior year amounts have been reclassified to conform with current year presentation in connection with the changes referenced above. The following tables set forth our operating results by segment for the three and nine months ended September 30, 2023 and 2022: Revenue Adjusted EBITDA Three Months Ended September 30, Three Months Ended September 30, (in thousands) 2023 2022 2023 2022 Healthcare Solutions $ 52,429  $ 64,203  $ 13,869  $ 13,787  Industrial Solutions 71,362  68,050  7,662  7,180  Total Reportable segments 123,791  132,253  21,531  20,967  Corporate and Other(1) —  —  (16,805) (21,288) Total Company $ 123,791  $ 132,253  $ 4,726  $ (321) Revenue Adjusted EBITDA Nine Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Healthcare Solutions $ 162,028  $ 200,294  $ 30,328  $ 45,705  Industrial Solutions 211,193  205,005  16,828  16,473  Total Reportable segments 373,221  405,299  47,156  62,178  Corporate and Other(1) —  —  (59,422) (63,155) Total Company $ 373,221  $ 405,299  $ (12,266) $ (977) (1) Corporate and Other is not an operating segment, but reflects expenses not directly attributable to and, accordingly, not allocated to our reportable segments. These expenses relate to corporate functions such as human resources, finance, and legal and include expenses such as salaries, benefits, and other related costs. Similar to the Company's operating segments, Corporate results are reported to and reviewed by the Company’s CODM on the basis of Adjusted EBITDA. The following table provides a reconciliation of the Company’s reported net loss to the total of our reportable segment Adjusted EBITDA and Corporate and Other Adjusted EBITDA for the three and nine months ended September 30, 2023 and 2022: Three Months Ended Nine Months Ended (in thousands) September 30, 2023 September 30, 2022 September 30, 2023 September 30, 2022 Net loss attributable to 3D Systems Corporation $ (11,704) $ (37,398) $ (70,020) $ (97,158) Interest (income) expense, net (4,909) (2,029) (13,118) (4,019) Provision (benefit) for income taxes 174  338  404  2,911  Depreciation expense 5,084  5,142  15,690  15,992  Amortization expense 3,179  4,293  9,676  10,273  Stock-based compensation expense (3,142) 11,447 15,140 31,508 Acquisition and divestiture-related expense (4,055) 2,728 134 9,382 Legal expenses 2,145 9,707 4,880 20,467 Restructuring expense 1,504 67  6,712  376  Redeemable non-controlling interest (57) (147) (149) (184) Loss on equity method investment 605 —  747 —  Asset impairment charges 13,595 2,909 14,211 2,885 Other non-operating (income) expense 2,307 2,622 3,427 6,590 Adjusted EBITDA $ 4,726  $ (321) $ (12,266) $ (977)

v3.23.3

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	(18) Commitments and Contingencies Indemnification In the normal course of business, we periodically enter into agreements to indemnify customers or suppliers against claims of intellectual property infringement that may be made by third parties and arise from the use of our products. Historically, costs related to these indemnification provisions have not been significant, and we are unable to estimate the maximum potential impact of these indemnification provisions on our future results of operations. To the extent permitted under Delaware law, we indemnify our directors and officers for certain events or occurrences, when the director or officer is, or was, serving at our request in such capacity, subject to limited exceptions. The maximum potential amount of future payments we could be required to make under these indemnification obligations is unlimited; however, we have directors and officers insurance coverage that may enable us to recover future amounts paid, subject to a deductible and the policy limits. There is no assurance that the policy limits will be sufficient to cover all damages, if any. Other Commitments Government Settlement As previously disclosed, beginning in October 2017, the Company undertook an internal investigation relating to possible violations of U.S. export control laws, including the International Traffic in Arms Regulations administered by the Directorate of Defense Trade Controls of the Department of State (“DDTC”) and the Export Administration Regulations administered by the Bureau of Industry and Security of the Department of Commerce (“BIS”). In February 2023, the Company settled these matters with the U.S. Department of Justice (“DOJ”), DDTC and BIS. As a part of these settlement agreements, the Company agreed to pay $15,048 in civil monetary penalties to these agencies, with an additional $10,000 in suspended penalty amounts to be allocated to remedial compliance measures required by DDTC. The penalty amounts were broken down as follows: DDTC, $10,000 (in three installments over a three-year period); BIS, $2,778; and DOJ, $2,270. The first penalty installment payment to DDTC and the full penalty payments to BIS and to DOJ were made in the first quarter of 2023. The $10,000 suspended penalty has not been recognized as a liability as of September 30, 2023 and will be recognized as incurred during the three-year term of the settlement agreement and any portion not expended at the end of the three-year term of the settlement agreement will be paid by the Company to DDTC. Litigation Shareholder Suits The Company and certain of its current and former executive officers have been named as defendants in a consolidated putative stockholder class action lawsuit pending in the United States District Court for the Eastern District of New York (the “District Court”). The action is styled In re 3D Systems Securities Litigation, No. 1:21-cv-01920-NGG-TAM (E.D.N.Y.) (the “Securities Class Action”). On July 14, 2021, the Court appointed a Lead Plaintiff for the putative class and approved his choice of Lead Counsel. Lead Plaintiff filed his Consolidated Amended Complaint (the “Amended Complaint”) on September 13, 2021, alleging that defendants violated the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and SEC Rule 10b-5 promulgated thereunder by making false and misleading statements and omissions, and that the current and former executive officers named as defendants are control persons under Section 20(a) of the Exchange Act. The Amended Complaint was filed on behalf of stockholders who purchased shares of the Company’s Common Stock between May 6, 2020 and March 5, 2021, and seeks monetary damages on behalf of the purported class. Defendant moved to dismiss the Amended Complaint on February 15, 2022, and the motion was fully briefed in May 2022. On October 28, 2022, the parties notified the District Court that they reached an agreement in principle resolving this action, and on December 19, 2022, Lead Plaintiff filed a motion seeking entry of an order preliminarily approving the settlement and establishing notice procedures. The settlement is subject to both preliminary and final approval by the District Court. On June 5, 2023, following the District Court’s referral of Lead Plaintiff’s motion to a Magistrate Judge for a Report and Recommendation on the motion, the Magistrate Judge issued a Report and Recommendation recommending that the District Court grant Lead Plaintiff’s motion for preliminary approval of the settlement. The District Court adopted the Report and Recommendation and preliminarily approved the settlement on July 19, 2023. A final hearing on the settlement is scheduled for November 21, 2023. The settlement is subject to both preliminary and final approval by the District Court. On April 15, 2022, the Company was informed that the SEC is conducting a formal investigation of the Company related to, among other things, the allegations in the Securities Class Action, and the Company received subpoenas from the SEC for the production of documents and information related to its investigation as a follow on to a previous voluntary request for documents. The Company is cooperating with the SEC. The Company has been named as a nominal defendant and certain of its current and former executive officers and directors have been named as defendants in derivative lawsuits pending in the United States District Court for the Eastern District of New York, the South Carolina Court of Common Pleas for the 16th Circuit, York County, and the Supreme Court of the State of New York, Kings County. The actions are styled Nguyen v. Joshi, et al., No. 21-cv-03389-NGG-TAM (E.D.N.Y.) (the “Nguyen Action”), Lesar v. Graves, et al., No. 2021CP4602308 (S.C., Ct. of Common Pleas for the 16th Judicial Cir., Cty. of York) (the “Lesar Action”), Scanlon v. Graves, et al., No. 2021CP4602312 (S.C., Ct. of Common Pleas for the 16th Judicial Cir., Cty. of York) (the “Scanlon Action”), Bohus v. Joshi, et al., No. 22-cv-2203-CBA-RML (E.D.N.Y.) (the “Bohus Action”), and Fernicola v. Clinton, et. al., No. 512613/2022 (N.Y., Kings County Supreme Court) (the “Fernicola Action”). The Complaints in the Nguyen and Bohus Actions, which were filed on June 15, 2021 and April 18, 2022, respectively, assert breach of fiduciary duty claims against all defendants and claims for contribution under the federal securities laws against certain of the defendants. The Complaints in the Lesar and Scanlon Actions, which were filed on July 26, 2021, assert breach of fiduciary duty and unjust enrichment claims against the defendants. The Complaint in the Fernicola Action was filed on May 2, 2022, and asserts claims for breach of fiduciary duty and waste of corporate assets against the director defendants. On August 27, 2021, the Nguyen Action was stayed until 30 days after the earlier of: (i) the close of discovery in the Securities Class Action, or (ii) the deadline for appealing a dismissal of the Securities Class Action with prejudice. On October 26, 2021, the Lesar Action and the Scanlon Action were consolidated into a single stockholder derivative action, styled as In Re 3D Systems Corp. Shareholder Derivative Litigation, No. 2021CP4602308 (S.C., Ct. of Common Pleas for the 16th Judicial Cir., Cty. Of York) (the “South Carolina Derivative Action”). On March 3, 2022, the South Carolina Derivative Action was stayed until 30 days after the earlier of: (i) the close of discovery in the Securities Class Action, or (ii) the deadline for appealing a dismissal of the Securities Class Action with prejudice. On June 16, 2022, the Bohus Action was consolidated with the Nguyen Action (the “E.D.N.Y. Derivative Action”). The E.D.N.Y. Derivative Action is stayed until 30 days after the earlier of: (i) the close of discovery in the Securities Class Action, or (ii) the deadline for appealing a dismissal of the Securities Class Action with prejudice. On August 15, 2022, the Fernicola Action was voluntarily dismissed without prejudice. The Company believes the claims alleged in the putative securities class action and derivative lawsuits are without merit and the Company intends to defend itself and its current and former officers vigorously. Letter of Credit On June 2, 2023, we issued $1,161 of guarantees in the form of a standby letter of credit as security for a long-term real estate lease. The letter of credit has an initial maturity date of June 2024 with automatic one-year extensions not beyond July 1, 2033. We have not recorded any liability for this guarantee as we believe the likelihood of having to perform under the letter of credit is remote. In connection with this transaction, we pledged an equal amount of cash to the issuing bank of this letter of credit. The cash pledged is recorded as restricted cash, included in other assets on our condensed consolidated balance sheets. Other We are involved in various other legal matters incidental to our business. Although we cannot predict the results of the litigation with certainty, we believe that the disposition of all of these various other legal matters will not have a material adverse effect, individually or in the aggregate, on our consolidated results of operations, consolidated cash flows or consolidated financial position. In connection with the foregoing matters, we recognized a liability of $16,044 during the year ended December 31, 2022, which includes the $10,000 DDTC civil monetary penalty being recognized at a discount using the risk-free interest rate in effect at the time of recognition. During the nine months ended September 30, 2023, we have paid $8,548 of this liability in accordance with the settlement agreements discussed above. Refer to Note 9 for details regarding our remaining short-term and long-term liabilities recorded for legal contingencies.

v3.23.3

Fair Value Measurements	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	(19) Fair Value Measurements Fair value is the exchange price to sell an asset or transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. Fair value measurements use market data or assumptions market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs may be readily observable, corroborated by market data, or generally unobservable. Valuation techniques maximize the use of observable inputs and minimize use of unobservable inputs. The accounting guidance for fair value measurements and disclosures establishes a three-level fair value hierarchy: •Level 1 - Inputs are based on quoted prices in active markets for identical assets and liabilities. •Level 2 - Inputs are based on observable inputs other than quoted prices in active markets for identical or similar assets and liabilities. •Level 3 - One or more inputs are unobservable and significant. Financial and nonfinancial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Cash equivalents are valued utilizing the market approach to measure fair value for financial assets and liabilities. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. The carrying amounts of our cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities approximate fair value as of September 30, 2023 and December 31, 2022 because of the relatively short duration of these instruments. We did not have any transfers of assets or liabilities between Level 1, Level 2 and Level 3 of the fair value measurement hierarchy during the three and nine months ended September 30, 2023. Assets measured at fair value on a recurring basis as of December 31, 2022 are summarized below. During the three months ended September 30, 2023, we sold all of our remaining Level 2 short-term investments included in the table below. Fair Value Measurement as of December 31, 2022 Fair Value Measurement Balance Sheet Classification (in thousands) Fair Value Level Cost Basis Unrealized Gains (Losses) Fair Value Cash and Cash Equivalents Short-term Investments Money market funds Level 1 $ 232,018  $ —  $ 232,018  $ 232,018  $ —  Certificates of deposit Level 2 990  6  996  —  996  Commercial paper Level 2 1,281  6  1,287  —  1,287  Short-term bond mutual funds Level 2 100,242  (99) 100,143  —  100,143  Corporate bonds(a) Level 2 78,418  (241) 78,177  —  78,177  Total $ 412,949  $ (328) $ 412,621  $ 232,018  $ 180,603  (a) Includes $745 and $743 of cost basis and fair market value, respectively, with a weighted average maturity of 1.3 years.

v3.23.3

Restructuring	9 Months Ended
	Sep. 30, 2023
Restructuring and Related Activities [Abstract]
Restructuring	(20) Restructuring During the three months ended June 30, 2023, the Company announced a restructuring initiative intended to improve internal operating efficiencies, as well as long-term valuation creation. Actions taken by the Company primarily consisted of a reduction in headcount of approximately 6% of the Company's workforce, with the majority of the workforce reduction occurring in corporate and business support functions predominately located in the US and Europe. Since initiating the plan, the Company has accrued severance and termination costs totaling $3,724, which have been reported within selling, general, and administrative expense on the Company's condensed consolidated statement of operations and reflect the total costs expected to be incurred in connection with this activity. As the reduction in workforce was concentrated within corporate and business support functions, the reported results of the Company's Healthcare Solutions and Industrial Solutions segments were not impacted by this restructuring initiative. The settlement of all costs accrued in connection with this restructuring initiative is expected to occur prior to the end of the year ending December 31, 2023. The following table provides additional details regarding the restructuring costs incurred during the period, the portion of such costs that were settled with cash as of September 30, 2023, and the remaining accrued liability reported in our condensed consolidated balance sheet as of September 30, 2023: (in thousands) Accrued liability as of December 31, 2022 Costs incurred during 2023 Amounts settled with cash Accrued liability as of September 30, 2023 Severance, termination benefits and other employee costs $ —  $ 3,724  $ 2,693  $ 1,031  Total $ —  $ 3,724  $ 2,693  $ 1,031  In addition to the recognition of severance and termination costs, the Company recognized an impairment charge of $628 related to certain fixed assets that were retired.

v3.23.3

Subsequent Events	9 Months Ended
	Sep. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	(21) Subsequent Events On October 25, 2023, the Company announced the next evolution of its restructuring initiative designed to improve operating efficiencies throughout the organization and drive long-term value creation. This additional phase of the restructuring initiative will target to deliver expected annualized savings of between $45 million and $55 million by the end of 2024, with the majority of the cost takeout to occur by the end of the first quarter of 2024. This initiative is primarily targeted at continuing to rationalize headcount and geographic locations in all functions across the Company. As this latest phase of the Company's multi-faceted restructuring initiative contemplates the execution of new strategic actions that may be taken with respect to certain of the Company’s previously acquired businesses and/or other asset groups, certain asset groups could become subject to impairment tests triggered by (1) an adverse change in the extent or manner in which the long-lived asset (or asset group) is being used, (2) a current expectation that it is more likely than not that the long-lived asset (or asset group) will be sold or otherwise disposed of significantly before the end of its previously estimated useful life, or (3) other factors triggered by the Company's restructuring initiative. If required, a quantitative impairment test related to any of our asset groups could result in the recognition of a material impairment charge.

v3.23.3

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net (loss) income attributable to 3D Systems Corporation	$ (11,704)	$ (37,398)	$ (70,020)	$ (97,158)

v3.23.3

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

v3.23.3

Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	The accompanying unaudited condensed consolidated financial statements include the accounts of 3D Systems Corporation and all majority and wholly-owned subsidiaries and entities in which a controlling interest is maintained (“3D Systems” or the “Company” or “we” or “our” or “us”). All significant intercompany accounts and transactions have been eliminated in consolidation.  A non-controlling interest in a subsidiary reflects an ownership interest in a majority-owned subsidiary that is not attributable to the Company. For the periods presented, the Company's financial statements include a redeemable non-controlling interest (“RNCI”), which has been reported in temporary equity in the consolidated balance sheets. The net income (loss) attributable to the RNCI is presented as an adjustment to the Company's consolidated net income (loss) to arrive at net income (loss) attributable to 3D Systems Corporation in the consolidated statements of operations and consolidated statements of comprehensive income (loss). Furthermore, adjustments to record the RNCI at its redemption value are recorded to additional paid-in capital, and the excess redemption value is recognized as a reduction to the net income, or increase to the net loss, attributable to 3D Systems’ shareholders for purposes of reporting earnings or loss per share. See Note 11 for a summary of the activity related to the reported RNCI balance during the period. The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) applicable to interim reports. Accordingly, our unaudited condensed consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022 (“2022 Form 10-K”). The year-end balance sheet data reported on our unaudited condensed consolidated balance sheet has been derived from the balance sheet included in our 2022 Form 10-K. The Company believes that the disclosures included in this Form 10-Q are adequate to make the information presented not misleading. In the opinion of management, the unaudited condensed consolidated financial statements include all adjustments, consisting of adjustments of a normal recurring nature, necessary to present fairly the financial position, results of operations, and cash flows for the periods presented. The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results may differ from those estimates and assumptions. Our annual reporting period is the calendar year. Our results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for the full year. All dollar amounts and other amounts presented in the accompanying footnotes are presented in thousands, except for per share information.
Goodwill	Goodwill Goodwill is the excess of the cost of an acquired entity over the amounts assigned to the assets acquired and liabilities assumed in a business combination. Goodwill is not amortized. Goodwill is tested for impairment annually during the fourth quarter of each year, and is tested for impairment between annual tests if an event occurs or circumstances change that would indicate the carrying amount may be impaired. Impairment testing for goodwill is done at a reporting unit level, with all goodwill assigned to a reporting unit. The test for impairment of goodwill requires the Company to make several estimates related to projected future cash flows to determine the fair value of the goodwill reporting units. The Company calculates the excess of each reporting unit's fair value over its carrying amount, including goodwill, utilizing a discounted cash flow analysis and other valuation techniques, as deemed appropriate. Internal operational budgets and long-range strategic plans are used as a basis for the cash flow analysis. The Company also utilizes assumptions for working capital, capital expenditures, and terminal growth rates. The discount rate applied to the cash flow analysis is based on the weighted average cost of capital (“WACC”) for each reporting unit. An impairment is recognized when the carrying amount of the reporting unit’s net assets exceeds the estimated fair value of the reporting unit. During the quarter ended September 30, 2023, the Company experienced a significant decline in its market capitalization as a result of a decrease in its stock price, and during the month ended September 30, 2023, the Company’s market capitalization fell slightly below its consolidated stockholders’ equity balance. We do not consider this to constitute a sustained decrease in the Company’s stock price as of September 30, 2023. Furthermore, the Company performed a qualitative goodwill impairment assessment as of September 30, 2023 and concluded that it is not more likely than not that the fair value of either of its reporting units is less than the reporting unit’s carrying value as of September 30, 2023. As a result, we concluded that no triggering event had occurred that would require the Company to perform a quantitative goodwill impairment test for either of its two reporting units as of September 30, 2023. However, the Company’s market capitalization has declined further since September 30, 2023, and if such a decline results in the estimated fair value of either of our reporting units being lower than the respective reporting unit’s carrying value, the Company would need to record a non-cash goodwill impairment charge, which could be material, in a future period – including as of our upcoming annual impairment testing date of November 1, 2023 (reflecting our annual goodwill impairment testing date commencing as of the current fiscal year).
Variable Interest Entities (VIEs)	Variable Interest Entities (VIEs) Upon making an investment in an entity, we assess whether the entity is a VIE. The determination of whether an entity in which we hold a direct or indirect variable interest is a VIE is based on several factors, including whether the entity’s total equity investment at risk upon inception is sufficient to finance the entity’s activities without additional subordinated financial support. We make judgments regarding the sufficiency of the equity at risk based first on a qualitative analysis, and then a quantitative analysis, if necessary. We analyze any investments in VIEs to determine if we are the primary beneficiary. We perform this assessment at the time that we become involved with a VIE and reevaluate our conclusion upon the occurrence of a reconsideration event. In evaluating whether we are the primary beneficiary, we evaluate our direct and indirect economic interests in the entity. Determining which reporting entity, if any, is the primary beneficiary of a VIE is primarily a qualitative approach focused on identifying which reporting entity has both (1) the power to direct the activities of a VIE that most significantly impact such entity’s economic performance and (2) the obligation to absorb losses or the right to receive benefits from such entity that could potentially be significant to such entity. Performance of such analysis requires the exercise of judgment, and we consider a variety of factors in identifying the entity that holds the power to direct matters that most significantly impact a VIE’s economic performance including, but not limited to, the ability to direct a VIE’s operating decisions and activities. In addition, we consider the rights of other investors to participate in those decisions.
Equity Securities without a Readily Determinable Value	Equity Securities without a Readily Determinable ValueWe recognize investments in equity securities without a readily determinable fair value at cost minus impairment. We assess these investments for potential impairment if an event occurs or circumstances change that would indicate the carrying amount may be impaired. If applicable, impairment charges taken with respect to these investments are reported within interest and other income (expense), net in the consolidated statements of operations in the period in which an investment becomes impaired (see Note 7).
Equity Method of Accounting	Equity Method of AccountingThe Company accounts for an investment in a joint venture using the equity method of accounting because it does not have a controlling interest and is not the primary beneficiary; however, the Company has the ability to exert significant influence. Under the equity method of accounting, the initial investment is recorded at cost, and the investment is subsequently adjusted for the Company’s proportionate share of the net earnings or losses and other comprehensive income or loss of the investee. Intra-entity profits or losses associated with the Company’s equity method investment are eliminated until realized by the investee in transactions with third parties. Income or loss from this investment is recorded as a separate line item in the consolidated statements of operations on a three-month lag. We evaluate material events occurring during the three-month lag period to determine whether the effects of such events should be disclosed in our financial statements. The Company will evaluate its investment in the joint venture for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment may not be recoverable.
Revenue Recognition	Collaboration and Licensing Agreements We enter into collaboration and licensing agreements with third parties. The nature of the activities to be performed and the consideration exchanged under these agreements varies on a contract-by-contract basis. We evaluate these agreements to determine whether they meet the definition of a customer relationship for which revenue should be recorded. These contracts may contain multiple performance obligations and may contain fees for licensing, research and development services, contingent milestone payments upon the achievement of contractual developmental criteria and/or royalty fees based on the licensees’ product revenue. We determine the revenue to be recognized for these agreements based on an evaluation of the distinct performance obligations, the identification and evaluation of material rights, the estimation of variable consideration and the determination of the pattern of transfer of control for each distinct performance obligation. During the three and nine-month periods ended September 30, 2023, the Company recognized $7,896 and $16,099, respectively, of revenue related to collaboration arrangements with customers. During the three and nine-month periods ended September 30, 2022, the Company recognized $3,301 and $9,075, respectively, of revenue related to collaboration arrangements with customers. Our revenue recognized under collaboration and licensing agreements for the three and nine months ended September 30, 2023 includes the effect of the Company increasing its estimate of the variable consideration included in the transaction price related to one of its licensing agreements. The increase in estimated recognizable variable consideration was due to (1) the execution of a modification to the related customer contract and (2) the Company's determination that incremental revenue attributable to milestone payments that are contingent upon the achievement of contractual developmental criteria would be earned under the modified contract. As a result, during the quarter ended September 30, 2023, the Company recognized incremental services revenue of $4,452, which reduced our reported basic and diluted loss per share by $0.03 and $0.03, respectively, for each of the three and nine months ended September 30, 2023. Contract Balances During the nine months ended September 30, 2023, we recognized revenue of $23,498 related to our contract liabilities at December 31, 2022. During the nine months ended September 30, 2022, we recognized revenue of $28,850 related to our contract liabilities at December 31, 2021. Contract assets were $7,379 and $677 as of September 30, 2023 and December 31, 2022, respectively. The increase in the contract assets balance as of September 30, 2023 primarily relates to the increase in the estimated variable consideration included in the transaction price related to one of the Company's collaboration and licensing agreements (refer to the discussion above of Collaboration and Licensing Agreements), which has resulted in the recognition of incremental revenue for which the Company did not have the right to invoice as of the balance sheet date. Revenue Concentrations For the three and nine months ended September 30, 2023, one customer accounted for approximately 10.7% and 14.4% of our consolidated revenue, respectively. For the three and nine months ended September 30, 2022, one customer accounted for approximately 20.8% and 24.1% of our consolidated revenue, respectively. We expect to maintain our relationship with this customer.
Fair Value Measurements	Cash equivalents are valued utilizing the market approach to measure fair value for financial assets and liabilities. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. The carrying amounts of our cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities approximate fair value as of September 30, 2023 and December 31, 2022 because of the relatively short duration of these instruments.

v3.23.3

Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2023
Business Combination and Asset Acquisition [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	Shown below is the preliminary purchase price allocation, which summarizes the fair values of the assets acquired and liabilities assumed at the date of acquisition: (in thousands) Current assets, including cash acquired of $148 $ 835  Intangible assets: Trade names $ 1,487  Product technology 2,231  Customer relationships 347  Total intangible assets 4,065  Goodwill 6,878  Other assets 475  Liabilities: Accounts payable and accrued liabilities $ 794  Long term liabilities 293  Total liabilities 1,087  Net assets acquired $ 11,166  Shown below is the final purchase price allocation, which summarizes the fair values of the assets acquired and liabilities assumed at the date of acquisition: (in thousands) Current assets, including cash acquired of $243 $ 301  Intangible assets: In-process research and development $ 4,989  Trade name 3,930  Total intangible assets 8,919  Goodwill 17,090  Other assets 765  Liabilities: Accounts payable and accrued liabilities $ 364  Deferred tax liability 845  Total liabilities 1,209  Net assets acquired $ 25,866  The table below reflects the fair value of both the consideration transferred and the RNCI attributable to this acquisition: (in thousands) Cash paid at acquisition $ 34,098  Deferred cash consideration 3,628  Estimated fair value of RNCI 1,559  Post-closing net working capital adjustment 149  Total fair value of consideration transferred $ 39,434  Shown below is the final purchase price allocation, summarizing the fair values of the assets acquired and liabilities assumed at the date of acquisition: (in thousands) Current assets, including cash acquired of $125 $ 1,407  Intangible assets: Product technology $ 20,770  Trade name 5,802  Total intangible assets 26,572  Goodwill 17,618  Other assets 705  Liabilities: Accounts payable and accrued liabilities $ 332  Deferred revenue 70  Deferred tax liability 6,466  Total liabilities 6,868  Net assets acquired $ 39,434  Shown below is the final purchase price allocation, summarizing the fair values of the assets acquired and liabilities assumed, as determined at the date of acquisition in accordance with valuation methodologies described in ASC 820: (in thousands) Current assets $ 661  Intangible assets: Product technology $ 15,940  Trade name 5,580  Total intangible assets 21,520  Goodwill 17,430  Other assets 68  Liabilities: Accounts payable and accrued liabilities $ 229  Deferred revenue 410  Total liabilities 639  Net assets acquired $ 39,040
Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination	The following table presents the finite-lived intangible assets acquired and their respective estimated useful lives: Useful Life Trade names 5 Product technology 15 Customer relationships 10
Schedule of Acquisition, Pro Forma Information	The following unaudited pro forma financial information summarizes the combined results of the Company and Wematter as if the acquisition had occurred on January 1, 2022. The pro forma results have been prepared for comparative purposes only, and do not necessarily represent what the results of operations would have been had the acquisition been completed on January 1, 2022. In addition, these pro forma results are not intended to be a projection of future operating results and do not reflect synergies that might be achieved. The unaudited pro forma financial information includes adjustments for the pro forma impact of our preliminary purchase price allocation, including the amortization for newly acquired intangible assets, the impact of transaction costs, and the alignment of accounting policies. Transaction costs have been included in the pro forma results for the periods ended September 30, 2022, consistent with the pro forma assumption that the acquisition occurred on January 1, 2022. Pro forma revenue information has not been presented, as pre-acquisition revenue reported by Wematter was not material and, accordingly, the impact on our reported consolidated revenue also would not have been material. Pro forma net loss is not presented in the table below for the three months ended September 30, 2023 because Wematter's results are reflected in 3D Systems consolidated numbers for the full period. Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2022 2023 2022 Net (loss) income attributable to 3D Systems Corporation $ (38,407) $ (71,076) $ (100,185)

v3.23.3

Revenue (Tables)	9 Months Ended
	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Schedule of Revenue by Geographic Region	Revenue by geographic region for the three and nine months ended September 30, 2023 and 2022 was as follows: Three Months Ended (in thousands) September 30, 2023 September 30, 2022 Americas $ 69,714  $ 80,455  EMEA 43,141  36,913  APAC 10,936  14,885  Total $ 123,791  $ 132,253  United States (included in Americas above) $ 68,840  $ 78,910  Nine Months Ended (in thousands) September 30, 2023 September 30, 2022 Americas $ 214,956  $ 234,511  EMEA 127,150  122,788  APAC 31,115  48,000  Total $ 373,221  $ 405,299  United States (included in Americas above) $ 211,717  $ 231,557

v3.23.3

Inventories (Tables)	9 Months Ended
	Sep. 30, 2023
Inventory Disclosure [Abstract]
Schedule of Components of Inventories	Components of inventories at September 30, 2023 and December 31, 2022 are summarized as follows: (in thousands) September 30, 2023 December 31, 2022 Raw materials $ 61,314  $ 59,907  Work in process 3,922  4,972  Finished goods and parts 87,769  72,953  Total inventories $ 153,005  $ 137,832

v3.23.3

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets Other Than Goodwill	At September 30, 2023 and December 31, 2022, the Company's intangible assets with finite lives were as follows: September 30, 2023 December 31, 2022 (in thousands) Gross Accumulated Amortization Net Gross Accumulated Amortization Net Intangible assets with finite lives: Customer relationships $ 51,160  $ (49,417) $ 1,743  $ 51,137  $ (48,695) $ 2,442  Acquired technology 45,894  (11,925) 33,969  55,480  (10,707) 44,773  Trade names 30,496  (13,705) 16,791  35,930  (12,455) 23,475  Patent costs 18,714  (10,823) 7,891  18,673  (10,909) 7,764  Acquired patents 16,426  (14,716) 1,710  17,499  (15,661) 1,838  Other 13,170  (9,120) 4,050  13,255  (8,765) 4,490  Total intangible assets $ 175,860  $ (109,706) $ 66,154  $ 191,974  $ (107,192) $ 84,782

v3.23.3

Goodwill (Tables)	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The following table reflects the changes in the carrying amount of goodwill by reporting unit for the nine months ended September 30, 2023: Nine Months Ended September 30, 2023 Healthcare Industrial Consolidated (in thousands) Gross Goodwill Impairments Net Goodwill Gross Goodwill Impairments Net Goodwill Gross Goodwill Impairments Net Goodwill Balance at beginning of year $ 143,431  $ (32,055) $ 111,376  $ 316,265  $ (42,329) $ 273,936  $ 459,696  $ (74,384) $ 385,312  Acquisitions and measurement period adjustments 1,005  —  1,005  7,735  —  7,735  8,740  —  8,740  Foreign currency translation adjustments (1,175) —  (1,175) (1,552) —  (1,552) (2,727) —  (2,727) Balance at end of period $ 143,261  $ (32,055) $ 111,206  $ 322,448  $ (42,329) $ 280,119  $ 465,709  $ (74,384) $ 391,325

v3.23.3

Investments and Notes Receivable (Tables)	9 Months Ended
	Sep. 30, 2023
Equity Method Investments and Joint Ventures [Abstract]
Schedule of Equity Investments	The following table summarizes our investment balances as of September 30, 2023 and December 31, 2022: (in thousands) September 30, 2023 December 31, 2022 Equity investments under the equity method of accounting $ 5,782  $ —  Equity investments without readily determinable fair values 20,962  12,953  Other(1) 200  200  Total equity investments $ 26,944  $ 13,153  Long-term note receivable(2) $ 530  $ 515  Total notes receivable $ 530  $ 515  (1) Reflects warrant investment carried at fair value. The fair value of these warrants is measured using Level 3 fair value measurement inputs. Refer to Note 19 for a description of these inputs. (2) Includes interest amounts that have been accrued on, recorded to and reported as part of the notes receivable balance.

v3.23.3

Leases (Tables)	9 Months Ended
	Sep. 30, 2023
Leases [Abstract]
Schedule of Balance Sheet Classifications	Classifications of the lease amounts reported on our balance sheets as of September 30, 2023 and December 31, 2022 are summarized below: September 30, 2023 December 31, 2022 (in thousands) Right-of-use assets Current lease liabilities Long-term lease liabilities Right-of-use assets Current lease liabilities Long-term lease liabilities Operating leases $ 60,973  $ 9,616  $ 59,428  $ 39,502  $ 8,343  $ 38,499  Finance leases 12,047  1,068  11,867  3,244  693  3,280  Total $ 73,020  $ 10,684  $ 71,295  $ 42,746  $ 9,036  $ 41,779

v3.23.3

Accrued and Other Liabilities (Tables)	9 Months Ended
	Sep. 30, 2023
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities at September 30, 2023 and December 31, 2022 are summarized as follows: (in thousands) September 30, 2023 December 31, 2022 Compensation and benefits $ 15,492  $ 19,814  Accrued taxes 9,633  10,694  Legal contingencies 4,850  9,948  Product warranty liability 2,409  3,677  Other accrued liabilities 11,191  11,438  Total $ 43,575  $ 55,571
Schedule of Recognized Warranty Revenue and Incurred Warranty Costs	Changes in the product warranty obligation for the nine months ended September 30, 2023 and 2022 are summarized below: (in thousands) Beginning Balance Settlements Made Accruals for Warranties Issued Ending Balance September 30, 2023 $ 3,677  $ (2,983) $ 1,715  $ 2,409  September 30, 2022 $ 3,585  $ (5,266) $ 5,257  $ 3,576
Schedule of Other Liabilities	Other liabilities at September 30, 2023 and December 31, 2022 are summarized as follows: (in thousands) September 30, 2023 December 31, 2022 Long-term employee indemnity $ 4,634  $ 4,817  Long-term tax liability 5,568  5,711  Defined benefit pension obligation 4,963  5,050  Long-term deferred revenue 1,858  4,974  Earnout liability —  17,244  Legal contingencies 2,916  6,096  Other long-term liabilities 428  289  Total $ 20,367  $ 44,181

v3.23.3

Redeemable Non-Controlling Interest (Tables)	9 Months Ended
	Sep. 30, 2023
Noncontrolling Interest [Abstract]
Schedule of Redeemable Noncontrolling Interest	The following table shows changes in the reported RNCI balance during the nine months ended September 30, 2023: Nine Months Ended September 30, 2023 (in thousands) Balance at December 31, 2022 $ 1,760  Net loss (149) Redemption value in excess of carrying value 321  Translation adjustments (4) Balance at September 30, 2023 $ 1,928  The following table shows changes in the reported RNCI balance during the nine months ended September 30, 2022: Nine Months Ended September 30, 2022 (in thousands) Balance at December 31, 2021 $ —  Fair value at the date of acquisition 1,559  Net Loss (184) Redemption value in excess of carrying value 462  Translation Adjustments (183) Balance at September 30, 2022 $ 1,654

v3.23.3

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-based Compensation Expense	The following table shows the stock-based compensation expense recognized during the three and nine months ended September 30, 2023 and 2022: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Stock-based compensation expense $ (3,142) $ 11,447  $ 15,140  $ 31,508  Tax benefit $ —  $ —  $ —  $ —

v3.23.3

Interest and Other Income (Expense), Net (Tables)	9 Months Ended
	Sep. 30, 2023
Other Income and Expenses [Abstract]
Schedule of Interest and Other Income (Expenses), Net	Interest and other income (expense), net consisted of the following amounts for the three and nine months ended September 30, 2023 and 2022: Three Months Ended Nine Months Ended (in thousands) September 30, 2023 September 30, 2022 September 30, 2023 September 30, 2022 Interest and other income (expense), net Foreign exchange (loss), net $ (2,202) $ (764) $ (3,847) $ (4,193) Interest income, net 4,909  2,029  13,118  4,019  Other (expense) income, net (105) (4,767) 420  (5,282) Total interest and other income (expense), net $ 2,602  $ (3,502) $ 9,691  $ (5,456)

v3.23.3

Net Earnings (Loss) Per Share (Tables)	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Schedule of Net Loss Per Share Reconciliation	Three Months Ended Nine Months Ended (in thousands, except per share amounts) September 30, 2023 September 30, 2022 September 30, 2023 September 30, 2022 Numerator for basic and diluted net (loss) income per share: Net (loss) income attributable to 3D Systems Corporation $ (11,704) $ (37,398) $ (70,020) $ (97,158) Redeemable non-controlling interest redemption value in excess of carrying value (61) (462) (321) (462) Net (loss) income attributable to common stock shareholders $ (11,765) $ (37,860) $ (70,341) $ (97,620) Denominator for net (loss) income per share: Weighted average shares – basic and diluted(1) 130,263  127,991  129,780  127,478  Net income (loss) per share – basic and diluted $ (0.09) $ (0.30) $ (0.54) $ (0.77) (1) Equity awards are deemed anti-dilutive for the three and nine month periods ended September 30, 2023 and 2022 because we reported a net loss for these periods. The following table presents the potentially dilutive shares that have been excluded from the computation of diluted earnings (loss) per share attributable to Common Stock shareholders because their effect is considered anti-dilutive for the three and nine months ended September 30, 2023 and 2022: Three and Nine Months Ended (in thousands) September 30, 2023 September 30, 2022 Restricted stock and restricted stock units 6,653  5,030  Stock options 420  420  Total 7,073  5,450

v3.23.3

Accumulated Other Comprehensive Loss (Tables)	9 Months Ended
	Sep. 30, 2023
Stockholders' Equity Note [Abstract]
Schedule of Accumulated Other Comprehensive Loss	For the three and nine months ended September 30, 2023 and 2022, the changes in the balances of accumulated other comprehensive loss by component are as follows: Three Months Ended September 30, 2023 (in thousands) Foreign currency translation adjustment Defined benefit pension plan Unrealized loss on short-term investments Total Balance at June 30, 2023 $ (50,069) $ 689  $ —  $ (49,380) Other comprehensive income (loss) (7,352) (20) —  (7,372) Amounts reclassified from accumulated other comprehensive income (loss) —  (11) —  (11) Balance at September 30, 2023 $ (57,421) $ 658  $ —  $ (56,763) Nine Months Ended September 30, 2023 (in thousands) Foreign currency translation adjustment Defined benefit pension plan Unrealized loss on short-term investments Total Balance at December 31, 2022 $ (54,194) $ 700  $ (328) $ (53,822) Other comprehensive income (loss) (3,227) (8) 108  (3,127) Amounts reclassified from accumulated other comprehensive income (loss) (a) —  (34) 220  186  Balance at September 30, 2023 $ (57,421) $ 658  $ —  $ (56,763) Three Months Ended September 30, 2022 (in thousands) Foreign currency translation adjustment Defined benefit pension plan Unrealized loss on short-term investments Total Balance at June 30, 2022 $ (55,196) $ (1,976) $ (4,023) $ (61,195) Other comprehensive income (loss) (22,135) 164  (32) (22,003) Amounts reclassified from accumulated other comprehensive income (loss) (a) —  (8) 2,402  2,394  Balance at September 30, 2022 $ (77,331) $ (1,820) $ (1,653) $ (80,804) Nine Months Ended September 30, 2022 (in thousands) Foreign currency translation adjustment Defined benefit pension plan Unrealized loss on short-term investments Total Balance at December 31, 2021 $ (35,464) $ (2,242) $ —  $ (37,706) Other comprehensive income (loss) (41,867) 311  (4,055) (45,611) Amounts reclassified from accumulated other comprehensive income (loss) (a) —  111  2,402  2,513  Balance at September 30, 2022 $ (77,331) $ (1,820) $ (1,653) $ (80,804) (a) Amount reclassified into interest and other income (expense), net on the statement of operations. See Note 19 for details regarding fair value measurements and unrealized gains (losses) on short-term investments.

v3.23.3

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
Schedule of Segment Reporting Information by Segment	The following tables set forth our operating results by segment for the three and nine months ended September 30, 2023 and 2022: Revenue Adjusted EBITDA Three Months Ended September 30, Three Months Ended September 30, (in thousands) 2023 2022 2023 2022 Healthcare Solutions $ 52,429  $ 64,203  $ 13,869  $ 13,787  Industrial Solutions 71,362  68,050  7,662  7,180  Total Reportable segments 123,791  132,253  21,531  20,967  Corporate and Other(1) —  —  (16,805) (21,288) Total Company $ 123,791  $ 132,253  $ 4,726  $ (321) Revenue Adjusted EBITDA Nine Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Healthcare Solutions $ 162,028  $ 200,294  $ 30,328  $ 45,705  Industrial Solutions 211,193  205,005  16,828  16,473  Total Reportable segments 373,221  405,299  47,156  62,178  Corporate and Other(1) —  —  (59,422) (63,155) Total Company $ 373,221  $ 405,299  $ (12,266) $ (977) (1) Corporate and Other is not an operating segment, but reflects expenses not directly attributable to and, accordingly, not allocated to our reportable segments. These expenses relate to corporate functions such as human resources, finance, and legal and include expenses such as salaries, benefits, and other related costs. Similar to the Company's operating segments, Corporate results are reported to and reviewed by the Company’s CODM on the basis of Adjusted EBITDA. The following table provides a reconciliation of the Company’s reported net loss to the total of our reportable segment Adjusted EBITDA and Corporate and Other Adjusted EBITDA for the three and nine months ended September 30, 2023 and 2022: Three Months Ended Nine Months Ended (in thousands) September 30, 2023 September 30, 2022 September 30, 2023 September 30, 2022 Net loss attributable to 3D Systems Corporation $ (11,704) $ (37,398) $ (70,020) $ (97,158) Interest (income) expense, net (4,909) (2,029) (13,118) (4,019) Provision (benefit) for income taxes 174  338  404  2,911  Depreciation expense 5,084  5,142  15,690  15,992  Amortization expense 3,179  4,293  9,676  10,273  Stock-based compensation expense (3,142) 11,447 15,140 31,508 Acquisition and divestiture-related expense (4,055) 2,728 134 9,382 Legal expenses 2,145 9,707 4,880 20,467 Restructuring expense 1,504 67  6,712  376  Redeemable non-controlling interest (57) (147) (149) (184) Loss on equity method investment 605 —  747 —  Asset impairment charges 13,595 2,909 14,211 2,885 Other non-operating (income) expense 2,307 2,622 3,427 6,590 Adjusted EBITDA $ 4,726  $ (321) $ (12,266) $ (977)

v3.23.3

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis	Assets measured at fair value on a recurring basis as of December 31, 2022 are summarized below. During the three months ended September 30, 2023, we sold all of our remaining Level 2 short-term investments included in the table below. Fair Value Measurement as of December 31, 2022 Fair Value Measurement Balance Sheet Classification (in thousands) Fair Value Level Cost Basis Unrealized Gains (Losses) Fair Value Cash and Cash Equivalents Short-term Investments Money market funds Level 1 $ 232,018  $ —  $ 232,018  $ 232,018  $ —  Certificates of deposit Level 2 990  6  996  —  996  Commercial paper Level 2 1,281  6  1,287  —  1,287  Short-term bond mutual funds Level 2 100,242  (99) 100,143  —  100,143  Corporate bonds(a) Level 2 78,418  (241) 78,177  —  78,177  Total $ 412,949  $ (328) $ 412,621  $ 232,018  $ 180,603  (a) Includes $745 and $743 of cost basis and fair market value, respectively, with a weighted average maturity of 1.3 years.

v3.23.3

Restructuring (Tables)	9 Months Ended
	Sep. 30, 2023
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Reserve by Type of Cost	(in thousands) Accrued liability as of December 31, 2022 Costs incurred during 2023 Amounts settled with cash Accrued liability as of September 30, 2023 Severance, termination benefits and other employee costs $ —  $ 3,724  $ 2,693  $ 1,031  Total $ —  $ 3,724  $ 2,693  $ 1,031

v3.23.3

Basis of Presentation (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Maximum exposure to losses	$ 13,782

v3.23.3

Acquisitions (Narrative) (Details) € in Thousands					3 Months Ended	9 Months Ended
	Jul. 01, 2023 USD ($)	Oct. 04, 2022 USD ($)	Apr. 01, 2022 USD ($)	Jan. 21, 2019 USD ($)	Mar. 31, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Jul. 01, 2023 EUR (€)	Dec. 31, 2018
Business Acquisition [Line Items]
Unrecognized stock-based compensation expense						$ 52,508,000
Unrecognized stock-based compensation expense, period for recognize						2 years
Installment payments						$ 0	$ 2,300,000
Wematter
Business Acquisition [Line Items]
Acquired ownership percentage	100.00%							100.00%
Payment in cash	$ 10,224,000
Additional payments | €								€ 2,000
Additional payment period	2 years
Unrecognized stock-based compensation expense | €								€ 2,000
Unrecognized stock-based compensation expense, period for recognize	2 years
Acquisition related expenses	$ 847,000
Business combination, consideration transferred, debt	942,000
Purchase price	11,166,000
Goodwill expected to be tax deductible	$ 0
Dp polar GmbH
Business Acquisition [Line Items]
Acquired ownership percentage		100.00%
Payment in cash		$ 19,604,000
Additional payments		2,229,000
Purchase price		25,866,000
Issuance of shares amount		7,091,000
Estimated post closing purchase price adjustment		829,000
Goodwill expected to be tax deductible		$ 0
Kumovis GmbH
Business Acquisition [Line Items]
Acquired ownership percentage			93.75%
Payment in cash			$ 37,875,000
Purchase price			39,434,000
Goodwill expected to be tax deductible			0
Fair value of RNCI			1,559,000
Deferred cash consideration			$ 3,628,000
Cash deferment period			15 months
Equity interest percentage			50.00%
Acquisition years			5 years 9 months
Purchase price			$ 39,434,000
Kumovis GmbH | Kumovis GmbH
Business Acquisition [Line Items]
Ownership percentage			6.25%
Titan Additive LLC
Business Acquisition [Line Items]
Acquired ownership percentage			100.00%
Payment in cash			$ 39,040,000
Purchase price			$ 39,040,000
Easyway
Business Acquisition [Line Items]
Acquired ownership percentage				30.00%					70.00%
Purchase price				$ 13,500,000
Installment payments					$ 2,300,000

v3.23.3

Acquisitions (Assets and Liabilities Assumed) (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jul. 01, 2023	Dec. 31, 2022	Oct. 04, 2022	Apr. 01, 2022
Intangible assets:
Goodwill	$ 391,325		$ 385,312
Wematter
Business Acquisition [Line Items]
Current assets, including cash acquired		$ 835
Intangible assets:
Total intangible assets		4,065
Goodwill		6,878
Other assets		475
Liabilities:
Accounts payable and accrued liabilities		794
Long term liabilities		293
Total liabilities		1,087
Net assets acquired		11,166
Cash acquired		148
Wematter | Trade names
Intangible assets:
Total intangible assets		1,487
Wematter | Product technology
Intangible assets:
Total intangible assets		2,231
Wematter | Customer relationships
Intangible assets:
Total intangible assets		$ 347
Dp polar GmbH
Business Acquisition [Line Items]
Current assets, including cash acquired				$ 301
Intangible assets:
Total intangible assets				8,919
Goodwill				17,090
Other assets				765
Liabilities:
Accounts payable and accrued liabilities				364
Deferred tax liability				845
Total liabilities				1,209
Net assets acquired				25,866
Cash acquired				243
Dp polar GmbH | Trade names
Intangible assets:
Total intangible assets				3,930
Dp polar GmbH | In-process research and development
Intangible assets:
Total intangible assets				$ 4,989
Kumovis GmbH
Business Acquisition [Line Items]
Current assets, including cash acquired					$ 1,407
Intangible assets:
Total intangible assets					26,572
Goodwill					17,618
Other assets					705
Liabilities:
Accounts payable and accrued liabilities					332
Deferred revenue					70
Deferred tax liability					6,466
Total liabilities					6,868
Net assets acquired					39,434
Cash acquired					125
Kumovis GmbH | Trade names
Intangible assets:
Total intangible assets					5,802
Kumovis GmbH | Product technology
Intangible assets:
Total intangible assets					20,770
Titan Additive LLC
Business Acquisition [Line Items]
Current assets, including cash acquired					661
Intangible assets:
Total intangible assets					21,520
Goodwill					17,430
Other assets					68
Liabilities:
Accounts payable and accrued liabilities					229
Deferred revenue					410
Total liabilities					639
Net assets acquired					39,040
Titan Additive LLC | Trade names
Intangible assets:
Total intangible assets					5,580
Titan Additive LLC | Product technology
Intangible assets:
Total intangible assets					$ 15,940

v3.23.3

Acquisitions (Definite-Lived Intangible Assets) (Details) - Wematter	Jul. 01, 2023
Trade names
Business Acquisition [Line Items]
Finite-lived intangible assets average useful life (in years)	5 years
Product technology
Business Acquisition [Line Items]
Finite-lived intangible assets average useful life (in years)	15 years
Customer relationships
Business Acquisition [Line Items]
Finite-lived intangible assets average useful life (in years)	10 years

v3.23.3

Acquisitions (Acquisition, Pro Forma Information) (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Wematter
Business Acquisition [Line Items]
Net (loss) income attributable to 3D Systems Corporation	$ (38,407)	$ (71,076)	$ (100,185)

v3.23.3

Acquisitions (Fair Value of Consideration Transferred) (Details) - Kumovis GmbH $ in Thousands	Apr. 01, 2022 USD ($)
Business Acquisition [Line Items]
Cash paid at acquisition	$ 34,098
Deferred cash consideration	3,628
Estimated fair value of RNCI	1,559
Post-closing net working capital adjustment	149
Total fair value of consideration transferred	$ 39,434

v3.23.3

Revenue (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Outstanding performance obligation	$ 62,579		$ 62,579
Revenue	123,791	$ 132,253	373,221	$ 405,299
Amounts included in contract liability at the beginning of period			23,498	28,850
Unbilled receivables	7,379		7,379		$ 677
Services
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue	43,376	$ 35,916	$ 119,253	$ 104,637
Recognized revenue	$ 4,452
Adjustment to basic and diluted loss per share (in dollars per share)	$ (0.03)		$ (0.03)
One Customer | Revenue from Contract with Customer Benchmark | Customer Concentration Risk
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Concentration risk (as a percentage)	10.70%	20.80%	14.40%	24.10%
Collaborative Arrangement
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue	$ 7,896	$ 3,301	$ 16,099	$ 9,075
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Axis]: 2023-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Outstanding performance obligation	$ 39,418		$ 39,418
Remaining performance obligation (as a percentage)	90.00%		90.00%
Performance obligations expected to be satisfied, expected timing	12 months		12 months
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Axis]: 2024-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation (as a percentage)	4.00%		4.00%
Performance obligations expected to be satisfied, expected timing	3 months		3 months

v3.23.3

Revenue (Revenue by Geographic Region) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Total revenue	$ 123,791	$ 132,253	$ 373,221	$ 405,299
Americas
Disaggregation of Revenue [Line Items]
Total revenue	69,714	80,455	214,956	234,511
EMEA
Disaggregation of Revenue [Line Items]
Total revenue	43,141	36,913	127,150	122,788
APAC
Disaggregation of Revenue [Line Items]
Total revenue	10,936	14,885	31,115	48,000
United States (included in Americas above)
Disaggregation of Revenue [Line Items]
Total revenue	$ 68,840	$ 78,910	$ 211,717	$ 231,557

v3.23.3

Inventories (Components of Inventories) (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 61,314	$ 59,907
Work in process	3,922	4,972
Finished goods and parts	87,769	72,953
Total inventories	$ 153,005	$ 137,832

v3.23.3

Inventories (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Jun. 30, 2023	Sep. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventory reserve		$ 16,711	$ 15,550
Business exit costs	$ 450
Long-term purchase commitment, amount		$ 2,735

v3.23.3

Intangible Assets (Intangible Assets Other Than Goodwill) (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Gross	$ 175,860	$ 191,974
Accumulated Amortization	(109,706)	(107,192)
Net	66,154	84,782
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross	51,160	51,137
Accumulated Amortization	(49,417)	(48,695)
Net	1,743	2,442
Acquired technology
Finite-Lived Intangible Assets [Line Items]
Gross	45,894	55,480
Accumulated Amortization	(11,925)	(10,707)
Net	33,969	44,773
Trade names
Finite-Lived Intangible Assets [Line Items]
Gross	30,496	35,930
Accumulated Amortization	(13,705)	(12,455)
Net	16,791	23,475
Patent costs
Finite-Lived Intangible Assets [Line Items]
Gross	18,714	18,673
Accumulated Amortization	(10,823)	(10,909)
Net	7,891	7,764
Acquired patents
Finite-Lived Intangible Assets [Line Items]
Gross	16,426	17,499
Accumulated Amortization	(14,716)	(15,661)
Net	1,710	1,838
Other
Finite-Lived Intangible Assets [Line Items]
Gross	13,170	13,255
Accumulated Amortization	(9,120)	(8,765)
Net	$ 4,050	$ 4,490

v3.23.3

Intangible Assets (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Asset impairment	$ 13,597		$ 14,856	$ 2,359
Amortization expense	3,179	$ 4,293	9,676	$ 10,273
Remainder of 2023	2,085		2,085
Amortization expense for intangible assets, 2024	8,318		8,318
Amortization expense for intangible assets, 2025	8,029		8,029
Amortization expense for intangible assets, 2026	7,083		7,083
Amortization expense for intangible assets, 2027	6,733		6,733
Indefinite-lived intangible assets	$ 5,382		$ 5,382		$ 5,448

v3.23.3

Goodwill (Roll Forward) (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
Goodwill [Roll Forward]
Balance at beginning of year, gross	$ 459,696
Balance at beginning of year, dispositions, acquisitions and impairments	(74,384)
Balance at beginning of period	385,312
Acquisitions and measurement period adjustments	8,740
Foreign currency translation adjustments	(2,727)
Balance at ending of year, gross	465,709
Balance at ending of year, dispositions, acquisitions and impairments	(74,384)
Balance at end of period	391,325
Healthcare Solutions
Goodwill [Roll Forward]
Balance at beginning of year, gross	143,431
Balance at beginning of year, dispositions, acquisitions and impairments	(32,055)
Balance at beginning of period	111,376
Acquisitions and measurement period adjustments	1,005
Foreign currency translation adjustments	(1,175)
Balance at ending of year, gross	143,261
Balance at ending of year, dispositions, acquisitions and impairments	(32,055)
Balance at end of period	111,206
Industrial Solutions
Goodwill [Roll Forward]
Balance at beginning of year, gross	316,265
Balance at beginning of year, dispositions, acquisitions and impairments	(42,329)
Balance at beginning of period	273,936
Acquisitions and measurement period adjustments	7,735
Foreign currency translation adjustments	(1,552)
Balance at ending of year, gross	322,448
Balance at ending of year, dispositions, acquisitions and impairments	(42,329)
Balance at end of period	$ 280,119

v3.23.3

Investments and Notes Receivable (Schedule of Equity Investments) (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Equity Method Investments and Joint Ventures [Abstract]
Equity investments under the equity method of accounting	$ 5,782	$ 0
Equity investments without readily determinable fair values	20,962	12,953
Other	200	200
Total equity investments	26,944	13,153
Long-term note receivable	530	515
Total notes receivable	$ 530	$ 515

v3.23.3

Investments and Notes Receivable (Narrative) (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023	Jun. 30, 2023	Apr. 30, 2023	Feb. 28, 2023	Dec. 31, 2022	Mar. 31, 2022
Schedule of Equity Method Investments [Line Items]
Initial investment	$ 5,782,000	$ 5,782,000				$ 0
Total carrying value of the VIEs	20,962,000	20,962,000				12,953,000
Saudi Arabian Industrial Investments Company
Schedule of Equity Method Investments [Line Items]
Initial investment				$ 3,065,000			$ 6,500,000
Escrow deposit				$ 3,435,000		3,435,000
Ownership percentage					49.00%
Theradaptive, Inc
Schedule of Equity Method Investments [Line Items]
Total carrying value of the VIEs			$ 8,000,000
Ownership percentage			8.25%
Investment impairment charge	0	0
Theradaptive, Inc | Series A Preferred Stock | Preferred Stock
Schedule of Equity Method Investments [Line Items]
Ownership percentage			9.15%
Entach Inc
Schedule of Equity Method Investments [Line Items]
Total carrying value of the VIEs	6,900,000	6,900,000				6,900,000	$ 10,000
Ownership percentage							26.60%
Investment impairment charge	0	0
Fair value of investment							$ 9,670,000
Historical impairment charges	$ 2,770,000	$ 2,770,000				$ 2,770,000
Entach Inc | Warrant
Schedule of Equity Method Investments [Line Items]
Fair value of investment							$ 330,000

v3.23.3

Leases (Narrative) (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($) ft² building
Lessee, Lease, Description [Line Items]
Number of buildings | building	2
Area of building | ft²	396,100
Remaining minimum base lease payments	$ 47,634
Remaining minimum base lease payments, December 31, 2023	1,006
Remaining minimum base lease payments, December 31, 2024	4,516
Remaining minimum base lease payments, December 31, 2025	5,093
Remaining minimum base lease payments, December 31, 2026	5,234
Remaining minimum base lease payments, December 31, 2027	5,380
Remaining minimum base lease payments, thereafter	$ 26,405
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease term	1 year
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease term	15 years

v3.23.3

Leases (Balance Sheet Classifications) (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Right-of-use assets
Operating leases	$ 60,973	$ 39,502
Finance leases	12,047	3,244
Right-of-use assets	73,020	42,746
Current lease liabilities
Operating leases	9,616	8,343
Finance leases	1,068	693
Current lease liabilities	10,684	9,036
Long-term lease liabilities
Operating leases	59,428	38,499
Finance leases	11,867	3,280
Long-term lease liabilities	$ 71,295	$ 41,779
Operating lease, right-of-use asset, statement of financial position, extensible list	Right-of-use assets	Right-of-use assets
Finance lease, right-of-use asset, statement of financial position, extensible list	Right-of-use assets	Right-of-use assets
Operating lease, liability, current, statement of financial position, extensible list	Current lease liabilities	Current lease liabilities
Finance lease, liability, current, statement of financial position, extensible list	Current lease liabilities	Current lease liabilities, Right-of-use assets
Operating lease, liability, noncurrent, statement of financial position, extensible list	Long-term lease liabilities	Long-term lease liabilities
Finance lease, liability, noncurrent, statement of financial position, extensible list	Long-term lease liabilities	Long-term lease liabilities

v3.23.3

Accrued and Other Liabilities (Schedule of Accrued Liabilities) (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Compensation and benefits	$ 15,492	$ 19,814
Accrued taxes	9,633	10,694
Legal contingencies	4,850	9,948
Product warranty liability	2,409	3,677
Other accrued liabilities	11,191	11,438
Total	$ 43,575	$ 55,571

v3.23.3

Accrued and Other Liabilities (Schedule of Recognized Warranty Revenue and Incurred Warranty Costs) (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Warrant Obligation [Roll Forward]
Deferred Warranty Revenue	$ 2,409	$ 3,576	$ 3,677	$ 3,585
Settlements Made	(2,983)	(5,266)
Accruals For Warranties Issued	1,715	5,257
Deferred Warranty Revenue	$ 2,409	$ 3,576	$ 3,677	$ 3,585

v3.23.3

Accrued and Other Liabilities (Schedule of Other Liabilities) (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Long-term employee indemnity	$ 4,634	$ 4,817
Long-term tax liability	5,568	5,711
Defined benefit pension obligation	4,963	5,050
Long-term deferred revenue	1,858	4,974
Earnout liability	0	17,244
Legal contingencies	2,916	6,096
Other long-term liabilities	428	289
Total	$ 20,367	$ 44,181

v3.23.3

Borrowings (Details)		3 Months Ended			9 Months Ended		12 Months Ended
	Nov. 16, 2021 USD ($) day $ / shares	Dec. 31, 2023 USD ($)	Sep. 30, 2023 USD ($) $ / shares	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) $ / shares	Sep. 30, 2022 USD ($)	Dec. 31, 2026 USD ($)	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2022 $ / shares	Jun. 30, 2022 $ / shares
Line of Credit Facility [Line Items]
Common stock, par value (in dollars per share) | $ / shares	$ 0.001		$ 0.001		$ 0.001					$ 0.001	$ 0.001
Amortization of debt issuance costs			$ 671,000	$ 670,000	$ 2,010,000	$ 2,006,000
Convertible Senior Notes Due 2026 | Convertible Debt
Line of Credit Facility [Line Items]
Issued amount	$ 460,000,000
Interest rate (as a percentage)	0.00%
Net proceeds from offering	$ 446,534,000
Discounts and expenses	$ 13,466,000
Unamortized amount			8,480,000		8,480,000
Effective interest rate	0.594%
Percentage of conversion price	130.00%
Threshold trading days | day	20
Threshold consecutive trading days | day	30
Threshold consecutive trading days, sale price per share | day	5
Measurement period | day	5
Threshold percentage of sales price per share	98.00%
Conversion ratio	0.0278364
Conversion price (in dollars per share) | $ / shares	$ 35.92
Redemption percentage of principal amount	100.00%
Fair value of notes			$ 331,297,000		$ 331,297,000
Forecast
Line of Credit Facility [Line Items]
Amortization of debt issuance costs		$ 673,000					$ 2,395,000	$ 2,714,000	$ 2,698,000

v3.23.3

Redeemable Non-Controlling Interest (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Apr. 01, 2022
Redeemable Noncontrolling Interest Equity [Roll Forward]
Beginning balance			$ 1,760	$ 0
Fair value at the date of acquisition				1,559
Net loss	$ (57)	$ (147)	(149)	(184)
Redemption value in excess of carrying value	61	462	321	462
Translation adjustments			(4)	(183)
Ending balance	$ 1,928	$ 1,654	$ 1,928	$ 1,654
Kumovis GmbH
Redeemable Noncontrolling Interest [Line Items]
Ownership percentage by existing shareholders					6.25%

v3.23.3

Stock-Based Compensation (Narrative) (Details) $ / shares in Units, shares in Thousands, $ in Thousands			3 Months Ended			9 Months Ended
	Oct. 04, 2022 USD ($) shares	Dec. 01, 2021 USD ($) milestone	Sep. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) $ / shares shares	Sep. 30, 2022 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period						3 years
Stock based compensation expense reversal			$ 21,527			$ 18,392
Basic (in dollars per share) | $ / shares			$ 0.17			$ 0.14
Diluted (in dollars per share) | $ / shares			$ 0.17			$ 0.14
Stock-based compensation expense			$ (3,142)		$ 11,447	$ 15,140	$ 31,508
Unrecognized stock-based compensation expense			52,508			$ 52,508
Unrecognized stock-based compensation expense, period for recognize						2 years
Share-Based Payment Arrangement, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage						33.33%
Share-Based Payment Arrangement, Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage						33.33%
Share-Based Payment Arrangement, Tranche Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage						33.33%
Volumetric
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional payments		$ 355,000
Number of milestones | milestone		7
Earnout payment milestone			65
Aggregate grant date fair value of outstanding and unvested				$ 4,773
Stock-based compensation expense			(10,140)		1,989	$ (8,640)	5,969
Dp polar GmbH
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional payments	$ 2,229
Issuance of shares (in shares) | shares	250
Stock-based compensation expense			$ 175			$ 727
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of non-financial milestones | milestone		4
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period						3 years
Granted (in shares) | shares			111			3,990
Granted (in dollars per share) | $ / shares			$ 8.11			$ 10.95
Market-Based Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period						3 years
Granted (in shares) | shares						681
Granted (in dollars per share) | $ / shares						$ 18.91
Incentive Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense			$ (1,055)		1,282	$ 0	3,123
Phantom Share Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense			$ (1,246)		$ 254	$ (1,113)	$ 746
Phantom Share Units (PSUs) | Systemic Bio Phantom Unit Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period						4 years
Granted (in shares) | shares			589
Deferred compensation			$ 183
Phantom Share Units (PSUs) | Minimum | Systemic Bio Phantom Unit Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense, period for recognize			40 months 15 days
Phantom Share Units (PSUs) | Maximum | Systemic Bio Phantom Unit Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense, period for recognize			48 months

v3.23.3

Stock-Based Compensation (Schedule of Stock-based Compensation Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock-based compensation expense	$ (3,142)	$ 11,447	$ 15,140	$ 31,508
Tax benefit	$ 0	$ 0	$ 0	$ 0

v3.23.3

Interest and Other Income (Expense), Net (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Other Income and Expenses [Abstract]
Foreign exchange (loss), net	$ (2,202)	$ (764)	$ (3,847)	$ (4,193)
Interest income, net	4,909	2,029	13,118	4,019
Other (expense) income, net	(105)	(4,767)	420	(5,282)
Total interest and other income (expense), net	2,602	(3,502)	9,691	(5,456)
Interest income	5,841	2,753	15,730	6,103
Interest expenses	$ 932	$ 724	$ 2,612	$ 2,084

v3.23.3

Income Taxes (Narrative) (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Effective income tax rate	(1.60%)	(0.90%)	(0.60%)	(3.10%)

v3.23.3

Net Earnings (Loss) Per Share (Schedule of Net Income (Loss) Per Share Reconciliation) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Numerator for basic and diluted net (loss) income per share:
Net (loss) income attributable to 3D Systems Corporation	$ (11,704)	$ (37,398)	$ (70,020)	$ (97,158)
Redeemable non-controlling interest redemption value in excess of carrying value	(61)	(462)	(321)	(462)
Net (loss) income attributable to common stock shareholders	$ (11,765)	$ (37,860)	$ (70,341)	$ (97,620)
Denominator for net (loss) income per share:
Weighted average shares - basic (in shares)	130,263	127,991	129,780	127,478
Weighted average shares diluted (in shares)	130,263	127,991	129,780	127,478
Net income (loss) per share - basic (in dollars per share)	$ (0.09)	$ (0.30)	$ (0.54)	$ (0.77)
Net income (loss) per share - diluted (in dollars per share)	$ (0.09)	$ (0.30)	$ (0.54)	$ (0.77)

v3.23.3

Net Earnings (Loss) Per Share (Equity Awards) (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Shares excluded from diluted loss per share calculation (in shares)	7,073	5,450	7,073	5,450
Restricted stock and restricted stock units
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Shares excluded from diluted loss per share calculation (in shares)	6,653	5,030	6,653	5,030
Stock options
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Shares excluded from diluted loss per share calculation (in shares)	420	420	420	420
Incentive Awards
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Shares excluded from diluted loss per share calculation (in shares)		233		233

v3.23.3

Net Earnings (Loss) Per Share (Narrative) (Details) - USD ($) $ / shares in Units, shares in Thousands		3 Months Ended		9 Months Ended
	Nov. 16, 2021	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023
Subsidiary, Sale of Stock [Line Items]
Shares excluded from diluted loss per share calculation (in shares)		7,073	5,450	7,073	5,450
Share price (in dollars per share)						$ 13.11
Dp polar GmbH
Subsidiary, Sale of Stock [Line Items]
Shares excluded from diluted loss per share calculation (in shares)		110		110
Incentive Awards
Subsidiary, Sale of Stock [Line Items]
Shares excluded from diluted loss per share calculation (in shares)			233		233
Shares Issuable
Subsidiary, Sale of Stock [Line Items]
Shares excluded from diluted loss per share calculation (in shares)			506		506
Convertible Senior Notes Due 2026 | Senior Notes
Subsidiary, Sale of Stock [Line Items]
Issued amount	$ 460,000,000
Interest rate (as a percentage)	0.00%
Conversion price (in dollars per share)	$ 35.92

v3.23.3

Accumulated Other Comprehensive Loss (Schedule of Accumulated Other Comprehensive Loss By Component) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	$ 711,004	$ 783,658	$ 749,944	$ 842,381
Other comprehensive income (loss)	(7,372)	(22,003)	(3,127)	(45,611)
Amounts reclassified from accumulated other comprehensive income (loss)	(11)	2,394	186	2,513
Ending balance	699,538	734,256	699,538	734,256
Accumulated Other Comprehensive Income (Loss)
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(49,380)	(61,195)	(53,822)	(37,706)
Ending balance	(56,763)	(80,804)	(56,763)	(80,804)
Foreign currency translation adjustment
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(50,069)	(55,196)	(54,194)	(35,464)
Other comprehensive income (loss)	(7,352)	(22,135)	(3,227)	(41,867)
Amounts reclassified from accumulated other comprehensive income (loss)	0	0	0	0
Ending balance	(57,421)	(77,331)	(57,421)	(77,331)
Defined benefit pension plan
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	689	(1,976)	700	(2,242)
Other comprehensive income (loss)	(20)	164	(8)	311
Amounts reclassified from accumulated other comprehensive income (loss)	(11)	(8)	(34)	111
Ending balance	658	(1,820)	658	(1,820)
Unrealized loss on short-term investments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	0	(4,023)	(328)	0
Other comprehensive income (loss)	0	(32)	108	(4,055)
Amounts reclassified from accumulated other comprehensive income (loss)	0	2,402	220	2,402
Ending balance	$ 0	$ (1,653)	$ 0	$ (1,653)

v3.23.3

Segment Information (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) segment	Sep. 30, 2022 USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments | segment			2
Revenue	$ 123,791	$ 132,253	$ 373,221	$ 405,299
Adjusted EBITDA	4,726	(321)	(12,266)	(977)
Net (loss) income attributable to 3D Systems Corporation	(11,704)	(37,398)	(70,020)	(97,158)
Interest (income) expense, net	(4,909)	(2,029)	(13,118)	(4,019)
Provision (benefit) for income taxes	174	338	404	2,911
Depreciation expense	5,084	5,142	15,690	15,992
Amortization expense	3,179	4,293	9,676	10,273
Stock-based compensation expense	(3,142)	11,447	15,140	31,508
Acquisition and divestiture-related expense	(4,055)	2,728	134	9,382
Legal expenses	2,145	9,707	4,880	20,467
Restructuring expense	1,504	67	6,712	376
Redeemable non-controlling interest	(57)	(147)	(149)	(184)
Loss on equity method investment	605	0	747	0
Asset impairment charges	13,595	2,909	14,211	2,885
Other non-operating (income) expense	2,307	2,622	3,427	6,590
Operating Segments
Segment Reporting Information [Line Items]
Revenue	123,791	132,253	373,221	405,299
Adjusted EBITDA	21,531	20,967	47,156	62,178
Corporate and other
Segment Reporting Information [Line Items]
Revenue	0	0	0	0
Adjusted EBITDA	(16,805)	(21,288)	(59,422)	(63,155)
Healthcare Solutions | Operating Segments
Segment Reporting Information [Line Items]
Revenue	52,429	64,203	162,028	200,294
Adjusted EBITDA	13,869	13,787	30,328	45,705
Industrial Solutions | Operating Segments
Segment Reporting Information [Line Items]
Revenue	71,362	68,050	211,193	205,005
Adjusted EBITDA	$ 7,662	$ 7,180	$ 16,828	$ 16,473

v3.23.3

Commitments and Contingencies (Narrative) (Details) $ in Thousands		1 Months Ended	9 Months Ended
	Jun. 02, 2023 USD ($)	Feb. 28, 2023 USD ($) installment	Sep. 30, 2023 USD ($)
Loss Contingencies [Line Items]
Litigation liability			$ 16,044
Financial Standby Letter of Credit
Loss Contingencies [Line Items]
Guarantor obligations	$ 1,161
Guarantor obligations, extension term, (in years)	1 year
Export Controls and Government Contracts Compliance
Loss Contingencies [Line Items]
Amount awarded		$ 15,048
Export Controls and Government Contracts Compliance | Directorate of Defense Trade Controls
Loss Contingencies [Line Items]
Amount awarded		$ 10,000
Number of installment payments | installment		3
Payment period		3 years	3 years
Suspended penalty amount			$ 10,000
Legal expenses			$ 8,548
Export Controls and Government Contracts Compliance | Bureau of Industry and Security of the Department of Commerce
Loss Contingencies [Line Items]
Amount awarded		$ 2,778
Export Controls and Government Contracts Compliance | U.S. Department of Justice
Loss Contingencies [Line Items]
Amount awarded		$ 2,270

v3.23.3

Fair Value Measurements (Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis) (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-Sale, Amortized Cost, Current		$ 412,949
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss), before Tax		(328)
Debt Securities, Available-for-Sale, Current		412,621
Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-Sale, Amortized Cost, Current		745
Debt Securities, Available-for-Sale, Current		743
Cash and Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-Sale, Current		232,018
Short-Term Investments [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-Sale, Current		180,603
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-Sale, Amortized Cost, Current		232,018
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss), before Tax		0
Debt Securities, Available-for-Sale, Current		232,018
Fair Value, Inputs, Level 1 [Member] | Cash and Cash Equivalents [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-Sale, Current		232,018
Fair Value, Inputs, Level 1 [Member] | Short-Term Investments [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-Sale, Current		0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average maturity	1 year 3 months 18 days
Fair Value, Inputs, Level 2 [Member] | Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-Sale, Amortized Cost, Current		990
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss), before Tax		6
Debt Securities, Available-for-Sale, Current		996
Fair Value, Inputs, Level 2 [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-Sale, Amortized Cost, Current		1,281
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss), before Tax		6
Debt Securities, Available-for-Sale, Current		1,287
Fair Value, Inputs, Level 2 [Member] | Short-Term Bond Mutual Fund [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-Sale, Amortized Cost, Current		100,242
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss), before Tax		(99)
Debt Securities, Available-for-Sale, Current		100,143
Fair Value, Inputs, Level 2 [Member] | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-Sale, Amortized Cost, Current		78,418
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss), before Tax		(241)
Debt Securities, Available-for-Sale, Current		78,177
Fair Value, Inputs, Level 2 [Member] | Cash and Cash Equivalents [Member] | Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-Sale, Current		0
Fair Value, Inputs, Level 2 [Member] | Cash and Cash Equivalents [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-Sale, Current		0
Fair Value, Inputs, Level 2 [Member] | Cash and Cash Equivalents [Member] | Short-Term Bond Mutual Fund [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-Sale, Current		0
Fair Value, Inputs, Level 2 [Member] | Cash and Cash Equivalents [Member] | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-Sale, Current		0
Fair Value, Inputs, Level 2 [Member] | Short-Term Investments [Member] | Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-Sale, Current		996
Fair Value, Inputs, Level 2 [Member] | Short-Term Investments [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-Sale, Current		1,287
Fair Value, Inputs, Level 2 [Member] | Short-Term Investments [Member] | Short-Term Bond Mutual Fund [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-Sale, Current		100,143
Fair Value, Inputs, Level 2 [Member] | Short-Term Investments [Member] | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-Sale, Current		$ 78,177

v3.23.3

Restructuring (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Sep. 30, 2023	Sep. 30, 2022
Restructuring Cost and Reserve [Line Items]
Percentage of positions eliminated		6.00%
Severance costs		$ 3,724
Asset impairment	$ 13,597		$ 14,856	$ 2,359
Severance, termination benefits and other employee costs
Restructuring Cost and Reserve [Line Items]
Asset impairment			$ 628

v3.23.3

Restructuring (Restructuring Reserve Activity) (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
Restructuring Reserve [Roll Forward]
Restructuring accrued liability, beginning balance	$ 0
Costs incurred	3,724
Amounts settled with cash	2,693
Restructuring accrued liability, ending balance	1,031
Severance, termination benefits and other employee costs
Restructuring Reserve [Roll Forward]
Restructuring accrued liability, beginning balance	0
Costs incurred	3,724
Amounts settled with cash	2,693
Restructuring accrued liability, ending balance	$ 1,031

v3.23.3

Subsequent Events (Details) - Subsequent Event $ in Millions	Oct. 25, 2023 USD ($)
Maximum
Subsequent Event [Line Items]
Reduction of annualized costs	$ 55
Minimum
Subsequent Event [Line Items]
Reduction of annualized costs	$ 45

---